ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction—Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction) Developed in Collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic SurgeonsEndorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine by Anderson, Jeffrey L. et al.
PI
T
B
A
a
u
J
E
m
i
A
m
U
l
Journal of the American College of Cardiology Vol. 50, No. 7, 2007
© 2007 by the American College of Cardiology Foundation and the American Heart Association, Inc. ISSN 0735-1097/07/$32.00
PACC/AHA GUIDELINE REVISION
ACC/AHA 2007 Guidelines for the Management of Patients
With Unstable Angina/Non–ST-Elevation Myocardial
Infarction—Executive Summary
A Report of the American College of Cardiology/American Heart Association Task Force
on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the
Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction)
Developed in Collaboration with the American College of Emergency Physicians, the Society for
Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons
Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and
the Society for Academic Emergency Medicine
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.02.028Writing
Committee
Membersnstable Angina/Non–ST-E
aboration with the Amerieffrey L. Anderson, MD, FACC, FAHA, Chair
ynthia D. Adams, RN, PHD, FAHA
lliott M. Antman, MD, FACC, FAHA
harles R. Bridges, SCD, MD, FACC, FAHA*
obert M. Califf, MD, MACC
onald E. Casey, JR, MD, MPH, MBA, FACP†
illiam E. Chavey II, MD, MS‡
rancis M. Fesmire, MD, FACEP§levation Myocardial Infarction): developed in col-
can College of Emergency Physicians, American
www.american
Request Formhomas N. Levin, MD, FACC, FSCAI
. Michael Lincoff, MD, FACC
ric D. Peterson, MD, MPH, FACC, FAHA
ierre Theroux, MD, FACC, FAHA
anette Kass Wenger, MD, FACC, FAHA
. Scott Wright, MD, FACC, FAHA
Society of Thoracic Surgeons Representative; †American College of Physi-
ians Representative; ‡American Academy of Family Physicians Representa-
ive; §American College of Emergency Physicians Representative; Society forJudith S. Hochman, MD, FACC, FAHA Cardiovascular Angiography and Interventions Representative
TABLE OF CONTENTS
reamble . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .654
. Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .655
A. Organization of Committee and Evidence
Review . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .655
B. Changes Since Publication of These
Guidelines in 2002 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .655
1. Purpose of These Guidelines . . . . . . . . . . . . . . . . . . . . . .657
C. Recommendations for Management of
Patients With UA/NSTEMI . . . . . . . . . . . . . . . . . . . . . . . . .657
1. Identification of Patients at Risk of
UA/NSTEMI . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .657
2. Initial Evaluation and Management . . . . . . . . . . . . . . .657
A. CLINICAL ASSESSMENT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .657
B. EARLY RISK STRATIFICATION . . . . . . . . . . . . . . . . . . . . . . . . . .658
C. IMMEDIATE MANAGEMENT . . . . . . . . . . . . . . . . . . . . . . . . . . . .658
3. Early Hospital Care . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .659
his document was approved by the American College of Cardiology Foundation
oard of Trustees in February 2007 and by the American Heart Association Science
dvisory and Coordinating Committee in February 2007.
When citing this document, the American College of Cardiology Foundation
nd the American Heart Association request that the following citation format be
sed: Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM, Casey DE
r, Chavey WE II, Fesmire FM, Hochman JS, Levin TN, Lincoff AM, Peterson
D, Theroux P, Wenger NK, Wright RS. ACC/AHA 2007 guidelines for the
anagement of patients with unstable angina/non–ST-elevation myocardial
nfarction— executive summary: a report of the American College of Cardiology/
merican Heart Association Task Force on Practice Guidelines (Writing Com-
ittee to Revise the 2002 Guidelines for the Management of Patients With
College of Physicians, Society for Academic Emergency Medicine, Society for
Cardiovascular Angiography and Interventions, and Society of Thoracic Sur-
geons. J Am Coll Cardiol 2007;50:652–726.
This article has been copublished in the August 14, 2007, issue of Circulation.
Copies: This document is available on the World Wide Web sites of the American
College of Cardiology (www.acc.org) and the American Heart Association (www.
americanheart.org). For copies of this document, please contact Elsevier Inc. Reprint
Department, fax (212) 633-3820, e-mail reprints@elsevier.com.
Permissions: Modification, alteration, enhancement and/or distribution of this
document are not permitted without the express permission of the American College
of Cardiology and the American Heart Association. Please contact the American
Heart Association: Instructions for obtaining permission are located at http://J
C
E
C
R
D
W
F
T
A
E
P
N
R
*
c
theart.org/presenter.jhtml?identifier4431. A link to the “Permission
” appears on the right side of the page.
II
I
V
V
V
653JACC Vol. 50, No. 7, 2007 Anderson et al.
August 14, 2007:652–726 ACC/AHA UA/NSTEMI Guideline RevisionA. ANTI-ISCHEMIC AND ANALGESIC THERAPY . . . . . . . . . . . . . . .659
B. ANTIPLATELET/ANTICOAGULANT THERAPY IN
PATIENTS FOR WHOM DIAGNOSIS OF UA/NSTEMI IS
LIKELY OR DEFINITE. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .660
C. INITIAL CONSERVATIVE VERSUS INITIAL INVASIVE
STRATEGIES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .662
D. RISK STRATIFICATION BEFORE DISCHARGE . . . . . . . . . . . . . . .662
4. Revascularization With PCI and CABG in
Patients With UA/NSTEMI . . . . . . . . . . . . . . . . . . . . . .663
A. PERCUTANEOUS CORONARY INTERVENTION . . . . . . . . . . . . . .663
B. CABG . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .663
5. Late Hospital Care, Hospital Discharge, and
Post-Hospital Discharge Care . . . . . . . . . . . . . . . . . . . . .664
A. MEDICAL REGIMEN AND USE OF MEDICATIONS . . . . . . . . . . .664
B. LONG-TERM MEDICAL THERAPY AND SECONDARY
PREVENTION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .664
C. POSTDISCHARGE FOLLOW-UP. . . . . . . . . . . . . . . . . . . . . . . . . .667
D. CARDIAC REHABILITATION . . . . . . . . . . . . . . . . . . . . . . . . . . . .668
6. Special Groups . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .668
A. WOMEN . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .668
B. DIABETES MELLITUS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .668
C. POST-CABG PATIENTS. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .668
D. OLDER ADULTS. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .668
E. CHRONIC KIDNEY DISEASE . . . . . . . . . . . . . . . . . . . . . . . . . . .669
F. COCAINE AND METHAMPHETAMINE USERS . . . . . . . . . . . . . . .669
G. VARIANT (PRINZMETAL’S) ANGINA . . . . . . . . . . . . . . . . . . . . . .669
H. CARDIOVASCULAR “SYNDROME X” . . . . . . . . . . . . . . . . . . . . .669
I. Overview of the Acute Coronary Syndromes. . . . . .669
A. Definition of Terms . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .669
B. Pathogenesis of UA/NSTEMI . . . . . . . . . . . . . . . . . . . . . .670
C. Presentations of UA and NSTEMI . . . . . . . . . . . . . . . . .670
D. Prevention of UA/NSTEMI . . . . . . . . . . . . . . . . . . . . . . . . .670
E. Onset of UA/NSTEMI . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .670
1. Recognition of Symptoms by Patient . . . . . . . . . . . . . .670
2. Silent and Unrecognized Events . . . . . . . . . . . . . . . . . . .670
II. Initial Evaluation and Management . . . . . . . . . . . . . . . .671
A. Clinical Assessment. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .671
1. Patient Transportation and ED or Outpatient
Facility Evaluation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .671
B. Early Risk Stratification . . . . . . . . . . . . . . . . . . . . . . . . . . .672
1. Estimation of the Level of Risk. . . . . . . . . . . . . . . . . . . .672
2. History . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .672
3. Tools to Estimate Risk at Presentation . . . . . . . . . . . .673
4. Electrocardiogram . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .673
5. Physical Examination . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .673
6. Noncardiac Causes of Symptoms and
Secondary Causes of Myocardial Ischemia . . . . . . . . .674
7. Cardiac Biomarkers of Necrosis and the
Redefinition of AMI. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .675
A. CREATINE KINASE-MB. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .676
B. CARDIAC TROPONINS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .676
C. MYOGLOBIN . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .676
D. CLINICAL USE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .676
8. Other Markers and Multimarker Approaches . . . . . .677
C. Immediate Management . . . . . . . . . . . . . . . . . . . . . . . . . . .677
1. Chest Pain Units . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .677
V. Early Hospital Care . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .678
A. Anti-Ischemic and Analgesic Therapy . . . . . . . . . . . .678
1. General Care . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .678
2. Use of Anti-Ischemic Therapies . . . . . . . . . . . . . . . . . . .678
A. NITRATES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .678B. MORPHINE SULFATE. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .678
C. BETA-ADRENERGIC BLOCKERS . . . . . . . . . . . . . . . . . . . . . . . . .679
D. CALCIUM CHANNEL BLOCKERS . . . . . . . . . . . . . . . . . . . . . . . .679
E. INHIBITORS OF THE RENIN-ANGIOTENSIN-ALDOSTERONE
SYSTEM . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .679
F. INTRA-AORTIC BALLOON COUNTERPULSATION . . . . . . . . . . . . .679
G. ANALGESIC THERAPY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .679
B. Antiplatelet/Anticoagulant Therapy in Patients
With Likely or Definite UA/NSTEMI . . . . . . . . . . . . . . .679
1. Antiplatelet Therapy (Aspirin, Ticlopidine,
Clopidogrel) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .680
A. ASPIRIN . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .680
B. ADENOSINE DIPHOSPHATE RECEPTOR ANTAGONISTS
AND OTHER ANTIPLATELET AGENTS . . . . . . . . . . . . . . . . . . . .681
2. Anticoagulants. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .686
A. UNFRACTIONATED HEPARIN . . . . . . . . . . . . . . . . . . . . . . . . . . .686
B. LOW-MOLECULAR-WEIGHT HEPARIN. . . . . . . . . . . . . . . . . . . . .686
C. DIRECT THROMBIN INHIBITORS . . . . . . . . . . . . . . . . . . . . . . . .689
D. FACTOR XA INHIBITORS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .690
E. LONG-TERM ANTICOAGULATION . . . . . . . . . . . . . . . . . . . . . . . .691
3. Platelet GP IIb/IIIa Receptor Antagonists. . . . . . . . .691
C. Initial Conservative Versus Initial Invasive
Strategies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .694
1. General Principles and Care Objectives . . . . . . . . . . . .694
2. Rationale for the Conservative Strategy . . . . . . . . . . . .695
3. Rationale for the Invasive Strategy . . . . . . . . . . . . . . . . .695
4. Comparison of Invasive and Conservative
Strategies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .695
A. SUBGROUPS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .697
5. Risk Stratification Before Discharge . . . . . . . . . . . . . . .697
A. GENERAL PRINCIPLES AND CARE OBJECTIVES . . . . . . . . . . . .697
B. NONINVASIVE TEST SELECTION . . . . . . . . . . . . . . . . . . . . . . . .697
C. SELECTION FOR CORONARY ANGIOGRAPHY . . . . . . . . . . . . . .697
. Coronary Revascularization . . . . . . . . . . . . . . . . . . . . . . . . .698
A. General Principles and Care Objectives. . . . . . . . . .698
1. Platelet Inhibitors and PCI . . . . . . . . . . . . . . . . . . . . . . . .699
B. Surgical Revascularization . . . . . . . . . . . . . . . . . . . . . . . .699
I. Late Hospital Care, Hospital Discharge, and
Post-Hospital Discharge Care . . . . . . . . . . . . . . . . . . . . . . .699
A. General Principles and Care Objectives. . . . . . . . . .699
1. Long-Term Medical Therapy. . . . . . . . . . . . . . . . . . . . . .700
B. Postdischarge Risk Assessment and
Follow-Up . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .700
C. Risk Factor Modification . . . . . . . . . . . . . . . . . . . . . . . . . . .700
D. Physical Activity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .700
E. Cardiac Rehabilitation . . . . . . . . . . . . . . . . . . . . . . . . . . . . .701
F. Return to Work and Disability . . . . . . . . . . . . . . . . . . . . .701
G. Other Activities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .701
H. Patient Records and Other Information
Systems . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .701
II. Special Groups . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .701
A. Women. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .701
1. Profile of UA/NSTEMI in Women . . . . . . . . . . . . . . .701
2. Stress Testing. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .701
3. Management . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .702
A. PHARMACOLOGICAL THERAPY . . . . . . . . . . . . . . . . . . . . . . . . .702
B. CORONARY ARTERY REVASCULARIZATION . . . . . . . . . . . . . . . .702
C. INITIAL INVASIVE VERSUS INITIAL CONSERVATIVE STRATEGY. . . . .702
AA
P
I
r
a
d
R
m
p
t
o
f
a
e
c
C
w
f
t
p
i
w
s
d
654 Anderson et al. JACC Vol. 50, No. 7, 2007
ACC/AHA UA/NSTEMI Guideline Revision August 14, 2007:652–726B. Diabetes Mellitus. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .702
1. Profile and Initial Management of Diabetic and
Hyperglycemic Patients With UA/NSTEMI . . . . . .702
2. Coronary Revascularization . . . . . . . . . . . . . . . . . . . . . . . .702
C. Post-CABG Patients . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .703
1. Pathological Findings . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .703
2. Clinical Findings and Approach . . . . . . . . . . . . . . . . . . .703
D. Older Adults . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .703
1. Pharmacological Management . . . . . . . . . . . . . . . . . . . . .703
2. Functional Studies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .704
3. Contemporary Revascularization Strategies in
Older Patients . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .704
E. Chronic Kidney Disease. . . . . . . . . . . . . . . . . . . . . . . . . . . .704
F. Cocaine and Methamphetamine Users . . . . . . . . . . .704ata and write guidelines. The process includes additional
r
g
c
t
o
o
m
i
c
e
c
a
p
m
c
i
C
m
a
s
i
e
t
m
r
r2. Treatment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .704
3. Methamphetamine Use and UA/NSTEMI . . . . . . . .705
G. Variant (Prinzmetal’s) Angina . . . . . . . . . . . . . . . . . . . . .705
1. Clinical Picture, Pathogenesis, and Diagnosis. . . . . .705
2. Treatment and Prognosis . . . . . . . . . . . . . . . . . . . . . . . . . .705
H. Cardiovascular “Syndrome X” . . . . . . . . . . . . . . . . . . . .705
1. Definition and Clinical Picture . . . . . . . . . . . . . . . . . . . .705
2. Treatment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .705
ppendix 1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .706
ppendix 2 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .7111. Pathophysiology and Presentation . . . . . . . . . . . . . . . . .704
References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .716
ACC/AHA
Task
Force
Members
Sidney C. Smith, JR, MD, FACC, FAHA,
Chair
Alice K. Jacobs, MD, FACC, FAHA, Vice-Chair
Cynthia D. Adams, RN, PHD, FAHA
Jeffrey L. Anderson, MD, FACC, FAHA
Elliot M. Antman, MD, FACC, FAHA¶
Jonathan L. Halperin, MD, FACC, FAHA
Sharon A. Hunt, MD, FACC, FAHA
Harlan M. Krumholz, MD, FACC, FAHA
Frederick G. Kushner, MD, FACC, FAHA
Bruce W. Lytle, MD, FACC, FAHA
Rick Nishimura, MD, FACC, FAHA
Joseph P. Ornato, MD, FACC, FAHA**
Richard L. Page, MD, FACC, FAHA
Barbara Riegel, DNSC, RN, FAHA
¶Immediate Past Chair; **Former Task Force member during this
writing effortreamble
t is important that the medical profession play a significant
ole in critically evaluating the use of diagnostic procedures
nd therapies as they are introduced and tested in the
etection, management, or prevention of disease states.
igorous and expert analysis of the available data docu-
enting absolute and relative benefits and risks of those
rocedures and therapies can produce helpful guidelines
hat improve the effectiveness of care, optimize patient
utcomes, and favorably affect the overall cost of care by
ocusing resources on the most effective strategies.
The American College of Cardiology Foundation (ACCF)
nd the American Heart Association (AHA) have jointly
ngaged in the production of such guidelines in the area of
ardiovascular disease since 1980. The American College of
ardiology (ACC)/AHA Task Force on Practice Guidelines,
hose charge is to develop, update, or revise practice guidelines
or important cardiovascular diseases and procedures, directs
his effort. Writing committees are charged with the task of
erforming an assessment of the evidence and acting as an
ndependent group of authors to develop, update, or revise
ritten recommendations for clinical practice.
Experts in the subject under consideration have been
elected from both organizations to examine subject-specificepresentatives from other medical practitioner and specialty
roups when appropriate. Writing committees are specifi-
ally charged to perform a formal literature review, weigh
he strength of evidence for or against a particular treatment
r procedure, and include estimates of expected health
utcomes where data exist. Patient-specific modifiers, co-
orbidities and issues of patient preference that might
nfluence the choice of particular tests or therapies are
onsidered as well as frequency of follow-up and cost-
ffectiveness. When available, information from studies on
ost will be considered; however, review of data on efficacy
nd clinical outcomes will constitute the primary basis for
reparing recommendations in these guidelines.
The ACC/AHA Task Force on Practice Guidelines
akes every effort to avoid any actual, potential, or per-
eived conflict of interest that may arise as a result of an
ndustry relationship or personal interest of the Writing
ommittee. Specifically, all members of the Writing Com-
ittee, as well as peer reviewers of the document, were
sked to provide disclosure statements of all such relation-
hips that may be perceived as real or potential conflicts of
nterest. Writing Committee members are also strongly
ncouraged to declare a previous relationship with industry
hat might be perceived as relevant to guideline develop-
ent. If a Writing Committee member develops a new
elationship with industry during their tenure, they are
equired to notify guideline staff in writing. The continued
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eviewed. These statements are reviewed by the parent task
orce, reported orally to all members of the Writing Com-
ittee at each meeting, and updated and reviewed by the
riting Committee as changes occur. Please refer to the
ethodology manual for ACC/AHA Guideline Writing
ommittees for further description of the relationships with
ndustry policy, available on ACC and AHA World Wide
eb sites (http://www.acc.org/clinical/manual/manual_
ntroltr.htm and http://circ.ahajournals.org/manual/). Please
ee Appendix 1 for author relationships with industry and
ppendix 2 for peer reviewer relationships with industry
hat are pertinent to these guidelines.
These practice guidelines are intended to assist health care
roviders in clinical decision making by describing a range of
enerally acceptable approaches for the diagnosis, management
nd prevention of specific diseases or conditions. Clinical
ecision making should consider the quality and availability of
xpertise in the area where care is provided. These guidelines
ttempt to define practices that meet the needs of most patients
n most circumstances. These guideline recommendations
eflect a consensus of expert opinion after a thorough review of
he available, current scientific evidence and are intended to
mprove patient care.
Patient adherence to prescribed and agreed upon medical
egimens and lifestyles is an important aspect of treatment.
rescribed courses of treatment in accordance with these
ecommendations will only be effective if they are followed.
ince lack of patient understanding and adherence may ad-
ersely affect treatment outcomes, physicians and other health
are providers should make every effort to engage the patient in
ctive participation with prescribed medical regimens and
ifestyles.
If these guidelines are used as the basis for regulatory/payer
ecisions, the ultimate goal is quality of care and serving the
atient’s best interests. The ultimate judgment regarding care
f a particular patient must be made by the health care provider
nd the patient in light of all of the circumstances presented by
hat patient. There are circumstances in which deviations from
hese guidelines are appropriate.
The guidelines will be reviewed annually by the ACC/AHA
ask Force on Practice Guidelines and will be considered
urrent unless they are updated, revised, or sunsetted and
ithdrawn from distribution. The executive summary and
ecommendations are published in the August 14, 2007, issue
f the Journal of the American College of Cardiology and the
ugust 14, 2007, issue of Circulation. The full-text guidelines
re e-published in the same issue of the journals noted above,
s well as posted on the ACC (www.acc.org) and AHA
www.americanheart.org) World Wide Web sites. Copies of
he full text and the executive summary are available from both
rganizations.
Sidney C. Smith, Jr., MD, FACC, FAHA
Chair, ACC/AHA Task Force on Practice Guidelines n. Introduction
. Organization of Committee and Evidence Review
he ACC/AHA Task Force on Practice Guidelines was
ormed to make recommendations regarding the diagnosis
nd treatment of patients with known or suspected cardio-
ascular disease. Coronary artery disease (CAD) is the
eading cause of death in the United States. Unstable angina
UA) and the closely related condition of non–ST-segment
levation myocardial infarction (NSTEMI) are very com-
on manifestations of this disease.
The committee members reviewed and compiled pub-
ished reports through a series of computerized literature
earches of the English-language literature since 2002 and a
nal manual search of selected articles. Details of the
pecific searches conducted for particular sections are pro-
ided when appropriate. Detailed evidence tables were
eveloped whenever necessary with the specific criteria
utlined in the individual sections. The recommendations
ade were based primarily on these published data. The
eight of the evidence was ranked highest (A) to lowest
C). The final recommendations for indications for a diag-
ostic procedure, a particular therapy, or an intervention in
atients with UA/NSTEMI summarize both clinical evi-
ence and expert opinion.
lassification of Recommendations
he schema for classification of recommendations and level
f evidence is summarized in Table 1, which also illustrates
ow the grading system provides an estimate of the size of
he treatment effect and an estimate of the certainty of the
reatment effect.
The Writing Committee consisted of acknowledged
xperts in general internal medicine representing the Amer-
can College of Physicians, family medicine from the Amer-
can Academy of Family Physicians, emergency medicine
rom the American College of Emergency Physicians,
horacic surgery from the Society of Thoracic Surgeons,
nterventional cardiology from the Society for Cardiovascu-
ar Angiography and Interventions (SCAI), and general and
ritical care cardiology, as well as individuals with recog-
ized expertise in more specialized areas, including nonin-
asive testing, preventive cardiology, coronary intervention,
nd cardiovascular surgery. Both the academic and private
ractice sectors were represented. This document was re-
iewed by 2 outside reviewers nominated by each of the
CC and AHA.
. Changes Since Publication
f These Guidelines in 2002
he writing committee considered evidence published since
002 and drafted revised recommendations to incorporate
esults from major clinical trials. The text has been reorga-
ized and rewritten to reflect these developments. Greater
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ACC/AHA UA/NSTEMI Guideline Revision August 14, 2007:652–726mphasis is placed on earlier access to medical evaluation of
he acute coronary syndrome (ACS) patient, including
voidance of delays inherent in patient self-medication, as
ell as facilitated emergency department (ED) diagnosis
nd triage. New imaging tests (cardiac magnetic resonance
maging and coronary computed tomographic [CT] angiog-
aphy) have emerged as diagnostic options in selected
atients. Troponins have become the dominant cardiac
iomarker of necrosis, have redefined NSTEMI, and have
hanged its demographics and prognosis. B-type natriuretic
eptide (BNP) now may be added to the list of biomarkers
hat are potentially useful in risk assessment. Clinical trials
ata continue to build support for an initial invasive strategy
or higher-risk UA/NSTEMI patients (as assessed by tro-
onin positivity or a formal risk score); in contrast, such a
trategy is not of benefit and may be harmful in low-risk
able 1. Applying Classification of Recommendations and Leve
Data available from clinical trials or registries about the usefulness/efficacy in different subpopu
ailure, and prior aspirin use. A recommendation with Level of Evidence B or C does not imply th
end themselves to clinical trials. Even though randomized trials are not available, there may b
CC/AHA Task Force on Practice Guidelines developed a list of suggested phrases to use when wr
complete thought, such that a recommendation, even if separated and presented apart from
ull intent of the recommendation. It is hoped that this will increase readers’ comprehension ofomen, in whom an initially conservative strategy is rec- pmmended. Two new anticoagulants, fondaparinux and
ivalirudin, have undergone favorable testing in clinical
rials and are recommended as alternatives to unfractionated
eparin (UFH) and low-molecular-weight heparins (LM-
Hs) for specific or more general applications. Support for
hienopyridine use (primarily with clopidogrel) continues to
row, including higher loading-dose options, earlier (up-
tream) administration, and longer administration (espe-
ially after drug-eluting stent placement). The question of
ow best to integrate thienopyridine use with parenteral
lycoprotein (GP) IIb/IIIa antagonists to provide optimal
ntiplatelet therapy early in the course of UA/NSTEMI
herapy, including cardiac catheterization, is an evolving
ubject and continues to present a challenge. These guide-
ines incorporate changes based on recent updates for
ercutaneous coronary intervention (PCI) and for secondary
vidence†
, such as gender, age, history of diabetes, history of prior myocardial infarction, history of heart
ecommendation is weak. Many important clinical questions addressed in the guidelines do not
y clear clinical consensus that a particular test or therapy is useful or effective. †In 2003, the
commendations. All guideline recommendations have been written in full sentences that express
t of the document (including headings above sets of recommendations), would still convey the
idelines and will allow queries at the individual recommendation level.l of E
lations
at the r
e a ver
iting rerevention as they impact patients with UA/NSTEMI. An
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eed to highlight specific diagnostic and therapeutic con-
iderations in patients with diverse characteristics. Care
rocesses are highlighted as another area important to
atient outcomes. These and other developments and ad-
ances also highlight important knowledge and treatment
aps, which should stimulate continued progress in UA/
STEMI through research and clinical application.
. Purpose of These Guidelines
hese guidelines address the diagnosis and management of
atients with UA and the closely related condition of
STEMI. These potentially life-threatening disorders are a
ajor cause of emergency medical care and hospitalization
n the United States. In 2004, the National Center for
ealth Statistics reported 1,565,000 hospitalizations for
rimary or secondary diagnosis of an ACS, 669,000 for UA
nd 896,000 for myocardial infarction (MI) (1). These
uidelines are intended to assist both cardiovascular special-
sts and nonspecialists in the proper evaluation and man-
gement of patients with an acute onset of symptoms
uggestive of these conditions. These clinical practice guide-
ines also provide recommendations and supporting evi-
ence for the continued management of patients with these
onditions in both inpatient and outpatient settings.
. Recommendations for
anagement of Patients With UA/NSTEMI
lassification of recommendations and level of evidence are
xpressed in the ACC/AHA format as described above and in
able 1. Recommendations are evidence-based and derived
rimarily from published data. The reader is referred to the
ull-text guidelines for a complete description of the rationale
nd evidence supporting these recommendations.
RECOMMENDATIONS
. Identification of Patients at Risk of UA/NSTEMI
LASS I
. Primary care providers should evaluate the presence and status of
control of major risk factors for coronary heart disease (CHD) for all
patients at regular intervals (approximately every 3 to 5 years).
(Level of Evidence: C)
. Ten-year risk (National Cholesterol Education Program global risk)
of developing symptomatic CHD should be calculated for all pa-
tients who have 2 or more major risk factors to assess the need for
primary prevention strategies (2,3). (Level of Evidence: B)
. Patients with established CHD should be identified for secondary
prevention efforts, and patients with a CHD risk equivalent (e.g.,
atherosclerosis in other vascular beds, diabetes mellitus, chronic
kidney disease, or 10-year risk greater than 20% as calculated by
Framingham equations) should receive equally intensive risk factor
intervention as those with clinically apparent CHD. (Level of Evi-dence: A). Initial Evaluation and Management
. CLINICAL ASSESSMENT
LASS I
. Patients with symptoms that may represent ACS (Table 2) should
not be evaluated solely over the telephone but should be referred to
a facility that allows evaluation by a physician and the recording of
a 12-lead ECG and biomarker determination (e.g., an ED or other
acute care facility). (Level of Evidence: C)
. Patients with symptoms of ACS (chest discomfort with or without
radiation to the arm[s], back, neck, jaw, or epigastrium; short-
ness of breath; weakness; diaphoresis; nausea; lightheadedness)
should be instructed to call 9-1-1 and should be transported to
the hospital by ambulance rather than by friends or relatives.
(Level of Evidence: B)
. Health care providers should actively address the following issues
regarding ACS with patients with or at risk for CHD and their families
or other responsible caregivers:
a. The patient’s heart attack risk; (Level of Evidence: C)
b. How to recognize symptoms of ACS; (Level of Evidence: C)
c. The advisability of calling 9-1-1 if symptoms are unimproved or
worsening after 5 min, despite feelings of uncertainty about the
symptoms and fear of potential embarrassment; (Level of Evi-
dence: C)
d. A plan for appropriate recognition and response to a potential
acute cardiac event, including the phone number to access
emergency medical services (EMS), generally 9-1-1 (4). (Level of
Evidence: C)
. Prehospital EMS providers should administer 162 to 325 mg of
aspirin (ASA; chewed) to chest pain patients suspected of having
ACS unless contraindicated or already taken by the patient. Al-
though some trials have used enteric-coated ASA for initial dosing,
more rapid buccal absorption occurs with non–enteric-coated for-
mulations. (Level of Evidence: C)
. Health care providers should instruct patients with suspected ACS
for whom nitroglycerin (NTG) has been prescribed previously to take
not more than 1 dose of NTG sublingually in response to chest
discomfort/pain. If chest discomfort/pain is unimproved or is wors-
ening 5 min after 1 NTG dose has been taken, it is recommended
that the patient or family member/friend/caregiver call 9-1-1 im-
mediately to access EMS before taking additional NTG. In patients
with chronic stable angina, if symptoms are significantly improved
by 1 dose of NTG, it is appropriate to instruct the patient or family
member/friend/caregiver to repeat NTG every 5 min for a maxi-
mum of 3 doses and call 9-1-1 if symptoms have not resolved
completely. (Level of Evidence: C)
. Patients with a suspected ACS with chest discomfort or other
ischemic symptoms at rest for greater than 20 min, hemodynamic
instability, or recent syncope or presyncope should be referred
immediately to an ED. Other patients with a suspected ACS who are
experiencing less severe symptoms and who have none of the
above high-risk features, including those who respond to an NTG
dose, may be seen initially in an ED or an outpatient facility able to
provide an acute evaluation. (Level of Evidence: C)
LASS IIa
. It is reasonable for health care providers and 9-1-1 dispatchers to
advise patients without a history of ASA allergy who have symptoms
of ACS to chew ASA (162 to 325 mg) while awaiting arrival of
prehospital EMS providers. Although some trials have used enteric-
23
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with non–enteric-coated formulations. (Level of Evidence: B)
. It is reasonable for health care providers and 9-1-1 dispatchers to
advise patients who tolerate NTG to repeat NTG every 5 min for a
maximum of 3 doses while awaiting ambulance arrival. (Level of
Evidence: C)
. It is reasonable that all prehospital EMS providers perform and
evaluate 12-lead electrocardiograms (ECGs) in the field (if available)
on chest pain patients suspected of ACS to assist in triage decisions.
Electrocardiographs with validated computer-generated interpreta-
tion algorithms are recommended for this purpose. (Level of Evi-
dence: B)
. If the 12-lead ECG shows evidence of acute injury or ischemia, it is
reasonable that prehospital ACLS providers relay the ECG to a
predetermined medical control facility and/or receiving hospital.
(Level of Evidence: B)
. EARLY RISK STRATIFICATION
LASS I
. A rapid clinical determination of the likelihood risk of obstructive
CAD (i.e., high, intermediate, or low) should be made in all patients
with chest discomfort or other symptoms suggestive of an ACS and
considered in patient management. (Level of Evidence: C)
. Patients who present with chest discomfort or other ischemic
symptoms should undergo early risk stratification for the risk of
cardiovascular events (e.g., death or [re]MI) that focuses on history,
including anginal symptoms, physical findings, ECG findings, and
biomarkers of cardiac injury and results should be considered in
patient management. (Level of Evidence: C)
. A 12-lead ECG should be performed and shown to an experienced
emergency physician as soon as possible after ED arrival, with a
goal of within 10 min of ED arrival for all patients with chest
discomfort (or anginal equivalent) or other symptoms suggestive of
ACS. (Level of Evidence: B)
. If the initial ECG is not diagnostic but the patient remains symptom-
atic and there is high clinical suspicion for ACS, serial ECGs, initially
at 15- to 30-min intervals, should be performed to detect the
potential for development of ST-segment elevation or depression.
(Level of Evidence: B)
. Cardiac biomarkers should be measured in all patients who present
with chest discomfort consistent with ACS. (Level of Evidence: B)
. A cardiac-specific troponin is the preferred marker, and if available,
it should be measured in all patients who present with chest
discomfort consistent with ACS. (Level of Evidence: B)
. Patients with negative cardiac biomarkers within 6 h of the onset of
symptoms consistent with ACS should have biomarkers remea-
sured in the time frame of 8 to 12 h after symptom onset. (The exact
timing of serummarker measurement should take into account the
uncertainties often present with the exact timing of onset of pain
and the sensitivity, precision, and institutional norms of the assay
being utilized as well as the release kinetics of the marker being
measured.) (Level of Evidence: B)
. The initial evaluation of the patient with suspected ACS should
include the consideration of noncoronary causes for the develop-
ment of unexplained symptoms. (Level of Evidence: C)
LASS IIa
. Use of risk-stratification models, such as the Thrombolysis In Myo-
cardial Infarction (TIMI) or Global Registry of Acute Coronary Events
(GRACE) risk score or the Platelet Glycoprotein IIb/IIIa in UnstableAngina: Receptor Suppression Using Integrilin Therapy (PURSUIT)
risk model, can be useful to assist in decision making with regard to
treatment options in patients with suspected ACS. (Level of Evi-
dence: B)
. It is reasonable to remeasure positive biomarkers at 6- to 8-h
intervals 2 to 3 times or until levels have peaked, as an index of
infarct size and dynamics of necrosis. (Level of Evidence: B)
. It is reasonable to obtain supplemental ECG leads V7 through V9 in
patients whose initial ECG is nondiagnostic to rule out MI due to left
circumflex occlusion. (Level of Evidence: B)
. Continuous 12-lead ECG monitoring is a reasonable alternative to
serial 12-lead recordings in patients whose initial ECG is nondiag-
nostic. (Level of Evidence: B)
LASS IIb
. For patients who present within 6 h of the onset of symptoms
consistent with ACS, assessment of an early marker of cardiac
injury (e.g., myoglobin) in conjunction with a late marker (e.g.,
troponin) may be considered. (Level of Evidence: B)
. For patients who present within 6 h of symptoms suggestive of ACS,
a 2-h delta CK-MB mass in conjunction with 2-h delta troponin may
be considered. (Level of Evidence: B)
. For patients who present within 6 h of symptoms suggestive of ACS,
myoglobin in conjunction with CK-MB mass or troponin when mea-
sured at baseline and 90 min may be considered. (Level of Evi-
dence: B)
. Measurement of BNP or NT-pro-BNP may be considered to supple-
ment assessment of global risk in patients with suspected ACS.
(Level of Evidence: B)
LASS III
otal CK (without MB), aspartate aminotransferase (AST, SGOT), ala-
ine transaminase, beta-hydroxybutyric dehydrogenase, and/or lactate
ehydrogenase should not be utilized as primary tests for the detection
f myocardial injury in patients with chest discomfort suggestive of
CS. (Level of Evidence: C)
. IMMEDIATE MANAGEMENT
LASS I
. The history, physical examination, 12-lead ECG, and initial cardiac
biomarker tests should be integrated to assign patients with chest
pain into 1 of 4 categories: a noncardiac diagnosis, chronic stable
angina, possible ACS, and definite ACS. (Level of Evidence: C)
. Patients with probable or possible ACS but whose initial 12-lead
ECG and cardiac biomarker levels are normal should be observed in
a facility with cardiac monitoring (e.g., chest pain unit or hospital
telemetry ward), and repeat ECG (or continuous 12-lead ECG mon-
itoring) and repeat cardiac biomarker measurement(s) should be
obtained at predetermined, specified time intervals (see Section
III.B). (Level of Evidence: B)
. In patients with suspected ACS in whom ischemic heart disease is
present or suspected, if the follow-up 12-lead ECG and cardiac
biomarkers measurements are normal, a stress test (exercise or
pharmacological) to provoke ischemia should be performed in the
ED, in a chest pain unit, or on an outpatient basis in a timely fashion
(within 72 h) as an alternative to inpatient admission. Low-risk
patients with a negative diagnostic test can be managed as outpa-
tients. (Level of Evidence: C)
. In low-risk patients who are referred for outpatient stress testing
(see above), precautionary appropriate pharmacotherapy (e.g., ASA,
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August 14, 2007:652–726 ACC/AHA UA/NSTEMI Guideline Revisionsublingual NTG, and/or beta blockers) should be given while await-
ing results of the stress test. (Level of Evidence: C)
. Patients with definite ACS and ongoing ischemic symptoms, posi-
tive cardiac biomarkers, new ST-segment deviations, new deep
T-wave inversions, hemodynamic abnormalities, or a positive stress
test should be admitted to the hospital for further management.
Admission to the critical care unit is recommended for those with
active, ongoing ischemia/injury and hemodynamic or electrical
instability. Otherwise, a telemetry step-down unit is reasonable.
(Level of Evidence: C)
. Patients with possible ACS and negative cardiac biomarkers who
are unable to exercise or who have an abnormal resting ECG should
undergo a pharmacological stress test. (Level of Evidence: B)
. Patients with definite ACS and ST-segment elevation in leads V7 to
V9 due to left circumflex should be evaluated for immediate reper-
fusion therapy. (Level of Evidence: A)
. Patients discharged from the ED or chest pain unit should be given
specific instructions for activity, medications, additional testing, and
follow-up with a personal physician. (Level of Evidence: C)
LASS IIa
n patients with suspected ACS with a low or intermediate probability of
AD, in whom the follow-up 12-lead ECG and cardiac biomarker
easurements are normal, performance of a noninvasive coronary
maging test (i.e., coronary CT angiography) is reasonable as an alter-
ative to stress testing. (Level of Evidence: B)
. Early Hospital Care
. ANTI-ISCHEMIC AND ANALGESIC THERAPY
LASS I
. Bed/chair rest with continuous ECGmonitoring is recommended for
all UA/NSTEMI patients during the early hospital phase. (Level of
Evidence: C)
. Supplemental oxygen should be administered to patients with
UA/NSTEMI with an arterial saturation less than 90%, respiratory
distress, or other high-risk features for hypoxemia. (Pulse oxim-
etry is useful for continuous measurement of SaO2.) (Level of
Evidence: B)
. Patients with UA/NSTEMI with ongoing ischemic discomfort should
receive sublingual NTG (0. 4 mg) every 5 min for a total of 3 doses,
after which assessment should be made about the need for intra-
venous NTG, if not contraindicated. (Level of Evidence: C)
. Intravenous NTG is indicated in the first 48 h after UA/NSTEMI for
treatment of persistent ischemia, heart failure (HF), or hyperten-
sion. The decision to administer intravenous NTG and the dose used
should not preclude therapy with other proven mortality-reducing
interventions such as beta blockers or angiotensin-converting en-
zyme (ACE) inhibitors. (Level of Evidence: B)
. Oral beta-blocker therapy should be initiated within the first 24 h for
patients who do not have 1 or more of the following: 1) signs of HF,
2) evidence of a low-output state, 3) increased risk* for cardiogenic
shock, or 4) other relative contraindications to beta blockade (PR
interval greater than 0.24 s, second or third degree heart block,
active asthma, or reactive airway disease). (Level of Evidence: B)
Risk factors for cardiogenic shock (the greater the number of risk factors present, the
igher the risk of developing cardiogenic shock): age greater than 70 years, systolic
lood pressure less than 120 mm Hg, sinus tachycardia greater than 110 or heart rate
ess than 60, increased time since onset of symptoms of UA/NSTEMI.. In UA/NSTEMI patients with continuing or frequently recurring isch-
emia and in whom beta blockers are contraindicated, a nondihydro-
pyridine calcium channel blocker (e.g., verapamil or diltiazem)
should be given as initial therapy in the absence of clinically
significant left ventricular (LV) dysfunction or other contraindica-
tions. (Level of Evidence: B)
. An ACE inhibitor should be administered orally within the first 24 h
to UA/NSTEMI patients with pulmonary congestion or LV ejection
fraction (LVEF) less than or equal to 0.40, in the absence of
hypotension (systolic blood pressure less than 100 mm Hg or less
than 30 mm Hg below baseline) or known contraindications to that
class of medications. (Level of Evidence: A)
. An angiotensin receptor blocker should be administered to UA/
NSTEMI patients who are intolerant of ACE inhibitors and have
either clinical or radiological signs of HF or LVEF less than or equal
to 0.40. (Level of Evidence: A)
. Because of the increased risks of mortality, reinfarction, hyperten-
sion, HF, and myocardial rupture associated with their use, nonste-
roidal anti-inflammatory drugs (NSAIDs), except for ASA, whether
nonselective or cyclooxygenase (COX)-2–selective agents, should be
discontinued at the time a patient presents with UA/NSTEMI. (Level
of Evidence: C)
LASS IIa
. It is reasonable to administer supplemental oxygen to all patients
with UA/NSTEMI during the first 6 h after presentation. (Level of
Evidence: C)
. In the absence of contradictions to its use, it is reasonable to
administer morphine sulfate intravenously to UA/NSTEMI patients if
there is uncontrolled ischemic chest discomfort despite NTG, pro-
vided that additional therapy is used to manage the underlying
ischemia. (Level of Evidence: B)
. It is reasonable to administer intravenous (IV) beta blockers at the
time of presentation for hypertension to UA/NSTEMI patients who
do not have 1 or more of the following: 1) signs of HF, 2) evidence of
a low-output state, 3) increased risk* for cardiogenic shock, or 4)
other relative contraindications to beta blockade (PR interval
greater than 0.24 s, second or third degree heart block, active
asthma, or reactive airway disease). (Level of Evidence: B)
. Oral long-acting nondihydropyridine calcium antagonists are rea-
sonable for use in UA/NSTEMI patients for recurrent ischemia in the
absence of contraindications after beta blockers and nitrates have
been fully used. (Level of Evidence: C)
. An ACE inhibitor administered orally within the first 24 h of UA/
NSTEMI can be useful in patients without pulmonary congestion or
LVEF less than or equal to 0.40 in the absence of hypotension
(systolic blood pressure less than 100 mm Hg or less than
30 mm Hg below baseline) or known contraindications to that class
of medications. (Level of Evidence: B)
. Intra-aortic balloon pump counterpulsation is reasonable in UA/
NSTEMI patients for severe ischemia that is continuing or recurs
frequently despite intensive medical therapy, for hemodynamic
instability in patients before or after coronary angiography, and for
mechanical complications of MI. (Level of Evidence: C)
LASS IIb
. The use of extended-release forms of nondihydropyridine calcium
antagonists instead of a beta blocker may be considered in patientswith UA/NSTEMI. (Level of Evidence: B)
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ence of adequate beta blockade may be considered in patients with
UA/NSTEMI with ongoing ischemic symptoms or hypertension.
(Level of Evidence: B)
LASS III
. Nitrates should not be administered to UA/NSTEMI patients with
systolic blood pressure less than 90 mm Hg or greater than or equal
to 30 mm Hg below baseline, severe bradycardia (less than 50
beats per min), tachycardia (more than 100 beats per min) in the
absence of symptomatic HF, or right ventricular infarction. (Level of
Evidence: C)
. Nitroglycerin or other nitrates should not be administered to pa-
tients with UA/NSTEMI who had received a phosphodiesterase
inhibitor for erectile dysfunction within 24 h of sildenafil or 48 h of
tadalafil use. The suitable time for the administration of nitrates
after vardenafil has not been determined. (Level of Evidence: C)
. Immediate-release dihydropyridine calcium antagonists should not
be administered to patients with UA/NSTEMI in the absence of a
beta blocker. (Level of Evidence: A)
. An intravenous ACE inhibitor should not be given to patients within
the first 24 h of UA/NSTEMI because of the increased risk of
hypotension. (A possible exception may be patients with refractory
hypertension.) (Level of Evidence: B)
. It may be harmful to administer IV beta blockers to UA/NSTEMI
patients who have contraindications to beta blockade, signs of HF or
low-output state, or other risk factors* for cardiogenic shock. (Level
of Evidence: A)
. Nonsteroidal anti-inflammatory drugs (except for ASA), whether
nonselective or COX-2--selective agents, should not be administered
during hospitalization for UA/NSTEMI because of the increased risks
of mortality, reinfarction, hypertension, HF, and myocardial rupture
associated with their use. (Level of Evidence: C)
. ANTIPLATELET/ANTICOAGULANT THERAPY IN PATIENTS FOR WHOM
IAGNOSIS OF UA/NSTEMI IS LIKELY OR DEFINITE
ecommendations are written as the reader follows through
he algorithm for Antiplatelet/Anticoagulant Therapy and
riage for Angiography (Figs. 6, 7, and 8). Letters after
ecommendations refer to the specific box in the algorithm.
ee Table 6 for dosing recommendations.
. ANTIPLATELET THERAPY
LASS I
1. Aspirin should be administered to UA/NSTEMI patients as soon as
possible after hospital presentation and continued indefinitely in
patients not known to be intolerant of that medication. (Level of
Evidence: A) (Figs. 6 and 7; Box A)
2. Clopidogrel (loading dose followed by daily maintenance dose)†
should be administered to UA/NSTEMI patients who are unable to
Risk factors for cardiogenic shock (the greater the number of risk factors present, the
igher the risk of developing cardiogenic shock): age greater than 70 years, systolic
lood pressure less than 120 mm Hg, sinus tachycardia greater than 110 or heart rate
ess than 60, increased time since onset of symptoms of UA/NSTEMI.
Some uncertainty exists about optimum dosing of clopidogrel. Randomized trials
stablishing its efficacy and providing data on bleeding risks used a loading dose of 300
g orally followed by a daily oral maintenance dose of 75 mg. Higher oral loading
oses such as 600 or 900 mg of clopidogrel more rapidly inhibit platelet aggregation
nd achieve a higher absolute level of inhibition of platelet aggregation, but the
dditive clinical efficacy and the safety of higher oral loading doses have not been
igorously established.
i
dtake ASA because of hypersensitivity or major gastrointestinal
intolerance. (Level of Evidence: A) (Figs. 6 and 7; Box A)
3. In UA/NSTEMI patients with a history of gastrointestinal bleeding,
when ASA and clopidogrel are administered alone or in combina-
tion, drugs to minimize the risk of recurrent gastrointestinal bleed-
ing (e.g., proton-pump inhibitors) should be prescribed concomi-
tantly. (Level of Evidence: B)
4. For UA/NSTEMI patients in whom an initial invasive strategy is
selected, antiplatelet therapy in addition to aspirin should be
initiated before diagnostic angiography (upstream) with either clo-
pidogrel (loading dose followed by daily maintenance dose)† or an
IV GP IIb/IIIa inhibitor. (Level of Evidence: A) Abciximab as the
choice for upstream GP IIb/IIIa therapy is indicated only if there is
no appreciable delay to angiography and PCI is likely to be per-
formed; otherwise, IV eptifibatide or tirofiban is the preferred choice
of GP IIb/IIIa inhibitor. (Level of Evidence: B)
5. For UA/NSTEMI patients in whom an initial conservative (i.e.,
noninvasive) strategy is selected (see Section IV.C), clopidogrel
(loading dose followed by daily maintenance dose)† should be
added to ASA and anticoagulant therapy as soon as possible after
admission and administered for at least 1month (Level of Evidence: A)
and ideally up to 1 year. (Level of Evidence: B) (Fig. 7; Box C2)
6. For UA/NSTEMI patients in whom an initial conservative strategy is
selected, if recurrent symptoms/ischemia, HF, or serious arrhyth-
mias subsequently appear, then diagnostic angiography should be
performed (Level of Evidence: A) (Fig. 7; Box D). Either an IV GP
IIb/IIIa inhibitor (eptifibatide or tirofiban; Level of Evidence: A) or
clopidogrel (loading dose followed by daily maintenance dose;
Level of Evidence: A)† should be added to ASA and anticoagulant
therapy before diagnostic angiography (upstream). (Level of Evi-
dence: C)
LASS IIa
. For UA/NSTEMI patients in whom an initial conservative strategy is
selected and who have recurrent ischemic discomfort with clopi-
dogrel, ASA, and anticoagulant therapy, it is reasonable to add a GP
IIb/IIIa antagonist before diagnostic angiography. (Level of Evi-
dence: C)
. For UA/NSTEMI patients in whom an initial invasive strategy is
selected, it is reasonable to initiate antiplatelet therapy with both
clopidogrel (loading dose followed by daily maintenance dose)† and
an IV GP IIb/IIIa inhibitor (Level of Evidence: B). Abciximab as the
choice for upstream GP IIb/IIIa therapy is indicated only if there is
no appreciable delay to angiography and PCI is likely to be per-
formed; otherwise, IV eptifibatide or tirofiban is the preferred choice
of GP IIb/IIIa inhibitor.‡ (Level of Evidence: B)
. For UA/NSTEMI patients in whom an initial invasive strategy is
selected, it is reasonable to omit upstream administration of an IV
GP IIb/IIIa antagonist before diagnostic angiography if bivalirudin is
selected as the anticoagulant and at least 300 mg of clopidogrel
was administered at least 6 h earlier than planned catheterization
or PCI. (Level of Evidence: B)
LASS IIb
or UA/NSTEMI patients in whom an initial conservative (i.e., noninva-
ive) strategy is selected, it may be reasonable to add eptifibatide or
Factors favoring administration of both clopidogrel and GP IIa/IIb inhibitor
nclude: delay to angiography, high-risk features, and early recurrent ischemic
iscomfort.
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August 14, 2007:652–726 ACC/AHA UA/NSTEMI Guideline Revisionirofiban to anticoagulant and oral antiplatelet therapy. (Level of Evi-
ence: B) (Fig. 7; Box C2)
LASS III
bciximab should not be administered to patients in whom PCI is not
lanned. (Level of Evidence: A)
I. ANTICOAGULANT THERAPY
ecommendations are written as the reader follows through
he algorithm for Antiplatelet/Anticoagulant Therapy and
riage for Angiography (Figs. 6, 7, and 8). Letters after
ecommendations refer to the specific box in the algorithm.
ee Table 6 for dosing recommendations.
LASS I
nticoagulant therapy should be added to antiplatelet therapy in
A/NSTEMI patients as soon as possible after presentation.
. For patients in whom an invasive strategy is selected, regimens with
established efficacy at a Level of Evidence: A include enoxaparin and
UFH (Fig. 6; Box B1), and those with established efficacy at a Level of
Evidence: B include bivalirudin and fondaparinux (Fig. 7; Box B1).
. For patients in whom a conservative strategy is selected, regimens
using either enoxaparin* or UFH (Level of Evidence: A) or fondapa-
rinux (Level of Evidence: B) have established efficacy. (Fig. 8; Box
C1)* See also Class IIa recommendation below.
. In patients in whom a conservative strategy is selected and who
have an increased risk of bleeding, fondaparinux is preferable.
(Level of Evidence: B) (Fig. 7; Box C1)
LASS IIa
or UA/NSTEMI patients in whom an initial conservative strategy is
elected, enoxaparin* or fondaparinux is preferable to UFH as antico-
gulant therapy, unless coronary artery bypass graft surgery (CABG) is
lanned within 24 h. (Level of Evidence: B)
II. ADDITIONAL MANAGEMENT CONSIDERATIONS FOR ANTIPLATELET AND
NTICOAGULANT THERAPY
ecommendations are written as the reader follows through
he algorithm for Antiplatelet/Anticoagulant Therapy and
riage for Angiography (Figs. 6, 7, and 8). Letters after
ecommendations refer to the specific box in the algorithm.
ee Table 6 for dosing recommendations.
LASS I
1. For UA/NSTEMI patients in whom an initial conservative strategy is
selected and no subsequent features appear that would necessi-
tate diagnostic angiography (recurrent symptoms/ischemia, HF, or
serious arrhythmias), a stress test should be performed. (Level of
Evidence: B) (Fig. 7; Box O)
a. If, after stress testing, the patient is classified as not at low risk,
diagnostic angiography should be performed. (Level of Evi-
dence: A) (Fig. 7; Box E1)
b. If, after stress testing, the patient is classified as being at low
risk (Fig. 7; Box E2), the instructions noted below should be
followed in preparation for discharge (Fig. 7; Box K) (Level of
Evidence: A):
1. Continue ASA indefinitely. (Level of Evidence: A)
2. Continue clopidogrel for at least 1month (Level of Evidence:
A) and ideally up to 1 year. (Level of Evidence: B)Limited data are available for the use of other LMWHs (e.g., dalteparin; see Tables
and 7) in UA/NSTEMI.
a
r3. Discontinue IV GP IIb/IIIa inhibitor if started previously.
(Level of Evidence: A)
4. Continue UFH for 48 h or administer enoxaparin or fondapa-
rinux for the duration of hospitalization, up to 8 d, and then
discontinue anticoagulant therapy. (Level of Evidence: A)
2. For UA/NSTEMI patients in whom CABG is selected as a postan-
giography management strategy, the instructions noted below
should be followed (Fig. 8; Box G).
a. Continue ASA. (Level of Evidence: A)
b. Discontinue clopidogrel 5 to 7 d before elective CABG. (Level of
Evidence: B) More urgent surgery, if necessary, may be per-
formed by experienced surgeons if the incremental bleeding
risk is considered acceptable. (Level of Evidence: C)
c. Discontinue IV GP IIb/IIIa inhibitor (eptifibatide or tirofiban) 4 h
before CABG. (Level of Evidence: B)
d. Anticoagulant therapy should be managed as follows:
1. Continue UFH. (Level of Evidence: B)
2. Discontinue enoxaparin* 12 to 24 h before CABG and dose
with UFH per institutional practice. (Level of Evidence: B)
3. Discontinue fondaparinux 24 h before CABG and dose with
UFH per institutional practice. (Level of Evidence: B)
4. Discontinue bivalirudin 3 h before CABG and dose with UFH
per institutional practice. (Level of Evidence: B)
3. For UA/NSTEMI patients in whom PCI has been selected as a
postangiography management strategy, the instructions noted be-
low should be followed (Fig. 8 C; Box H):
a. Continue ASA. (Level of Evidence: A)
b. Administer a loading dose of clopidogrel† if not started before
diagnostic angiography. (Level of Evidence: A)
c. Administer an IV GP IIb/IIIa inhibitor (abciximab, eptifibatide, or
tirofiban) if not started before diagnostic angiography for
troponin-positive and other high-risk patients. (Level of Evi-
dence: A) See Class IIa recommendation below if bivalirudin
was selected as the anticoagulant.
d. Discontinue anticoagulant therapy after PCI for uncomplicated
cases. (Level of Evidence: B)
4. For UA/NSTEMI patients in whom medical therapy is selected as a
postangiography management strategy and in whom no significant
obstructive CAD on angiography was found, antiplatelet and anti-
coagulant therapy should be administered at the discretion of the
clinician. (Level of Evidence: C) For patients in whom evidence of
coronary atherosclerosis is present (e.g., luminal irregularities or
intravascular ultrasound--demonstrated lesions), albeit without
flow-limiting stenoses, long-term treatment with ASA and other
secondary prevention measures should be prescribed. (Fig. 8; Box I)
(Level of Evidence: C)
5. For UA/NSTEMI patients in whom medical therapy is selected as a
postangiography management strategy and in whom CAD was
found on angiography, the following approach is recommended
(Fig. 8; Box J):
a. Continue ASA. (Level of Evidence: A)
b. Administer a loading dose of clopidogrel† if not given before
diagnostic angiography. (Level of Evidence: A)
Some uncertainty exists about optimum dosing of clopidogrel. Randomized trials
stablishing its efficacy and providing data on bleeding risks used a loading dose of 300
g orally followed by a daily oral maintenance dose of 75 mg. Higher oral loading
oses such as 600 or 900 mg of clopidogrel more rapidly inhibit platelet aggregation
nd achieve a higher absolute level of inhibition of platelet aggregation, but the
dditive clinical efficacy and the safety of higher oral loading doses have not been
igorously established.
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Evidence: B)
d. Anticoagulant therapy should be managed as follows:
1. Continue IV UFH for at least 48 h or until discharge if given
before diagnostic angiography. (Level of Evidence: A)
2. Continue enoxaparin for duration of hospitalization, up to
8 d, if given before diagnostic angiography. (Level of Evi-
dence: A)
3. Continue fondaparinux for duration of hospitalization, up to
8 d, if given before diagnostic angiography. (Level of Evi-
dence: B)
4. Either discontinue bivalirudin or continue at a dose of 0.25mg
per kg per h for up to 72 h at the physician’s discretion, if given
before diagnostic angiography. (Level of Evidence: B)
6. For UA/NSTEMI patients in whom a conservative strategy is se-
lected and who do not undergo angiography or stress testing, the
instructions noted below should be followed (Fig. 7; Box K):
a. Continue ASA indefinitely. (Level of Evidence: A)
b. Continue clopidogrel for at least 1 month (Level of Evidence: A)
and ideally up to 1 year. (Level of Evidence: B)
c. Discontinue IV GP IIb/IIIa inhibitor it started previously. (Level of
Evidence: A)
d. Continue UFH for 48 h or administer enoxaparin or fondapa-
rinux for the duration of hospitalization, up to 8 d, and then
discontinue anticoagulant therapy. (Level of Evidence: A)
7. For UA/NSTEMI patients in whom an initial conservative strategy is
selected and in whom no subsequent features appear that would
necessitate diagnostic angiography (recurrent symptoms/isch-
emia, HF, or serious arrhythmias), LVEF should be measured. (Level
of Evidence: B) (Fig. 7; Box L)
LASS IIa
. For UA/NSTEMI patients in whom PCI is selected as a postangiog-
raphy management strategy, it is reasonable to omit administration
of an IV GP IIb/IIIa antagonist if bivalirudin was selected as the
anticoagulant and at least 300 mg of clopidogrel was administered
at least 6 h earlier. (Level of Evidence: B) (Fig. 8)
. If LVEF is less than or equal to 0.40, it is reasonable to perform
diagnostic angiography. (Level of Evidence: B) (Fig. 7; Box M)
. If LVEF is greater than 0.40, it is reasonable to perform a stress test.
(Level of Evidence: B) (Fig. 7; Box N)
LASS IIb
or UA/NSTEMI patients in whom PCI is selected as a postangiography
anagement strategy, it may be reasonable to omit an IV GP IIb/IIIa
nhibitor if not started before diagnostic angiography for troponin-
egative patients without other clinical or angiographic high-risk fea-
ures. (Level of Evidence: C)
LASS III
ntravenous fibrinolytic therapy is not indicated in patients without
cute ST-segment elevation, a true posterior MI, or a presumed new left
undle-branch block. (Level of Evidence: A)
. INITIAL CONSERVATIVE VERSUS INITIAL INVASIVE STRATEGIES
LASS I
. An early invasive strategy (i.e., diagnostic angiography with intent to
perform revascularization) is indicated in UA/NSTEMI patients whohave refractory angina or hemodynamic or electrical instability(without serious comorbidities or contraindications to such proce-
dures). (Level of Evidence: B)
. An early invasive strategy (i.e., diagnostic angiography with intent to
perform revascularization) is indicated in initially stabilized UA/
NSTEMI patients (without serious comorbidities or contraindications
to such procedures) who have an elevated risk for clinical events
(see Table 5 and Sections III.B and IV.C.5). (Level of Evidence: A)
LASS IIb
. In initially stabilized patients, an initially conservative (i.e. a selec-
tively invasive) strategy may be considered as a treatment strategy
for UA/NSTEMI patients (without serious comorbidities or contrain-
dications to such procedures) who have an elevated risk for clinical
events (see Table 5 and Sections III.B and IV.C.5) including those
who are troponin positive. (Level of Evidence: B) The decision to
implement an initial conservative (vs. initial invasive) strategy in
these patients may be made by considering physician and patient
preference. (Level of Evidence: C)
. An invasive strategy may be reasonable in patients with chronic
renal insufficiency. (Level of Evidence: C)
LASS III
. An early invasive strategy (i.e., diagnostic angiography with intent to
perform revascularization) is not recommended in patients with
extensive comorbidities (e.g., liver or pulmonary failure, cancer), in
whom the risks of revascularization and comorbid conditions are
likely to outweigh the benefits of revascularization. (Level of Evi-
dence: C)
. An early invasive strategy (i.e., diagnostic angiography with intent to
perform revascularization) is not recommended in patients with
acute chest pain and a low likelihood of ACS. (Level of Evidence: C)
. An early invasive strategy (i.e., diagnostic angiography with intent to
perform revascularization) should not be performed in patients who
will not consent to revascularization regardless of the findings.
(Level of Evidence: C)
. RISK STRATIFICATION BEFORE DISCHARGE
LASS I
. Noninvasive stress testing is recommended in low-risk patients (Table
3) who have been free of ischemia at rest or with low-level activity and
of HF for a minimum of 12 to 24 h. (Level of Evidence: C)
. Noninvasive stress testing is recommended in patients at interme-
diate risk (Table 3) who have been free of ischemia at rest or with
low-level activity and of HF for a minimum of 12 to 24 h. (Level of
Evidence: C)
. Choice of stress test is based on the resting ECG, ability to perform
exercise, local expertise, and technologies available. Treadmill ex-
ercise is useful in patients able to exercise in whom the ECG is free
of baseline ST-segment abnormalities, bundle-branch block, LV
hypertrophy, intraventricular conduction defect, paced rhythm, pre-
excitation, and digoxin effect. (Level of Evidence: C)
. An imaging modality should be added in patients with resting
ST-segment depression (greater than or equal to 0.10 mV), LV
hypertrophy, bundle-branch block, intraventricular conduction de-
fect, preexcitation, or digoxin who are able to exercise. In patients
undergoing a low-level exercise test, an imaging modality can add
sensitivity. (Level of Evidence: B)
. Pharmacological stress testing with imaging is recommended when
physical limitations (e.g., arthritis, amputation, severe peripheral
vascular disease, severe chronic obstructive pulmonary disease, or
67
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dence: B)
. Prompt angiography without noninvasive risk stratification should
be performed for failure of stabilization with intensive medical
treatment. (Level of Evidence: B)
. A noninvasive test (echocardiogram or radionuclide angiogram) is
recommended to evaluate LV function in patients with definite ACS
who are not scheduled for coronary angiography and left ventricu-
lography. (Level of Evidence: B)
. Revascularization With PCI and CABG in Patients
ith UA/NSTEMI
. PERCUTANEOUS CORONARY INTERVENTION
LASS I
. An early invasive PCI strategy is indicated for patients with UA/
NSTEMI who have no serious comorbidity and who have coronary
lesions amenable to PCI and any of the high-risk features listed in
Section IV.5. (See Section 3.C for specific recommendations and
their Level of Evidence.)
. Percutaneous coronary intervention (or CABG) is recommended for
UA/NSTEMI patients with 1- or 2-vessel CAD with or without signif-
icant proximal left anterior descending CAD but with a large area of
viable myocardium and high-risk criteria on noninvasive testing.
(Level of Evidence: B)
. Percutaneous coronary intervention (or CABG) is recommended for
UA/NSTEMI patients with multivessel coronary disease with suit-
able coronary anatomy, with normal LV function, and without dia-
betes mellitus. (Level of Evidence: A)
. An intravenous platelet GP IIb/IIIa inhibitor is generally recom-
mended in UA/NSTEMI patients undergoing PCI. (Level of Evidence:
A) See Section IV.B.3. and Figures 6, 7, and 8 for details on timing
and dosing recommendations (see Table 6).
LASS IIa
. Percutaneous coronary intervention is reasonable for focal saphe-
nous vein graft (SVG) lesions or multiple stenoses in UA/NSTEMI
patients who are undergoing medical therapy and who are poor
candidates for reoperative surgery. (Level of Evidence: C)
. Percutaneous coronary intervention (or CABG) is reasonable for
UA/NSTEMI patients with 1- or 2-vessel CAD with or without signif-
icant proximal left anterior descending CAD but with a moderate
area of viable myocardium and ischemia on noninvasive testing.
(Level of Evidence: B)
. Percutaneous coronary intervention (or CABG) can be beneficial
compared with medical therapy for UA/NSTEMI patients with
1-vessel disease with significant proximal left anterior descending
CAD. (Level of Evidence: B)
. Use of PCI is reasonable in patients with UA/NSTEMI with significant
left main CAD (greater than 50% diameter stenosis) who are
candidates for revascularization but are not eligible for CABG or who
require emergent intervention at angiography for hemodynamic
instability. (Level of Evidence: B)
LASS IIb
. In the absence of high-risk features associated with UA/NSTEMI, PCI
may be considered in patients with single-vessel or multivessel CAD
who are undergoing medical therapy and who have 1 or more
lesions to be dilated with a reduced likelihood of success. (Level of
Evidence: B). Percutaneous coronary intervention may be considered for UA/
NSTEMI patients who are undergoing medical therapy who have 2-
or 3-vessel disease, significant proximal left anterior descending
CAD, and treated diabetes or abnormal LV function, with anatomy
suitable for catheter-based therapy. (Level of Evidence: B)
LASS III
1. Percutaneous coronary intervention (or CABG) is not recommended
for patients with 1- or 2-vessel CAD without significant proximal left
anterior descending CAD with no current symptoms or symptoms
that are unlikely to be due to myocardial ischemia and who have no
ischemia on noninvasive testing. (Level of Evidence: C)
2. In the absence of high-risk features associated with UA/NSTEMI,
PCI is not recommended for patients with UA/NSTEMI who have
single-vessel or multivessel CAD and no trial of medical therapy, or
who have 1 or more of the following:
a. Only a small area of myocardium at risk. (Level of Evidence: C)
b. All lesions or the culprit lesion to be dilated with morphology
that conveys a low likelihood of success. (Level of Evidence: C)
c. A high risk of procedure-related morbidity or mortality. (Level of
Evidence: C)
d. Insignificant disease (less than 50% coronary stenosis). (Level
of Evidence: C)
e. Significant left main CAD and candidacy for CABG. (Level of
Evidence: B)
3. A PCI strategy in stable patients with persistently occluded infarct-
related coronary arteries after NSTEMI is not indicated. (Level of
Evidence: B)
. CABG
LASS I
. Coronary artery bypass graft surgery is recommended for UA/
NSTEMI patients with significant left main CAD (greater than 50%
stenosis). (Level of Evidence: A)
. Coronary artery bypass graft surgery is recommended for UA/
NSTEMI patients with 3-vessel disease; the survival benefit is
greater in patients with abnormal LV function (LVEF less than 0.50).
(Level of Evidence: A)
. Coronary artery bypass graft surgery is recommended for UA/
NSTEMI patients with 2-vessel disease with significant proximal left
anterior descending CAD and either abnormal LV function (LVEF less
than 0.50) or ischemia on noninvasive testing. (Level of Evidence: A)
. Coronary artery bypass graft surgery is recommended for UA/
NSTEMI in patients in whom percutaneous revascularization is not
optimal or possible and who have ongoing ischemia not responsive
to maximal nonsurgical therapy. (Level of Evidence: B)
. Coronary artery bypass graft surgery (or PCI) is recommended for
UA/NSTEMI patients with 1- or 2-vessel CAD with or without signif-
icant proximal left anterior descending CAD but with a large area of
viable myocardium and high-risk criteria on noninvasive testing.
(Level of Evidence: B)
. Coronary artery bypass graft surgery (or PCI) is recommended for
UA/NSTEMI patients with multivessel coronary disease with suit-
able coronary anatomy, with normal LV function, and without dia-
betes mellitus. (Level of Evidence: A)
LASS IIa
. For patients with UA/NSTEMI and multivessel disease, CABG with
use of the internal mammary arteries can be beneficial over PCI in
patients being treated for diabetes. (Level of Evidence: B)
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for UA/NSTEMI patients with multivessel disease and treated dia-
betes mellitus. (Level of Evidence: B)
. Repeat CABG is reasonable for UA/NSTEMI patients with multiple
SVG stenoses, especially when there is significant stenosis of a graft
that supplies the left anterior descending coronary artery (LAD).
(Level of Evidence: C)
. Coronary artery bypass graft surgery (or PCI) is reasonable for
UA/NSTEMI patients with 1- or 2-vessel CAD with or without signif-
icant proximal left anterior descending CAD but with a moderate
area of viable myocardium and ischemia on noninvasive testing.
(Level of Evidence: B)
. Coronary artery bypass graft surgery (or PCI) can be beneficial
compared with medical therapy for UA/NSTEMI patients with
1-vessel disease with significant proximal left anterior descending
CAD. (Level of Evidence: B)
. Coronary artery bypass graft surgery (or PCI) with stenting is reason-
able for patients with multivessel disease and symptomatic myo-
cardial ischemia. (Level of Evidence: B)
LASS IIb
oronary artery bypass graft surgery may be considered in patients
ith UA/NSTEMI who have 1- or 2-vessel disease not involving the
roximal LAD with a modest area of ischemic myocardium when
ercutaneous revascularization is not optimal or possible. (If there is a
arge area of viable myocardium and high-risk criteria on noninvasive
esting, this recommendation becomes a Class I recommendation.)
Level of Evidence: B)
LASS III
oronary artery bypass graft surgery (or PCI) is not recommended for
atients with 1- or 2-vessel CAD without significant proximal left
nterior descending CAD with no current symptoms or symptoms that
re unlikely to be due to myocardial ischemia and who have no
schemia on noninvasive testing. (Level of Evidence: C)
. Late Hospital Care, Hospital Discharge, and Post-
ospital Discharge Care
. MEDICAL REGIMEN AND USE OF MEDICATIONS
RECOMMENDATIONS
LASS I
. Medications required in the hospital to control ischemia should be
continued after hospital discharge in patients with UA/NSTEMI who
do not undergo coronary revascularization, patients with unsuccess-
ful revascularization, and patients with recurrent symptoms after
revascularization. Upward or downward titration of the doses may
be required. (Level of Evidence: C)
. All post-UA/NSTEMI patients should be given sublingual or spray
NTG and instructed in its use. (Level of Evidence: C)
. Before hospital discharge, patients with UA/NSTEMI should be
informed about symptoms of worsening myocardial ischemia
and MI and should be instructed in how and when to seek
emergency care and assistance if such symptoms occur. (Level of
Evidence: C)
. Before hospital discharge, post-UA/NSTEMI patients and/or des-
ignated responsible caregivers should be provided with support-able, easily understood, and culturally sensitive instructions with
d
†respect to medication type, purpose, dose, frequency, and perti-
nent side effects. (Level of Evidence: C)
. In post-UA/NSTEMI patients, anginal discomfort lasting more
than 2 or 3 min should prompt the patient to discontinue physical
activity or remove himself or herself from any stressful event. If
pain does not subside immediately, the patient should be in-
structed to take 1 dose of NTG sublingually. If the chest discom-
fort/pain is unimproved or worsening 5 min after 1 NTG dose has
been taken, it is recommended that the patient or a family
member/friend call 9-1-1 immediately to access EMS. While
activating EMS access, additional NTG (at 5-min intervals 2
times) may be taken while lying down or sitting. (Level of
Evidence: C)
. If the pattern or severity of anginal symptoms changes, which
suggests worsening myocardial ischemia (e.g., pain is more fre-
quent or severe or is precipitated by less effort or now occurs at
rest), the patient should contact his or her physician without delay to
assess the need for additional treatment or testing. (Level of
Evidence: C)
. LONG-TERM MEDICAL THERAPY AND SECONDARY PREVENTION
. ANTIPLATELET THERAPY
LASS I
. For UA/NSTEMI patients treated medically without stenting, aspi-
rin* (75 to 162 mg per day) should be prescribed indefinitely (Level
of Evidence: A) clopidogrel† (75 mg per day) should be prescribed
for at least 1 month (Level of Evidence: A) and ideally for up to 1
year. (Level of Evidence: B)
. For UA/NSTEMI patients treated with bare-metal stents, aspirin*
162 to 325 mg per day should be prescribed for at least 1 month
(Level of Evidence: B), then continued indefinitely at a dose of 75 to
162 mg per day (Level of Evidence: A); clopidogrel should be
prescribed at a dose of 75 mg per day for a minimum of 1 month
and ideally for up to 1 year (unless the patient is at increased risk of
bleeding, then it should be given for a minimum of 2 weeks). (Level
of Evidence: B)
. For UA/NSTEMI patients treated with DES, aspirin* 162 to 325
mg per day should be prescribed for at least 3 months after
sirolimus-eluting stent implantation and 6 months after
paclitaxel-eluting stent implantation then continued indefinitely
at a dose of 75 to 162 mg per day. (Level of Evidence: B)
Clopidogrel 75 mg daily should be given for at least 12 months to
all post-PCI patients receiving DES. (Level of Evidence: B)
. Clopidogrel 75 mg daily (preferred) or ticlopidine (in the absence of
contraindications) should be given to patients recovering from
UA/NSTEMI when ASA is contraindicated or not tolerated because
of hypersensitivity or gastrointestinal intolerance (but with gastro-
protective agents such as proton-pump inhibitors). (Level of Evi-
dence: A)
LASS IIa
or UA/NSTEMI patients in whom the physician is concerned about the
isk of bleeding, a lower initial aspirin dose after PCI of 75 to 162 mg
er day is reasonable. (Level of Evidence: C)
For ASA-allergic patients, use clopidogrel alone (indefinitely), or try aspirin
esensitization.
For clopidogrel-allergic patients, use ticlopidine 250 mg by mouth twice daily.
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or UA/NSTEMI patients who have an indication for anticoagulation,
dd warfarin* to maintain an international normalization ratio of 2.0 to
.0.† (Level of Evidence: B)
LASS III
ipyridamole is not recommended as an antiplatelet agent in post-UA/
STEMI patients because it has not been shown to be effective. (Level
f Evidence: A)
I. BETA BLOCKERS
LASS I
. Beta blockers are indicated for all patients recovering from UA/
NSTEMI unless contraindicated. (For those at low risk, see Class IIa
recommendation below). Treatment should begin within a few days
of the event, if not initiated acutely, and should be continued
indefinitely. (Level of Evidence: B)
. Patients recovering from UA/NSTEMI with moderate or severe LV
failure should receive beta-blocker therapy with a gradual titration
scheme. (Level of Evidence: B)
LASS IIa
t is reasonable to prescribe beta blockers to low-risk patients (i.e.,
ormal LV function, revascularized, no high-risk features) recovering
rom UA/NSTEMI in the absence of absolute contraindications. (Level
f Evidence: B)
II. INHIBITION OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM
LASS I
. Angiotensin-converting enzyme inhibitors should be given and con-
tinued indefinitely for patients recovering from UA/NSTEMI with HF,
LV dysfunction (ejection fraction less than 0.40), hypertension, or
diabetes mellitus unless contraindicated. (Level of Evidence: A)
. An angiotensin receptor blocker should be prescribed at discharge
to those UA/NSTEMI patients who are intolerant of an ACE inhibitor
and who have either clinical or radiological signs of HF and LVEF less
than 0.40. (Level of Evidence: A)
. Long-term aldosterone receptor blockade should be prescribed for
UA/NSTEMI patients without significant renal dysfunction (esti-
mated creatinine clearance should be greater than 30 ml per min)
or hyperkalemia (potassium should be less than or equal to 5 mEq
per liter) who are already receiving therapeutic doses of an ACE
inhibitor, have an LVEF less than or equal to 0.40, and have either
symptomatic HF or diabetes mellitus. (Level of Evidence: A)
LASS IIa
. Angiotensin-converting enzyme inhibitors are reasonable for pa-
tients recovering from UA/NSTEMI in the absence of LV dysfunction,
hypertension, or diabetes mellitus unless contraindicated. (Level of
Evidence: A)
. Angiotensin-converting enzyme inhibitors are reasonable for pa-
tients with HF and LVEF greater than 0.40. (Level of Evidence: A)
. In UA/NSTEMI patients who do not tolerate ACE inhibitors, an
angiotensin receptor blocker can be useful as an alternative to ACE
inhibitors in long-term management provided there are either clin-
Continue ASA indefinitely and warfarin longer term as indicated for specific
onditions such as atrial fibrillation; LV thrombus; or cerebral, venous, or pulmonary
mboli.
An international normalized ratio of 2.0 to 2.5 is preferable while given with ASA
nd clopidogrel, especially in older patients and those with other risk factors for
leeding.
§
ical or radiological signs of HF and LVEF less than 0.40. (Level of
Evidence: B)
LASS IIb
he combination of an ACE inhibitor and an angiotensin receptor
locker may be considered in the long-term management of patients
ecovering from UA/NSTEMI with persistent symptomatic HF and LVEF
ess than 0.40‡ despite conventional therapy including an ACE inhibitor
r angiotensin receptor blocker alone. (Level of Evidence: B)
V. NITROGLYCERIN
LASS I
itroglycerin to treat ischemic symptoms is recommended. (Level of
vidence: C)
. CALCIUM CHANNEL BLOCKERS
LASS I
. Calcium channel blockers§ are recommended for ischemic symp-
toms when beta blockers are not successful. (Level of Evidence: B)
. Calcium channel blockers§ are recommended for ischemic symp-
toms when beta blockers are contraindicated or cause unaccept-
able side effects. (Level of Evidence: C)
I. WARFARIN THERAPY
LASS I
se of warfarin in conjunction with ASA and/or clopidogrel is associ-
ted with an increased risk of bleeding and should be monitored
losely. (Level of Evidence: A)
LASS IIb
arfarin either without (international normalized ratio 2.5 to 3.5) or with
ow-doseASA (75 to 81mgper d; international normalized ratio 2.0 to 2.5)
ay be reasonable for patients at high CAD risk and low bleeding risk who
o not require or are intolerant of clopidogrel. (Level of Evidence: B)
II. LIPID MANAGEMENT
LASS I
. The following lipid recommendations are beneficial:
a. Lipid management should include assessment of a fasting lipid
profile for all patients, within 24 h of hospitalization. (Level of
Evidence: C)
b. Hydroxymethyl glutaryl-coenzyme A reductase inhibitors (st-
atins), in the absence of contraindications, regardless of base-
line LDL-C and diet modification, should be given to post-UA/
NSTEMI patients, including postrevascularization patients.
(Level of Evidence: A)
c. For hospitalized patients, lipid-lowering medications should be
initiated before discharge. (Level of Evidence: A)
d. For UA/NSTEMI patients with elevated LDL-C (greater than or
equal to 100 mg per dL), cholesterol-lowering therapy should be
initiated or intensified to achieve an LDL-C of less than 100 mg
per dL. (Level of Evidence: A) Further titration to less than 70mg
per dL is reasonable. (Class IIa, Level of Evidence: A)
e. Therapeutic options to reduce non–HDL-C are recommended,
The safety of this combination has not been proven in patients also on aldosterone
ntagonist and is not recommended.
Short-acting dihydropyridine calcium channel antagonists should be avoided.
Non–HDL-C  total cholesterol minus HDL-C.
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dence: B)
f. Dietary therapy for all patients should include reduced intake of
saturated fats (to less than 7% of total calories), cholesterol (to
less than 200 mg per d), and trans fat (to less than 1% of
energy). (Level of Evidence: B)
g. Promoting daily physical activity and weight management are
recommended. (Level of Evidence: B)
. Treatment of triglycerides and non–HDL-C is useful, including the
following:
a. If triglycerides are 200 to 499mg per dL, non–HDL-C* should be
less than 130 mg per dL. (Level of Evidence: B)
b. If triglycerides are greater than or equal to 500 mg per dL†,
therapeutic options to prevent pancreatitis are fibrate‡ or nia-
cin‡ before LDL-lowering therapy is recommended. It is also
recommended that LDL-C be treated to goal after triglyceride-
lowering therapy. Achievement of a non–HDL-C* less than 130
mg per dL (i.e., 30 mg per dL greater than LDL-C target) if
possible is recommended. (Level of Evidence: C)
LASS IIa
he following lipid management strategies can be beneficial:
. Further reduction of LDL-C to less than 70 mg per dL is reasonable.
(Level of Evidence: A)
. If baseline LDL cholesterol is 70 to 100 mg per dL, it is reasonable
to treat LDL-C to less than 70 mg per dL. (Level of Evidence: B)
. Further reduction of non–HDL-C* to less than 100 mg per dL is
reasonable; if triglycerides are 200 to 499 mg per dL, non–HDL-C
target is less than 130 mg per dL. (Level of Evidence: B)
. Therapeutic options to reduce non–HDL-C* (after LDL-C lowering)
include niacin‡ or fibrate† therapy.
. Nicotinic acid (niacin)‡ and fibric acid derivatives (fenofibrate, gem-
fibrozil)† can be useful as therapeutic options (after LDL-C–lowering
therapy) for HDL-C less than 40 mg per dL. (Level of Evidence: B)
. Nicotinic acid (niacin)‡ and fibric acid derivatives (fenofibrate, gem-
fibrozil)† can be useful as therapeutic options (after LDL-C–lowering
therapy) for triglycerides greater than 200 mg per dL. (Level of
Evidence: B)
. The addition of plant stanol/sterols (2 g per d) and/or viscous fiber
(more than 10 g per d) is reasonable to further lower LDL-C. (Level of
Evidence: A)
LASS IIb
ncouraging consumption of omega-3 fatty acids in the form of fish§ or
n capsule form (1 g per d) for risk reduction may be reasonable. For
reatment of elevated triglycerides, higher doses (2 to 4 g per d) may be
sed for risk reduction. (Level of Evidence: B)
III. BLOOD PRESSURE CONTROL
LASS I
lood pressure control according to Joint National Committee on
Non–HDL-C  total cholesterol minus HDL-C.
Patients with very high triglycerides should not consume alcohol. The use of bile acid
equestrants is relatively contraindicated when triglycerides are greater than 200 mg
er dL.
The combination of high-dose statin plus fibrate can increase risk for severe
yopathy. Statin doses should be kept relatively low with this combination. Dietary
upplement niacin must not be used as a substitute for prescription niacin.
Pregnant and lactating women should limit their intake of fish to minimize exposure
o methylmercury.
N
Brevention, Detection, Evaluation, and Treatment of High Blood Pres-
ure guidelines is recommended (i.e., blood pressure less than
40/90mmHg or less than 130/80mmHg if the patient has diabetes
ellitus or chronic kidney disease). (Level of Evidence: A) Additional
easures recommended to treat and control blood pressure include
he following:
. Patients should initiate and/or maintain lifestyle modifications,
including weight control, increased physical activity, alcohol moder-
ation, sodium reduction, and emphasis on increased consumption of
fresh fruits, vegetables, and low-fat dairy products. (Level of Evi-
dence: B)
. For patients with blood pressure greater than or equal to 140/90
mm Hg (or greater than or equal to 130/80 mm Hg for individuals
with chronic kidney disease or diabetes mellitus), it is useful to add
blood pressure medication as tolerated, treating initially with beta
blockers and/or ACE inhibitors, with addition of other drugs such as
thiazides as needed to achieve target blood pressure. (Level of
Evidence: A)
X. DIABETES MELLITUS
LASS I
iabetes management should include lifestyle and pharmacotherapy
easures to achieve a near-normal hemoglobin A1c level of less than
%. (Level of Evidence: B) Diabetes management should also include
he following:
. Vigorous modification of other risk factors (e.g., physical activity,
weight management, blood pressure control, and cholesterol man-
agement) as recommended should be initiated and maintained.
(Level of Evidence: B)
. It is useful to coordinate the patient’s diabetic care with the patient’s
primary care physician or endocrinologist. (Level of Evidence: C)
. SMOKING CESSATION
LASS I
moking cessation and avoidance of exposure to environmental to-
acco smoke at work and home are recommended. Follow-up, referral
o special programs, or pharmacotherapy (including nicotine replace-
ent) is useful, as is adopting a stepwise strategy aimed at smoking
essation (the 5 As are: Ask, Advise, Assess, Assist, and Arrange).
Level of Evidence: B)
I. WEIGHT MANAGEMENT
LASS I
eight management, as measured by body mass index and/or waist
ircumference, should be assessed on each visit. A body mass index of
8.5 to 24.9 kg per m2 and a waist circumference (measured horizon-
ally at the iliac crest) of less than 40 inches for men and less than 35
nches for women is recommended. (Level of Evidence: B) Additional
eight management practices recommended include the following:
. On each patient visit, it is useful to consistently encourage weight
maintenance/reduction through an appropriate balance of physical
activity, caloric intake, and formal behavioral programs when indi-
cated to maintain/achieve a body mass index between 18.5 and
24.9 kg per m2. (Level of Evidence: B)
. If waist circumference is 35 inches or more in women or 40 inches
Chobanian AV, Bakris GL, Black HR, et al., for the National High Blood Pressure
ducation Program Coordinating Committee. The seventh report of the Joint
ational Committee on Prevention, Detection, Evaluation, and Treatment of High
lood Pressure: the JNC 7 report. JAMA 2003;289:2560–72 (6).
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August 14, 2007:652–726 ACC/AHA UA/NSTEMI Guideline Revisionor more in men, it is beneficial to initiate lifestyle changes and
consider treatment strategies for metabolic syndrome as indicated.
(Level of Evidence: B)
. The initial goal of weight loss therapy should be to reduce body
weight by approximately 10% from baseline. With success, further
weight loss can be attempted if indicated through further assess-
ment. (Level of Evidence: B)
II. PHYSICAL ACTIVITY
LASS I
. The patient’s risk after UA/NSTEMI should be assessed on the basis
of an in-hospital determination of risk. A physical activity history or
an exercise test to guide initial prescription is beneficial. (Level of
Evidence: B)
. Guided/modified by an individualized exercise prescription, patients
recovering from UA/NSTEMI generally should be encouraged to
achieve physical activity duration of 30 to 60 min per d, preferably
7 (but at least 5) d per week of moderate aerobic activity, such as
brisk walking, supplemented by an increase in daily lifestyle activi-
ties (e.g., walking breaks at work, gardening, and household work).
(Level of Evidence: B)
. Cardiac rehabilitation/secondary prevention programs are recom-
mended for patients with UA/NSTEMI, particularly those with mul-
tiple modifiable risk factors and/or those moderate- to high-risk
patients in whom supervised exercise training is particularly war-
ranted. (Level of Evidence: B)
LASS IIb
he expansion of physical activity to include resistance training on 2 d
er week may be reasonable. (Level of Evidence: C)
III. PATIENT EDUCATION
LASS I
eyond the detailed instructions for daily exercise, patients should be
iven specific instruction on activities (e.g., heavy lifting, climbing
tairs, yard work, and household activities) that are permissible and
hose that should be avoided. Specific mention should be made
egarding resumption of driving, return to work, and sexual activity.
Level of Evidence: C) Specific recommendations for physical activity
ollow in Section VI.E.
IV. INFLUENZA
LASS I
n annual influenza vaccination is recommended for patients with
ardiovascular disease. (Level of Evidence: B)
V. DEPRESSION
LASS IIa
t is reasonable to consider screening UA/NSTEMI patients for depres-
ion and refer/treat when indicated. (Level of Evidence: B)
VI. NONSTEROIDAL ANTI-INFLAMMATORY DRUGS
LASS I
t the time of preparation for hospital discharge, the patient’s need for
reatment of chronic musculoskeletal discomfort should be assessed,
nd a stepped-care approach to treatment should be used for selection
f treatments (see Fig. 21 in the full-text guideline). Pain relief should
egin with acetaminophen, small doses of narcotics, or nonacetylated
alicylates. (Level of Evidence: C)LASS IIa
t is reasonable to use nonselective NSAIDs such as naproxen, if initial
herapy with acetaminophen, small doses of narcotics, or nonacety-
ated salicylates is insufficient. (Level of Evidence: C)
LASS IIb
onsteroidal anti-inflammatory drugs with increasing degrees of rela-
ive COX-2 selectivity may be considered for pain relief only for situa-
ions in which intolerable discomfort persists despite attempts at
tepped-care therapy with acetaminophen, small doses of narcotics,
onacetylated salicylates, or nonselective NSAIDs. In all cases, the
owest effective doses should be used for the shortest possible time.
Level of Evidence: C)
LASS III
onsteroidal anti-inflammatory drugs with increasing degrees of rela-
ive COX-2 selectivity should not be administered to UA/NSTEMI pa-
ients with chronic musculoskeletal discomfort when therapy with
cetaminophen, small doses of narcotics, nonacetylated salicylates, or
onselective NSAIDs provides acceptable levels of pain relief. (Level of
vidence: C)
VII. HORMONE THERAPY
LASS III
. Hormone therapy with estrogen plus progestin, or estrogen alone,
should not be given de novo to postmenopausal women after
UA/NSTEMI for secondary prevention of coronary events. (Level of
Evidence: A)
. Postmenopausal women who are already taking estrogen plus
progestin, or estrogen alone, at the time of UA/NSTEMI in general
should not continue hormone therapy. However, women who are
more than 1 to 2 years past the initiation of hormone therapy who
wish to continue such therapy for another compelling indication
should weigh the risks and benefits, recognizing the greater risk of
cardiovascular events and breast cancer (combination therapy) or
stroke (estrogen). Hormone therapy should not be continued while
patients are on bedrest in the hospital. (Level of Evidence: B)
VIII. ANTIOXIDANT VITAMINS AND FOLIC ACID
LASS III
. Antioxidant vitamin supplements (e.g., vitamins E, C, or beta caro-
tene) should not be used for secondary prevention in UA/NSTEMI
patients. (Level of Evidence: A)
. Folic acid, with or without B6 and B12, should not be used for
secondary prevention in UA/NSTEMI patients. (Level of Evidence: A)
. POSTDISCHARGE FOLLOW-UP
RECOMMENDATIONS
LASS I
. Detailed discharge instructions for post-UA/NSTEMI patients should
include education on medications, diet, exercise, and smoking
cessation counseling (if appropriate), referral to a cardiac rehabili-
tation/secondary prevention program (when appropriate), and the
scheduling of a timely follow-up appointment. Low-risk medically
treated patients and revascularized patients should return in 2 to 6
weeks, and higher risk patients should return within 14 d. (Level of
Evidence: C)
. Patients with UA/NSTEMI managed initially with a conservative
strategy who experience recurrent signs or symptoms of UA or
34
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angina despite medical management who are suitable for revascu-
larization should undergo timely coronary angiography. (Level of
Evidence: B)
. Patients with UA/NSTEMI who have tolerable stable angina or no
anginal symptoms at follow-up visits should be managed with
long-term medical therapy for stable CAD. (Level of Evidence: B)
. Care should be taken to establish effective communication between
the post-UA/NSTEMI patient and health care team members to
enhance long-term compliance with prescribed therapies and rec-
ommended lifestyle changes. (Level of Evidence: B)
. CARDIAC REHABILITATION
LASS I
ardiac rehabilitation/secondary prevention programs, when avail-
ble, are recommended for patients with UA/NSTEMI, particularly
hose with multiple modifiable risk factors and those moderate- to
igh-risk patients in whom supervised or monitored exercise training is
arranted. (Level of Evidence: B)
. Special Groups
. WOMEN
LASS I
. Women with UA/NSTEMI should be managed with the same phar-
macological therapy as men both in the hospital and for secondary
prevention, with attention to antiplatelet and anticoagulant doses
based on weight and renal function; doses of renally cleared medi-
cations should be based on estimated creatinine clearance. (Level
of Evidence: B)
. Recommended indications for noninvasive testing in women with
UA/NSTEMI are similar to those for men. (Level of Evidence: B)
. For women with high-risk features for invasive strategy, recommenda-
tions are similar to those for men. (Level of Evidence: B)
. In women with low-risk features, a conservative strategy is recom-
mended. (Level of Evidence: B)
. DIABETES MELLITUS
LASS I
. Medical treatment in the acute phase of UA/NSTEMI and decisions
on whether to perform stress testing, angiography, and revascular-
ization should be similar in patients with and without diabetes
mellitus. (Level of Evidence: A)
. In all patients with diabetes mellitus and UA/NSTEMI, attention should
be directed toward aggressive glycemic management in accordance
with current standards of diabetes care endorsed by the American
Diabetes Association and the American College of Endocrinology.
Goals of therapy should include a preprandial glucose target of less
than 110 mg per dL and a maximum daily target of less than 180 mg
per dL. The postdischarge goal of therapy should be hemoglobin A1c
less than 7%, which should be addressed by primary care and cardiac
caregivers at every visit. (Level of Evidence: B)
. An intravenous platelet GP IIb/IIIa inhibitor should be administered
for patients with diabetes mellitus as recommended for all UA/
NSTEMI patients (Sections I.C.3.A and IV.B). (Level of Evidence: A)
The benefit may be enhanced in patients with diabetes mellitus.(Level of Evidence: B)LASS IIa
. For patients with UA/NSTEMI and multivessel disease, CABG with
use of the internal mammary arteries can be beneficial over PCI in
patients being treated for diabetes mellitus. (Level of Evidence: B)
. Percutaneous coronary intervention is reasonable for UA/NSTEMI
patients with diabetesmellitus with single-vessel disease and induc-
ible ischemia. (Level of Evidence: B)
. In patients with UA/NSTEMI and diabetes mellitus, it is reasonable
to administer aggressive insulin therapy to achieve a glucose less
than 150 mg per dL during the first 3 hospital (intensive care unit)
days and between 80 and 110 mg per dL thereafter whenever
possible. (Level of Evidence: B)
lease see Section V for further explanation of revascularization
trategies.
. POST-CABG PATIENTS
LASS I
. Medical treatment for UA/NSTEMI patients after CABG should fol-
low the same guidelines as for non–post-CABG patients with UA/
NSTEMI. (Level of Evidence: C)
. Because of the many anatomic possibilities that might be responsible
for recurrent ischemia, there should be a low threshold for angiography
in post-CABG patients with UA/NSTEMI. (Level of Evidence: C)
LASS IIa
. Repeat CABG is reasonable for UA/NSTEMI patients with multiple
SVG stenoses, especially when there is significant stenosis of a graft
that supplies the LAD. Percutaneous coronary intervention is rea-
sonable for focal saphenous vein stenosis. (Level of Evidence: C)
(Note that an intervention on a native vessel is generally preferable
to that on a vein graft that supplies the same territory, if possible.)
. Stress testing with imaging in UA/NSTEMI post-CABG patients is
reasonable. (Level of Evidence: C)
. OLDER ADULTS
LASS I
. Older patients with UA/NSTEMI should be evaluated for appropriate
acute and long-term therapeutic interventions in a similar manner
as younger patients with UA/NSTEMI. (Level of Evidence: A)
. Decisions onmanagement of older patients with UA/NSTEMI should
not be based solely on chronologic age but should be patient
centered, with consideration given to general health, functional and
cognitive status, comorbidities, life expectancy, and patient prefer-
ences and goals. (Level of Evidence: B)
. Attention should be given to appropriate dosing (i.e., adjusted by
weight and estimated creatinine clearance) of pharmacological
agents in older patients with UA/NSTEMI, because they often have
altered pharmacokinetics (due to reduced muscle mass, renal
and/or hepatic dysfunction, and reduced volume of distribution)
and pharmacodynamics (increased risks of hypotension and bleed-
ing). (Level of Evidence: B)
. Older UA/NSTEMI patients face increased early procedural risks
with revascularization relative to younger patients, yet the overall
benefits from invasive strategies are equal to or perhaps greater in
older adults and are recommended. (Level of Evidence: B)
. Consideration should be given to patient and family preferences,
quality-of-life issues, end-of-life preferences, and sociocultural dif-ferences in older patients with UA/NSTEMI. (Level of Evidence: C)
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LASS I
. Creatinine clearance should be estimated in UA/NSTEMI patients,
and the doses of renally cleared drugs should be adjusted appropri-
ately. (Level of Evidence: B)
. In chronic kidney disease patients undergoing angiography, isosmolar
contrast agents are indicated and are preferred. (Level of Evidence: A)
. COCAINE AND METHAMPHETAMINE USERS
LASS I
. Administration of sublingual or intravenous NTG and intravenous or
oral calcium antagonists is recommended for patients with ST-
segment elevation or depression that accompanies ischemic chest
discomfort after cocaine use. (Level of Evidence: C)
. Immediate coronary angiography, if possible, should be performed in
patients with ischemic chest discomfort after cocaine use whose ST
segments remain elevated after NTG and calcium antagonists; PCI is
recommended if occlusive thrombus is detected. (Level of Evidence: C)
. Fibrinolytic therapy is useful in patients with ischemic chest discom-
fort after cocaine use if ST segments remain elevated despite NTG
and calcium antagonists, if there are no contraindications, and if
coronary angiography is not possible. (Level of Evidence: C)
LASS IIa
. Administration of NTG or oral calcium channel blockers can be
beneficial for patients with normal ECGs or minimal ST-segment
deviation suggestive of ischemia after cocaine use. (Level of Evi-
dence: C)
. Coronary angiography, if available, is probably recommended for pa-
tients with ischemic chest discomfort after cocaine use with ST-
segment depression or isolated T-wave changes not known to be
previously present and who are unresponsive to NTG and calcium
antagonists. (Level of Evidence: C)
. Management of UA/NSTEMI patients with methamphetamine use
similar to that of patients with cocaine use is reasonable. (Level of
Evidence: C)
LASS IIb
dministration of combined alpha- and beta-blocking agents (e.g.,
abetalol) may be reasonable for patients after cocaine use with
ypertension (systolic blood pressure greater than 150 mm Hg) or
hose with sinus tachycardia (pulse greater than 100 beats per min)
rovided that the patient has received a vasodilator, such as NTG or a
alcium antagonist, within close temporal proximity (i.e., within the
revious hour). (Level of Evidence: C)
LASS III
oronary angiography is not recommended in patients with chest pain
fter cocaine use without ST-segment or T-wave changes and with a
egative stress test and cardiac biomarkers. (Level of Evidence: C)
. VARIANT (PRINZMETAL’S) ANGINA
LASS I
. Diagnostic investigation is indicated in patients with a clinical
picture suggestive of coronary spasm, with investigation for the
presence of transient myocardial ischemia and ST-segment eleva-
tion during chest pain. (Level of Evidence: A)
. Coronary angiography is recommended in patients with episodic
chest pain accompanied by transient ST-segment elevation. (Level
of Evidence: B) A. Treatment with nitrates and calcium channel blockers is recom-
mended in patients with variant angina whose coronary angiograms
show no or nonobstructive coronary artery lesions. Risk factor
modification is recommended, with patients with atherosclerotic
lesions considered to be at higher risk. (Level of Evidence: B)
LASS IIb
. Percutaneous coronary intervention may be considered in patients
with chest pain and transient ST-segment elevation and a significant
coronary artery stenosis. (Level of Evidence: B)
. Provocative testing may be considered in patients with no signifi-
cant angiographic CAD and no documentation of transient ST-
segment elevation when clinically relevant symptoms possibly ex-
plained by coronary artery spasm are present. (Level of Evidence: C)
LASS III
rovocative testing is not recommended in patients with variant angina
nd high-grade obstructive stenosis on coronary angiography. (Level of
vidence: B)
. CARDIOVASCULAR “SYNDROME X”
LASS I
. Medical therapy with nitrates, beta blockers, and calcium channel
blockers, alone or in combination, is recommended in patients with
cardiovascular syndrome X. (Level of Evidence: B)
. Risk factor reduction is recommended in patients with cardiovascu-
lar syndrome X. (Level of Evidence: B)
LASS IIb
. Intracoronary ultrasound to assess the extent of atherosclerosis and
rule out missed obstructive lesions may be considered in patients
with syndrome X. (Level of Evidence: B)
. If no ECGs during chest pain are available and coronary spasm
cannot be ruled out, coronary angiography and provocative testing
with acetylcholine, adenosine, or methacholine and 24-h ambula-
tory ECG may be considered. (Level of Evidence: C)
. If coronary angiography is performed and does not reveal a cause of
chest discomfort, and if syndrome X is suspected, invasive physio-
logical assessment (i.e., coronary flow reserve measurement) may
be considered. (Level of Evidence: C)
. Imipramine or aminophylline may be considered in patients with
syndrome X for continued pain despite implementation of Class I
measures. (Level of Evidence: C)
. Transcutaneous electrical nerve stimulation and spinal cord stimula-
tion for continued pain despite the implementation of Class Imeasures
may be considered for patients with syndrome X. (Level of Evidence: B)
LASS III
edical therapy with nitrates, beta blockers, and calcium channel block-
rs for patients with noncardiac chest pain is not recommended. (Level of
vidence: C)
I. Overview of the
cute Coronary Syndromes
. Definition of Terms
nstable angina/NSTEMI constitutes a clinical syndrome
ubset of ACS that is usually, but not always, caused by
therosclerotic CAD and is associated with an increased risk
f cardiac death and subsequent MI. In the spectrum of
CS, UA/NSTEMI is defined by ECG ST-segment de-
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iomarkers of necrosis (e.g., troponin) in the absence of
T-segment elevation and in an appropriate clinical setting
chest discomfort or anginal equivalent).
“Acute coronary syndrome” has evolved as a useful
perational term to refer to any constellation of clinical
ymptoms that are compatible with acute myocardial isch-
mia. It encompasses MI (STEMI and NSTEMI) and UA.
hese guidelines focus on 2 components of ACS: UA and
STEMI. The “Act in Time” initiative of the National
eart Attack Alert Program (7) summarizes the clinical
nformation needed to make the diagnosis of probable ACS
t the earliest phase of clinical evaluation and can be
ccessed at http://www.nhlbi.nih.gov/actintime/index.htm.
he implication of this early provisional diagnosis is that
atients should be placed in an environment with continu-
us ECG monitoring and defibrillation capability, where a
2-lead ECG can be obtained and interpreted expedi-
iously. The most urgent priority is to identify patients with
TEMI who should be considered for immediate reperfu-
ion therapy and managed according to the ACC/AHA
uidelines for the Management of Patients With ST-
levation Myocardial Infarction (8) and to recognize other
otentially catastrophic causes of patient symptoms, such as
ortic dissection. In these guidelines, UA and NSTEMI are
onsidered to be closely related conditions whose pathogen-
sis and clinical presentations are similar but of differing
everity, that is, whether the ischemia is severe enough to
ause myocardial injury with the release of a marker of
yocardial injury, most commonly troponin I, troponin T,
r CK-MB. The appearance of these biomarkers may be
elayed by up to several hours after the onset of ischemic
ymptoms, after which the differentiation between UA (i.e.,
o biomarkers in circulation; usually transient, if any, ECG
hanges of ischemia) and NSTEMI (i.e., elevated bio-
arkers) can be made definitively.
. Pathogenesis of UA/NSTEMI
hese conditions are characterized by an imbalance between
yocardial oxygen supply and demand. A relatively few
onexclusive causes are recognized (9). A reduction in
xygen supply is more commonly the principal mechanism
han an increased requirement for oxygen.
● The most common cause of UA/NSTEMI is reduced
myocardial perfusion due to coronary artery narrowing
caused by a thrombus, usually nonocclusive, that de-
velops on a disrupted atherosclerotic plaque. The
release of myocardial markers can be caused by micro-
embolization of platelet aggregates and plaque compo-
nents. The most common underlying molecular and
cellular pathophysiology of disrupted atherosclerotic
plaque is arterial inflammation.
● A less common cause is dynamic obstruction (i.e.,
intense focal epicardial coronary artery spasm, spasm
on top of plaque, or dynamic microvascular dysfunc-
tion/spasm). e● A third cause is severe narrowing alone (e.g., to
progressive atherosclerosis or restenosis after a PCI).
● A fourth cause is coronary artery dissection (e.g., as a
cause of ACS in peripartal women).
● The fifth mechanism is secondary UA, in which the
precipitating condition is extrinsic to the coronary
arterial bed, such as with fever, tachycardia, or thyro-
toxicosis; anemia; hypoxemia; or hypotension. Often
there is associated coronary atherosclerotic narrowing.
. Presentations of UA and NSTEMI
here are 3 principal presentations of UA: 1) rest angina, 2)
ew-onset (less than 2 months) severe angina, and 3)
ncreasing angina (in intensity, duration, and/or frequency)
10). Angina is graded according to the Canadian Cardio-
ascular Society classification (11). Non–ST-elevation MI
enerally presents as prolonged, more intense rest angina or
ngina equivalent.
. Prevention of UA/NSTEMI
he major risk factors for development of CHD and
A/NSTEMI are well established. Modification of these
isk factors can prevent the development of CHD (pri-
ary prevention) or reduce the risk of experiencing
A/NSTEMI in patients who have CHD (secondary
revention). The reader is referred to contemporary
revention guidelines for the evidence base and discus-
ion supporting these guidelines (3,12,13). All practitio-
ers should emphasize appropriate long-term preventive
are.
. Onset of UA/NSTEMI
. Recognition of Symptoms by Patient
ecognition of symptoms of UA/NSTEMI must occur
efore evaluation and treatment can be pursued. Many
eople are unaware that symptoms besides chest discomfort,
uch as shortness of breath (14), diaphoresis (15), or
xtreme fatigue, can represent anginal equivalents (16,17).
he average UA/NSTEMI patient does not seek medical
are for approximately 2 h after symptom onset (17).
easons for this delay have been studied and include a
ismatch between expectation and actual symptoms (18–
0) and an impression that symptoms are self-limited or are
ue to other chronic conditions (21).
. Silent and Unrecognized Events
s many as one-half of all AMIs are clinically silent or
nrecognized, and one third present with symptoms other
han chest discomfort (22). Patients without chest discom-
ort are more likely to be older, to be women, to have
iabetes mellitus, to have prior HF, and to delay going to
he hospital. They also are less likely to be diagnosed
orrectly initially and to receive appropriate therapies. Un-
xplained dyspnea, even without angina, is a common and
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ealth care providers should maintain a high index of
uspicion when evaluating groups at high risk for silent or
nrecognized UA/MI.
II. Initial Evaluation and Management
. Clinical Assessment
orbidity and mortality from ACS can be reduced signif-
cantly if patients and bystanders recognize symptoms early,
ctivate the EMS system, and shorten the time to definitive
reatment. Educational materials are available on the “Act in
ime” Web page (www.nhlbi.nih.gov/health/public/heart/
i/core_bk.pdf) (7). For symptoms of ACS, see Table 2.
When the patient makes contact with the medical care
ystem, the health care provider must assess whether the
ymptoms are potentially a manifestation of an ACS.
ealth care providers should advise patients with possible
CS that an evaluation cannot be performed solely via
he telephone, and they should especially target those
ith known CHD or CHD risk equivalents (24). They
hould also be sensitive to anginal risk equivalents,
specially in older and diabetic patients (22). Patients
ith known CHD should be instructed to proceed
apidly to an ED when symptoms occur. When symp-
oms are moderate to severe or sustained and MI is
uspected, they should be instructed to access the EMS
ystem directly by calling 9-1-1 and to be transported to
he hospital by ambulance (25,26). Every community
hould have a written protocol that guides EMS transport
o appropriate care facilities (8). All patients presenting
o the ED with symptoms suggestive of ACS should be
onsidered high-priority and should be evaluated with a
redetermined protocol (Fig. 1) (27). Patients should be
laced on a cardiac monitor, with emergency resuscita-
ion and defibrillation equipment nearby. An ECG
hould be performed and interpreted as soon as possible,
ith a goal of within 10 min of ED arrival. If STEMI is
resent, a primary reperfusion strategy should be imple-
ented (8).
The recommendation for self-medication has been to
ncourage earlier contacting of the EMS system, that is,
fter taking 1 dose of NTG for unrelieved symptoms
uggestive of ACS (Fig. 2) (8). (While awaiting ambu-
ance arrival, patients tolerating NTG can be instructed
o take additional NTG every 5 min, up to 3 doses.)
atients may be advised to chew ASA (162 to 325 mg)
hile emergency personnel are en route, may receive
SA en route to the hospital, or may be given ASA on
rrival at the hospital.
. Patient Transportation and ED or Outpatient
acility Evaluation
atients with chest discomfort at rest or other symptoms of
CS for more than 20 min, hemodynamic instability, or aecent syncope/presyncope should be referred immediately
o an ED. Patients with less severe symptoms and without
igh-risk features should be seen initially in an ED or an
ppropriate outpatient facility. High-risk patients should
eek emergency transportation if available in less than 20 to
0 min.
The initial evaluation should answer 2 questions: what is
he likelihood that the signs and symptoms represent ACS
econdary to obstructive CAD, and what is the likelihood of
n adverse clinical outcome? Traditional risk factors for
AD are less important than are symptoms, ECG findings,
able 2. Guidelines for the Identification
f ACS Patients by ED Registration Clerks or Triage Nurses
egistration/clerical staff
Patients with the following chief complaints require immediate assessment
by the triage nurse and should be referred for further evaluation:
● Chest pain, pressure, tightness, or heaviness; pain that radiates to neck,
jaw, shoulders, back, or 1 or both arms
● Indigestion or “heartburn”; nausea and/or vomiting associated with chest
discomfort
● Persistent shortness of breath
● Weakness, dizziness, lightheadedness, loss of consciousness
riage nurse
Patients with the following symptoms and signs require immediate
assessment by the triage nurse for the initiation of the ACS protocol:
● Chest pain or severe epigastric pain, nontraumatic in origin, with
components typical of myocardial ischemia or MI:
Œ Central/substernal compression or crushing chest pain
Œ Pressure, tightness, heaviness, cramping, burning, aching sensation
Œ Unexplained indigestion, belching, epigastric pain
Œ Radiating pain in neck, jaw, shoulders, back, or 1 or both arms
● Associated dyspnea
● Associated nausea and/or vomiting
● Associated diaphoresis
If these symptoms are present, obtain stat ECG.
edical history
The triage nurse should take a brief, targeted, initial history with an
assessment of current or past history of:
● CABG, PCI, CAD, angina on effort, or MI
● NTG use to relieve chest discomfort
● Risk factors, including smoking, hyperlipidemia, hypertension, diabetes
mellitus, family history, and cocaine or methamphetamine use
● Regular and recent medication use
The brief history must not delay entry into the ACS protocol.
pecial considerations
Women may present more frequently than men with atypical chest pain and
symptoms.
Diabetic patients may have atypical presentations due to autonomic
dysfunction.
Elderly patients may have atypical symptoms such as generalized weakness,
stroke, syncope, or a change in mental status.
dapted from National Heart Attack Alert Program. Emergency Department: rapid identification
nd treatment of patients with acute myocardial infarction. Bethesda, MD: US Department of
ealth and Human Services. US Public Health Service. National Institutes of Health. National
eart, Lung and Blood Institute, September 1993. NIH Publication No. 93–3278 (23).
ACS acute coronary syndrome; CABG coronary artery bypass graft surgery; CAD coronary
rtery disease; ECG  electrocardiogram; ED  emergency department; MI  myocardial
nfarction; NTG  nitroglycerin; PCI  percutaneous coronary intervention.nd cardiac biomarkers.
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. Estimation of the Level of Risk
he initial medical history, physical examination, ECG, as-
essment of renal function, and cardiac biomarker measure-
ents in patients with symptoms suggestive of ACS can be
ntegrated into an estimation of the risk of death and nonfatal
ardiac events (Table 3). An estimation of risk is useful in
election of the site of care and selection of initial medical and
nterventional therapies. The TIMI, GRACE, and PURSUIT
isk scores, developed for short- and longer-term risk assess-
ent, are discussed in Section III.B.3 below. Overall, risk is
ighest at the time of presentation and subsequently declines
ut remains elevated beyond the acute phase.
. History
he 5 most important factors on the initial history, in order
f importance, are 1) the nature of the anginal symptoms, 2)
rior history of CAD, 3) sex (male), 4) older age, and 5) an
ncreasing number of traditional risk factors (29,30). In
atients without preexisting clinical CHD, older age is the
ost important factor.
Patients with UA/NSTEMI may have discomfort typical of
hronic angina (31) except that the episodes are more severe,
igure 1. Algorithm for Evaluation and Management of Patients Su
o facilitate interpretation of this algorithm and a more detailed discussion in the te
er that is allocated from left to right across the diagram on a given level. ACC/AHA
yndrome; ECG  electrocardiogram; LV  left ventricular.re prolonged, occur at rest, or are precipitated by less exertion. ratients often do not perceive anginal symptoms to be true
chest pain”; hence, “chest discomfort” is preferentially used in
hese guidelines. Some patients have no chest discomfort but
resent solely with jaw, neck, arm, shoulder, back, or epigastric
iscomfort or with unexplained dyspnea without discomfort
14,32,33). Features of discomfort not characteristic of UA
nclude pleuritic pain (i.e., sharp pain brought on by respiration
r cough); primary or sole location in the middle or lower
bdominal region; pain localized to a fingertip; pain repro-
uced with movement or palpation; very brief episodes (e.g., a
ew seconds or less); and radiation into the lower extremities.
evertheless, uncharacteristic features do not entirely exclude
CS (34), and the relief of chest discomfort by sublingual
TG is not reliably predictive of ACS (35), nor does the relief
f discomfort by a “GI cocktail” reliably predict its absence
36).
A history of MI increases the risk of obstructive and
ultivessel CAD. Presentations also can differ by sex (see
ection VII.A) and age (see Section VII.D). Traditional
isk factors are only weakly predictive of the likelihood of
cute ischemia (37), and they are less important than
ymptoms, ECG findings, and cardiac biomarkers. How-
ver, diabetes mellitus and extracardiac disease are major
ted of Having ACS
h box is assigned a letter code that reflects its level in the algorithm and a num-
erican College of Cardiology/American Heart Association; ACS  acute coronaryspec
xt, eac
 Amisk factors for poor outcomes in patients with ACS.
3T
i
o
i
a
P
d
a
a
a
t
o
p
m
G
i
m
4
T
p
i
o
s
d
d
b
n
e
(
C
A
N
i
P
q
p
a
m
a
i
5
T
i
e
F
D
I
i
g
i
h
o
n
t rapid
m
673JACC Vol. 50, No. 7, 2007 Anderson et al.
August 14, 2007:652–726 ACC/AHA UA/NSTEMI Guideline Revision. Tools to Estimate Risk at Presentation
he TIMI risk score tool, composed of 7 (1-point) risk
ndicators rated on presentation (Table 4), has been devel-
ped and validated for UA/NSTEMI patients (38,46) and
s available at www.timi.org. It is useful to predict both 30-d
nd 1-year mortality. A second model is based on the
URSUIT trial (39). Risk models based on the GRACE
atabase have been developed and validated for in-hospital
nd 6-month outcomes (40,47). The sum of 9 scores is
pplied to a reference monogram to determine risk of
ll-cause mortality (Fig. 3). The GRACE clinical applica-
ion tool is available at www.outcomes-umassmed.
rg/grace. Among patients with UA/NSTEMI, there is
rogressively greater benefit with increasing risk score from
ore aggressive therapies, such as LMWH (41,42), platelet
P IIb/IIIa inhibition (43), and an invasive strategy with
ncreasing risk score (44). Dynamic risk modeling promises
ore sophisticated predictive modeling in the future (45).
. Electrocardiogram
he 12-lead ECG is central to the diagnostic and triage
athway for ACS (Fig. 1) and provides important prognostic
nformation (48). Transient ST-segment changes (greater than
r equal to 0.05 mV [ie, 0.5 mm]) that develop during a
igure 2. Patient (Advance) Instructions for NTG Use and EMS
iscomfort/Pain
f patients experience chest discomfort/pain and have been previously prescribed N
nstructed (in advance) to take 1 dose of NTG immediately in response to symptoms
ually, it is recommended that the patient call 9-1-1 immediately to access EMS. In
ng 1 NTG, it is appropriate to instruct the patient or family member/friend/caregive
ave not totally resolved. If patients are not previously prescribed NTG (left side of a
r worsening 5 min after it starts. If the symptoms subside within 5 min of when the
ew-onset chest discomfort who have not been prescribed NTG, it is appropriate to
ive].) *Although some trials have used enteric-coated aspirin for initial dosing, more
edical services; NTG  nitroglycerin.ymptomatic episode at rest strongly suggest acute ischemia gue to severe CAD. Patients who present with ST-segment
epression can have either UA or NSTEMI, the distinction
eing based on the later detection of biomarkers of myocardial
ecrosis. Inverted T waves, especially if marked (greater than or
qual to 2 mm [0.2 mV]), also can indicate UA/NSTEMI
49). Q waves suggesting prior MI indicate a high likelihood of
AD. However, a normal ECG does not completely exclude
CS: 1% to 6% of such patients prove to have had an
STEMI, and at least 4% will be found to have UA (50).
Approximately 4% of MI patients show ST elevation
solated to the posterior chest leads V7 through V9 (51).
osterior ST elevation is diagnostically important because it
ualifies the patient for reperfusion therapy as a STEMI
atient (8,52).
Serial or continuous ECGs increase diagnostic sensitivity,
lthough the yield is greater with serial cardiac biomarker
easurements (53–55). Electrocardiogram monitoring is
lso recommended, because ST elevation on 12-lead ECG
s the principal criterion for reperfusion therapy.
. Physical Examination
he major objectives of the physical examination are to
dentify potential precipitating causes of myocardial isch-
mia, such as uncontrolled hypertension, thyrotoxicosis, or
tact in the Setting of Non–Trauma-Related Chest
have it available (right side of algorithm), it is recommended that they be
est discomfort/pain is unimproved or worsening 5 min after taking 1 NTG sublin-
ts with chronic stable angina, if the symptoms are significantly improved after tak-
eat NTG every 5 minutes for a maximum of 3 doses and call 9-1-1 if symptoms
m), it is recommended that they call 9-1-1 if chest discomfort/pain is unimproved
n, patients should notify their physician of the episode. (For those patients with
rage them from seeking someone else’s NTG [e.g., from a neighbor, friend, or rela-
buccal absorption occurs with non–enteric-coated formulations. EMS  emergencyCon
TG and
. If ch
patien
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ACC/AHA UA/NSTEMI Guideline Revision August 14, 2007:652–726ould impact therapeutic risk and decision making, such as
ulmonary disease and malignancies, as well as to assess the
emodynamic impact of the ischemic event. In every patient
able 3. Short-Term Risk of Death or Nonfatal MI in Patients W
High Risk
Feature
At least 1 of the following features
must be present:
No high
istory Accelerating tempo of ischemic
symptoms in preceding 48 h
Prior MI, per
or CABG;
haracter of pain Prolonged ongoing (greater than 20 min)
rest pain
Prolonged (g
now resol
likelihood
Rest angina
with rest o
Nocturnal an
New-onset o
angina in
prolonged
but with in
CAD (see
linical findings Pulmonary edema, most likely due to
ischemia
New or worsening MR murmur
S3 or new/worsening rales
Hypotension, bradycardia, tachycardia
Age greater than 75 years
Age greater
CG Angina at rest with transient ST-segment
changes greater than 0.5 mm
Bundle-branch block, new or presumed
new
Sustained ventricular tachycardia
T-wave chan
Pathological
less than
(anterior,
ardiac markers Elevated cardiac TnT, TnI, or CK-MB (e.g.,
TnT or TnI greater than 0.1 ng per ml)
Slightly eleva
(e.g., TnT
0.1 ng pe
Estimation of the short-term risks of death and nonfatal cardiac ischemic events in UA (or NSTE
his table is meant to offer general guidance and illustration rather than rigid algorithms. Adapte
994 (28).
CABG  coronary artery bypass graft surgery; CAD  coronary artery disease; CCS  Canad
yocardial infarction; MR  mitral regurgitation; NTG  nitroglycerin; TnI  troponin I; TnT  tr
able 4. TIMI Risk Score for
nstable Angina/Non–ST-Elevation MI
TIMI Risk Score
All-Cause Mortality, New or Recurrent MI,
or Severe Recurrent Ischemia Requiring
Urgent Revascularization Through 14 d
After Randomization, %
0–1 4.7
2 8.3
3 13.2
4 19.9
5 26.2
6–7 40.9
he TIMI risk score is determined by the sum of the presence of 7 variables at admission; 1 point
s given for each of the following variables: age 65 y or older; at least 3 risk factors for CAD; prior
oronary stenosis of 50% or more; ST-segment deviation on ECG presentation; at least 2 anginal
vents in prior 24 h; use of aspirin in prior 7 d; elevated serum cardiac biomarkers. Prior coronary
tenosis of 50% or more remained relatively insensitive to missing information and remained a
ignificant predictor of events. Reprinted with permission from Antman EM, Cohen M, Bernink PJ,
t al. The TIMI risk score for unstable angina/non-ST elevation MI: a method for prognostication
nd therapeutic decision making. JAMA 2000;284:835–42 (46). Copyright © 2000 American
edical Association.o
CAD  coronary artery disease; ECG  electrocardiogram; MI  myocardial infarction; y 
ear.ith suspected ACS, vital signs should be routinely mea-
ured (blood pressure, in both arms if dissection is sus-
ected; heart rate; temperature), and such patients should
ndergo a focused but thorough cardiovascular examination.
he physical examination can also lead to important alter-
ative diagnoses, such as aortic dissection (unequal pulses)
r acute pericarditis (friction rub). Cardiogenic shock man-
fested by hypotension and evidence of organ hypoperfusion
an occur in patients with NSTEMI or STEMI and
onstitutes a medical emergency (56).
. Noncardiac Causes of Symptoms and Secondary
auses of Myocardial Ischemia
hree fourths of patients evaluated in the ED for suspected
CS will be found not to have acute ischemia (57). This
ncludes patients with noncardiac pain (e.g., pulmonary
mbolism, musculoskeletal or esophageal discomfort) or
ardiac pain not caused by myocardial ischemia (e.g., acute
ericarditis). The remaining patients should be evaluated for
econdary causes of UA, for example, aortic stenosis and
ypertrophic cardiomyopathy; anemia due to gastrointesti-
al bleeding; hypoxemia due to worsening of chronic
A/NSTEMI
rmediate Risk Low Risk
feature, but must have
the following:
No high- or intermediate-risk feature but
may have any of the following features:
l or cerebrovascular disease,
spirin use
than 20 min) rest angina,
ith moderate or high
D
er than 20 min) or relieved
lingual NTG
ressive CCS class III or IV
st 2 weeks without
ter than 20 min) rest pain
ediate or high likelihood of
6)
Increased angina frequency, severity, or
duration
Angina provoked at a lower threshold
New onset angina with onset 2 weeks to
2 months prior to presentation
0 years
ves or resting ST-depression
in multiple lead groups
r, lateral)
Normal or unchanged ECG
ardiac TnT, TnI, or CK-MB
r than 0.01 but less than
Normal
complex multivariable problem that cannot be fully specified in a table such as this; therefore,
AHCPR Clinical Practice Guidelines No. 10, Unstable Angina: Diagnosis and Management, May
rdiovascular Society; CK-MB  creatine kinase, MB fraction; ECG  electrocardiogram; MI 
T; UA/NSTEMI  unstable angina/non–ST-elevation myocardial infarction.ith U
Inte
-risk
1 of
iphera
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stula placed for renal dialysis.
. Cardiac Biomarkers of Necrosis and the
edefinition of AMI
ardiac biomarkers have proliferated to address various
igure 3. GRACE Prediction Score Card and Nomogram for All-Cau
eprinted with permission from Eagle KA, Lim MJ, Dabbous OH, et al. A validated pr
ostdischarge death in an international registry. JAMA 2004;291:2727–33 (47). Copacets of ACS pathophysiology. Favorable biomarker fea- rures of biomarkers of necrosis are high concentrations in
he myocardium and absence in nonmyocardial tissue,
elease into the blood within a convenient diagnostic time
indow and in proportion to the extent of myocardial
njury, and quantification with reproducible, inexpensive,
ortality From Discharge to 6 Months
n model for all forms of acute coronary syndrome: estimating the risk of 6-month
© 2004 American Medical Association.se Mapid, and easily applied assays (58). The cardiac troponins
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ACC/AHA UA/NSTEMI Guideline Revision August 14, 2007:652–726ossess many of these features, have gained wide acceptance
s the biomarkers of choice, and have inspired redefinitions
f MI (59). Myocardial necrosis now is defined by an
levation of troponin above the 99th percentile of normal.
yocardial infarction, which is necrosis related to ischemia,
s further defined by the addition of at least 1 of the
ollowing criteria: ischemic ST and T-wave changes, new
eft bundle-branch block, new Q waves, PCI-related marker
levation, or imaging showing a new loss of myocardium.
. CREATINE KINASE-MB
reatine kinase-MB, long a standard marker for the diag-
osis of MI, is less sensitive and specific for MI than the
ardiac troponins; however, it remains useful for the diag-
osis of early infarct extension (reinfarction) and periproce-
ural MI because its short half-life better permits the
etection of secondary increases in marker levels (60).
. CARDIAC TROPONINS
he troponin subunits T and I are derived from heart-
pecific genes; hence, the term “cardiac troponins” (cTn)
pecifically refers to cardiac troponin T (cTnT) or I (cTnI).
ecause cTnT and cTnI generally are not detected in the
lood of healthy persons, the cutoff values for elevated cTnT
nd cTnI levels may be set to slightly above the upper limits
f the performance characteristics of the assay for a normal
ealthy population. Assays for cTnI and cTnT have evolved
hrough several generations (61); hence, physicians need to
now the characteristics of tests used in their hospitals.
. MYOGLOBIN
yoglobin, a low-molecular-weight heme protein found in
oth cardiac and skeletal muscle, is not cardiac specific, but
t is released rapidly (as early as 2 h) after the onset of
yocardial necrosis. Because it is not cardiac specific, it may
e more useful to assist in rapidly “ruling out” rather than
ruling in” NSTEMI, which should be confirmed by tro-
onin measurements (62).
. CLINICAL USE
lthough troponins can be detected in blood as early as 2 to
h after the onset of symptoms, elevation can be delayed for
p to 8 to 12 h. This timing of elevation is similar to that of
K-MB but persists longer, for up to 5 to 14 days (Fig. 4).
pproximately 30% to 40% of ACS patients without
T-segment elevation who would be diagnosed as having
A on the basis of the absence of CK-MB elevation have
STEMI when assessed by troponin assays. The result is a
hange in case mix and overall survival by a troponin-based
efinition of NSTEMI (63). Troponin elevation also con-
eys prognostic information incremental to clinical charac-
eristics, the ECG, and the predischarge exercise test
64–68) (Fig. 5). Although cTn accurately identifies myo-
ardial necrosis, it does not inform as to the cause(s) of
ecrosis, which can be multiple (69). Therefore, in making
he diagnosis of NSTEMI, cardiac troponins should be used
n conjunction with other criteria. TTroponin elevation also permits the identification of
igh-risk patients who will benefit from aggressive therapies
uch as the LMWHs (vs. UFH) (41,42,71) and platelet GP
Ib/IIIa inhibitors, alone (72,73) or in addition to clopi-
ogrel (74), and in conjuction with overall risk assessment,
routine invasive strategy (75,76). When troponin and
K-MB are used together, those with both markers positive
re at highest short-term risk, those with troponin elevation
lone are at intermediate risk, and those with isolated
K-MB are at lowest risk, equivalent to those with normal
arker levels (77). Equivalent diagnostic and prognostic
nformation is provided by cTnI and cTnT except in
atients with renal dysfunction (78), in whom cTnT is less
pecific but retains predictive ability (79).
Cardiac markers can be measured in the central chemistry
aboratory or with point-of-care instruments in the ED
64). To date, bedside testing has not succeeded in becom-
ng widely accepted or applied.
LINICAL USE OF MARKER CHANGE SCORES
newer method aims to identify or exclude MI within 6 h
f symptoms by relying on changes in serum marker levels
delta values) over an abbreviated time interval (e.g., 2 h).
igure 4. Timing of Release of Various Biomarkers
fter Acute Ischemic Myocardial Infarction
he biomarkers are plotted showing the multiples of the cutoff for acute myocardial
nfarction (AMI) over time. The dashed horizontal line shows the upper limit of nor-
al (ULN; defined as the 99th percentile from a normal reference population with-
ut myocardial necrosis; the coefficient of variation of the assay should be 10% or
ess). The earliest rising biomarkers are myoglobin and CK isoforms (leftmost
urve). CKMB (dashed curve) rises to a peak of 2 to 5 times the ULN and typically
eturns to the normal range within 2 to 3 d after AMI. The cardiac-specific troponins
how small elevations above the ULN in small infarctions (e.g., as is often the
ase with NSTEMI) but rise to 20 to 50 times the ULN is the setting of large infarc-
ions (e.g., as is typically the case in STEMI). The troponin levels may stay elevated
bove the ULN for 7 d or more after AMI. Modified from Shapiro BP, Jaffe AS. Car-
iac biomarkers. In: Murphy JG, Lloyd MA, editors. Mayo Clinic Cardiology: Concise
extbook. 3rd ed. Rochester, MN: Mayo Clinic Scientific Press and New York:
nforma Healthcare USA, 2007:773–80 (70). Used with permission of Mayo Foun-
ation for Medical Education and Research. CK  creatine kinase; CKMB  MB
raction of creatine kinase; CV  coefficient of variation; MI  myocardial infarc-
ion; NSTEMI  non–ST-elevation myocardial infarction; UA/NSTEMI  unstable
ngina/non–ST-elevation myocardial infarction.his method focuses on increasing values while still in their
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ion of patients for more aggressive anti-ischemic therapies
54,55).
. Other Markers and Multimarker Approaches
esides biomarkers of myocardial necrosis, markers of other
athophysiological mechanisms implicated in ACS are un-
er investigation, including markers of ischemia, coagula-
ion, platelet activation, inflammation, and HF. B-type
atriuretic peptide, one of these newer biomarkers (mea-
ured as BNP or N-terminal proBNP), has been shown to
rovide incremental prognostic value in patient cohorts with
TEMI and UA/NSTEMI (80–82) and is now included as
ossibly useful in guideline recommendations. A multi-
arker approach to risk stratification of UA/NSTEMI
e.g., simultaneous assessment of cTnI, C-reactive protein,
nd BNP) has been advocated as a potential advance over
ingle biomarker assessment (83) but will require further
ssessment.
. Immediate Management
y integrating information from the history, physical exami-
ation, 12-lead ECG, and initial cardiac biomarker tests,
linicians can assign patients to 1 of 4 categories: noncardiac
iagnosis, chronic stable angina, possible ACS, and definite
CS, which is further divided into UA/NSTEMI and
TEMI, based on the initial ECG (Fig. 1). Patients with a low
ikelihood of CAD should be evaluated for noncoronary
resentations (Fig. 1, B1). Patients found to have an alternative
igure 5. Troponin I Levels to Predict
he Risk of Mortality in Acute Coronary Syndromes
ortality rates are at 42 d (without adjustment for baseline characteristics) in
atients with acute coronary syndrome. The numbers at the bottom of each bar are
he numbers of patients with cardiac troponin I levels in each range, and the num-
ers above the bars are percentages. p less than 0.001 for the increase in the
ortality rate (and the risk ratio for mortality) with increasing levels of cardiac tro-
onin I at enrollment. Reprinted with permission from Antman EM, Tanasijevic MJ,
hompson B, et al. Cardiac-specific troponin I levels to predict the risk of mortality
n patients with acute coronary syndromes. N Engl J Med 1996;335:1342–9 (66).
opyright © 1996 Massachusetts Medical Society. All rights reserved.iagnosis should be referred for appropriate follow-up care bFig. 1, C1). Chronic stable angina diagnosed in this setting
Fig. 1, B2) should be managed according to the ACC/AHA
002 Guideline Update for the Management of Patients With
hronic Stable Angina (31). Patients with possible ACS (Fig.
, B3 and D1) are candidates for additional observation (Fig. 1,
1). Those with definite ACS (Fig. 1, B4) are triaged based on
he 12-lead ECG. Patients with ST-segment elevation (Fig. 1,
3) are evaluated for reperfusion therapy (Fig. 1, D3) and
anaged according to the ACC/AHA Guidelines for the
anagement of Patients With ST-Elevation Myocardial In-
arction (8), whereas those without ST-segment elevation (Fig.
, C2) are either managed by additional observation (Fig. 1,
1) or admitted to the hospital (Fig. 1, H3). Patients with
ow-risk ACS (negative initial testing) (Fig. 1, H1) may be
ischarged and treated as outpatients (Fig. 1, I1).
. Chest Pain Units
o facilitate appropriate evaluation while avoiding both
nnecessary hospital admissions and ED discharges, special
D “chest pain units” have been established (84,85). Here,
atients at low risk of ACS undergo a predetermined
bservation period with serial cardiac biomarkers and
CGs, are reevaluated, and may then undergo functional
ardiac testing or a noninvasive coronary imaging study (i.e.,
oronary CT angiography). Those with abnormal findings
re admitted for inpatient management (Fig. 1, H3).
Extension of the use of chest pain units to intermediate-
isk patients has been favorably tested (86). Such a strategy
s facilitated by making available diagnostic (stress/imaging)
esting 7 d per week. An appropriate inpatient telemetry
nit may serve as an alternative to an ED-based chest pain
nit when the latter is not available.
Patients with positive findings during ED/chest pain
nit initial evaluation or follow-up observation (Fig. 1,
2, F2) should be admitted to the hospital (Fig. 1, H3)
nd managed as described in Section IV. Patients at low
CS risk (Fig. 1, F1) may be considered for a pre-
ischarge stress test or coronary CT angiography (Fig. 1,
1). Alternatively, the patient may be discharged, with
ppropriate precautionary medication and instructions,
nd return for testing within 72 h. In general, a physician
hould see patients as soon after discharge from the ED
r chest pain unit as practical and appropriate, that is,
sually within 72 h.
Two newer imaging modalities, cardiac magnetic res-
nance and multidetector CT for coronary calcification
nd coronary CT angiography, are undergoing clinical
alidation and application and hold promise as alternative
r supplementary imaging modalities for the assessment
f patients presenting with chest pain syndromes (87–
9). Coronary CT angiography may be particularly ap-
ropriate for those with acute chest pain syndromes with
ow to intermediate pretest probability of CAD in the
etting of nondiagnostic ECG and negative cardiac
iomarkers (88).
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atients with definite or probable UA/NSTEMI who are
table hemodynamically should be admitted to an inpatient
nit for bed rest with continuous rhythm monitoring and
areful observation for recurrent ischemia and managed with
ither an invasive or conservative strategy (Fig. 1, Table 5).
igh-risk patients, including those with continuing discomfort
nd/or hemodynamic instability, should be hospitalized in a
oronary care unit and observed for at least 24 h without any
ajor complications. (Shorter periods might be appropriate for
atients who are successfully reperfused, have normal LV
unction, and have minimal or no necrosis.)
After admission, standard medical therapy is indicated. The
ptimal management of UA/NSTEMI has the twin goals of
elief of ischemia and prevention of serious adverse outcomes.
his is accomplished with anti-ischemic therapy, anticoagulant
herapy, ongoing risk stratification, and appropriate use of
nvasive procedures. Unless contraindicated, treatment gener-
lly should include ASA, a beta blocker, anticoagulant therapy,
GP IIb/IIIa receptor antagonist, and a thienopyridine (i.e.,
lopidogrel; initiation may be deferred until a revascularization
ecision is made). A critical early decision is the choice of an
ngiographic (invasive) or an initially conservative strategy
Table 5). Assessment of LV function, which can influence
anagement, is recommended.
. Anti-Ischemic and Analgesic Therapy
. General Care
atients should be placed on bed rest initially but can be
obilized to a chair and use a bedside commode when
able 5. Selection of Initial Treatment Strategy:
nvasive Versus Conservative Strategy
Preferred Strategy Patient Characteristics
nvasive Recurrent angina or ischemia at rest or with low-level
activities despite intensive medical therapy
Elevated cardiac biomarkers (TnT or TnI)
New or presumably new ST-segment depression
Signs or symptoms of HF or new or worsening mitral
regurgitation
High-risk findings from noninvasive testing
Hemodynamic instability
Sustained ventricular tachycardia
PCI within 6 months
Prior CABG
High risk score (e.g., TIMI, GRACE)
Reduced left ventricular function (LVEF less than
40%)
onservative Low risk score (e.g., TIMI, GRACE)
Patient or physician preference in the absence of
high-risk features
ABG coronary artery bypass graft surgery; GRACE Global Registry of Acute Coronary Events;
F  heart failure; LVEF  left ventricular ejection fraction; PCI  percutaneous coronary
ntervention; TIMI  Thrombolysis In Myocardial Infarction; TnI  troponin I; TnT  troponin T.ymptom free. Subsequent activity should be liberalized Ihen response to treatment occurs. Patients with or at risk
or hypoxemia should receive supplemental oxygen. A short
eriod of initial routine oxygen supplementation is reason-
ble during stabilization of the patient. Patients should
ndergo continuous ECG monitoring during their early
ospital phases, because ventricular fibrillation is the major
reventable cause of early death.
. Use of Anti-Ischemic Therapies
. NITRATES
he rationale for NTG use in UA/NSTEMI is extrapolated
rom STEMI and from pathophysiological principles and
xtensive clinical observations (90). Nitroglycerin is an
ndothelium-independent vasodilator with both peripheral
nd coronary vascular effects that result in reduction in
yocardial oxygen demand and enhancement of myocardial
xygen delivery. Nitroglycerin promotes the dilation of large
oronary arteries, as well as collateral flow and redistribution
f coronary blood flow to ischemic regions.
Intravenous NTG can benefit patients who are unrespon-
ive to sublingual NTG and beta blockers. Intravenous
TG is also useful in patients with HF or hypertension.
ide effects include headache and hypotension.
Intravenous NTG may be initiated at a rate of 10 mcg per
in and increased by 10 mcg per min every 3 to 5 min until
elief of symptoms or blood pressure response is noted. A
eiling dose of 200 mcg per min is commonly used. Systolic
lood pressure generally should not be reduced to less than
10 mm Hg in previously normotensive patients or to more
han 25% below the starting mean arterial blood pressure if
ypertension was present. Nitroglycerin should be avoided
n patients with initial systolic blood pressure less than 90
m Hg or 30 mm Hg or more below their baseline, or with
arked bradycardia or tachycardia.
Topical or oral nitrates are acceptable alternatives for
atients without ongoing refractory ischemic symptoms.
fter medical stabilization, intravenous NTG generally
hould be converted within 24 h to a nonparenteral alter-
ative administered in a non–tolerance-producing regimen
lower and/or intermittent dosing) if ongoing therapy is
equired (91).
. MORPHINE SULFATE
orphine sulfate (1 to 5 mg intravenously [IV]) is reason-
ble for patients whose symptoms either are not relieved
espite NTG or recur despite adequate anti-ischemic ther-
py. Hypotension, nausea, and respiratory depression are
otential adverse effects of morphine. A large observational
egistry that included patients with UA/NSTEMI sug-
ested a higher adjusted likelihood of death with morphine
se (92). Although subject to uncontrolled selection biases,
hese results raise a safety concern and suggest the need for
randomized trial. Meanwhile, the recommendation for
orphine use has been downgraded from a class I to a classIa recommendation.
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eta blockers act by competitively blocking the effects of
atecholamines on cell membrane beta receptors. The ben-
fits of routine early intravenous use of beta blockers in
arlier studies in AMI have been less impressive based on
ata in the reperfusion era (93,94). In the 45,852-patient
hinese COMMIT study (93% with STEMI, 7% with
STEMI) (94), neither the composite of death, reinfarc-
ion, or cardiac arrest nor death alone was reduced for up to
8 d in the hospital. A modest reduction in reinfarction and
entricular fibrillation was counterbalanced by an increase in
ardiogenic shock, primarily in those who were hemody-
amically compromised. Thus, early aggressive beta block-
de poses a net hazard in hemodynamically unstable patients
nd should be avoided. In an attempt to balance the
vidence base overall for UA/NSTEMI patients, beta
lockers are recommended to be initiated orally, in the
bsence of contraindications (e.g., HF), within the first
4 h. Greater caution is suggested in the early use of
ntravenous beta blockers, which should be targeted to
pecific indications and should be avoided with HF, hypo-
ension, and hemodynamic instability. (In contrast, oral beta
lockers are strongly recommended for secondary preven-
ion before hospital discharge in those with compensated
F or LV systolic dysfunction) (95,96).
The rationale for use of beta blockers for secondary
revention after UA and NSTEMI derives from limited
rial data and extrapolations from chronic angina, HF, and
TEMI studies (95). Pooled results from relatively contem-
orary anticoagulant therapy trials in patients with ACS
ndergoing PCI and given beta-blocker therapy have shown
educed death rates at 30 d (0.6% vs. 2.0%) and 6 months
1.7% vs. 3.7%; both p less than 0.001) (96). High- or
ntermediate-risk patients undergoing cardiac or noncardiac
urgery also have been shown to benefit (97).
. CALCIUM CHANNEL BLOCKERS
lthough members of the calcium channel blocker class of
rugs are structurally diverse, the superiority of 1 agent over
nother in UA/NSTEMI has not been demonstrated,
xcept for the increased risk posed by rapid-release nifedi-
ine (98,99). The calcium channel blocker evidence base for
enefit is greatest for verapamil and diltiazem (100,101).
eneficial effects in UA/NSTEMI are believed to be due to
ecreased myocardial oxygen demand and improved myo-
ardial flow (90). Side effects include hypotension, worsen-
ng HF, bradycardia, and atrioventricular block.
Calcium channel blockers may be used to control
schemia-related symptoms in patients unresponsive to or
ntolerant of nitrates and beta blockers and in patients with
ariant angina. Rapid-release, short-acting dihydropyridines
e.g., nifedipine) must be avoided in the absence of con-
omitant beta blockade (98,99). Verapamil and diltiazem
hould be avoided in patients with pulmonary edema or
evere LV dysfunction (100,101). Caution is indicated when
beta-blocker and calcium channel blocker are combined, jecause they act in synergy to depress LV function and sinus
nd atrioventricular node conduction.
. INHIBITORS OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM
ngiotensin-converting enzyme inhibitors have been shown
o reduce mortality rates in patients with AMI and in those
ho recently had an MI and have LV systolic dysfunction
102), in patients with diabetes mellitus with LV dysfunc-
ion (103), and in a broad spectrum of patients with
igh-risk chronic CAD, including patients with normal LV
unction (104). Angiotensin receptor blockers may be useful
n post-MI and ischemic HF patients intolerant of ACE
nhibitors (105,106).
The selective aldosterone receptor blocker eplerenone,
sed in patients with MI complicated by LV dysfunction
nd either HF or diabetes mellitus, has been shown to
educe morbidity and mortality (107). Spironolactone de-
reased morbidity and death in patients with severe HF,
ne-half of whom had an ischemic origin of the HF (108).
. INTRA-AORTIC BALLOON COUNTERPULSATION
ntra-aortic balloon counterpulsation has been used for
ore than 30 years for refractory UA after MI, for cardio-
enic shock, for hemodynamic support during catheteriza-
ion and/or angioplasty, before high-risk surgery, and for
echanical complications of MI (109), although random-
zed data to support its benefit are limited.
. ANALGESIC THERAPY
ecause of the known increased risk of cardiovascular events
mong patients taking COX-2 inhibitors and NSAIDs (110–
12), patients who are taking them at the time of UA/
STEMI should discontinue them immediately (see Section
.2.16 in the full text for additional discussion). A secondary
nalysis of the Enoxaparin and Thrombolysis Reperfusion for
cute Myocardial Infarction Treatment (EXTRACT)-
IMI-25 data (113) demonstrated an increased risk of death,
einfarction, HF, or shock among patients who were taking
SAIDs within 7 d of enrollment. Longer-term management
s considered in Section VI.C.
. Antiplatelet/Anticoagulant Therapy in Patients
ith Likely or Definite UA/NSTEMI
nticoagulant therapy is essential to modify the ACS
isease process and its adverse consequences. A combina-
ion of ASA, an anticoagulant, and additional antiplatelet
herapy represents the most effective therapy. The intensity
f treatment is tailored to individual risk, and triple-
nticoagulant treatment is used in patients with continuing
schemia or with other high-risk features and in patients
riented to an early invasive strategy (see Table 5 and Figs.
, 7, and 8). Table 6 shows the recommended doses of the
arious agents. A problematic group of patients are those
ho present with UA/NSTEMI but who are therapeuti-
ally anticoagulated with warfarin. In such patients, clinical
udgment is needed.
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. ASPIRIN
rials of ASA in UA/NSTEMI have consistently docu-
ented a benefit to its use compared with placebo (114–
17). Platelets represent one of the principal participants in
hrombus formation after plaque disruption. Aspirin acts
romptly to inhibit COX-1 within platelets, which prevents
he formation of thromboxane A2, diminishing the platelet
ggregation promoted by this pathway. Indirect compari-
igure 6. Algorithm for Patients With UA/NSTEMI Managed by an
hen multiple drugs are listed, they are in alphabetical order and not in order of pre
anagement strategy. ‡Evidence exists that GP IIb/IIIa inhibitors may not be necess
h earlier (Class I, Level of Evidence B for clopidogrel administration) and bivalirudi
lycoprotein; IV  intravenous; LOE  level of evidence; UA/NSTEMI unstable angons of doses ranging from less than 75 to 1,500 mg per day cave shown similar reductions in the odds of vascular events;
owever, there is a dose-dependent increase in bleeding
118). Therefore, maintenance doses of 75 to 162 mg of
SA are recommended.
It is recommended that ASA be initiated as soon as the
iagnosis of ACS is made or suspected unless contraindi-
ated and that it be continued indefinitely. On the basis of
rior randomized trial protocols and clinical experience, the
nitial dose of ASA should be between 162 and 325 mg.
ore rapid buccal absorption occurs with non–enteric-
l Invasive Strategy
e (e.g., Boxes B, B1, and B2).*See dosing Table 6. †See Table 5 for selection of
the patient received a preloading dose of at least 300 mg of clopidogrel at least
lected as the anticoagulant (Class IIa, Level of Evidence B). ASA  aspirin; GP 
n–ST-elevation myocardial infarction; UFH  unfractionated heparin.Initia
ferenc
ary ifoated formulationsthan with enteric-coated formulations
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SA of 325 mg per day has been recommended for 1 month
fter bare-metal stent implantation and 3 to 6 months after
rug-eluting stent implementation, which had been modi-
ed to an initial dose range of 162 to 325 mg per day based
n the risk of excess bleeding with higher doses and an
pdate of current evidence of outcomes after PCI (Table 6,
ig. 9).
Because of an interaction between ibuprofen and ASA, an
lternative NSAID should be used, or ibuprofen should be
aken at least 30 min after or at least 8 h before ASA
igure 7. Algorithm for Patients With UA/NSTEMI Managed by
hen multiple drugs are listed, they are in alphabetical order and not in order of pre
anagement strategy. ‡Recurrent symptoms/ischemia, heart failure, serious arrhyth
evel of evidence; LVEF  left ventricular ejection fraction; UA/NSTEMI  unstable awww.fda.gov/drug/infopage/ibuprofen/science_paper.html). areported interaction of ASA and ACE inhibitors does not
ppear to interfere importantly with clinical benefits (120).
. ADENOSINE DIPHOSPHATE RECEPTOR ANTAGONISTS AND OTHER
NTIPLATELET AGENTS
wo thienopyridines—ticlopidine and clopidogrel—are
denosine diphosphate receptor (P2Y12) antagonists ap-
roved for antiplatelet therapy. The platelet effects of
iclopidine and clopidogrel are irreversible but take several
ays to achieve maximal effect in the absence of a loading
ose. Ticlopidine has been used successfully for the second-
nitial Conservative Strategy
e (e.g., Boxes C1, and C2). *See dosing Table 6. †See Table 5 for selection of
SA  aspirin; EF  ejection fraction; GP  glycoprotein; IV  intravenous; LOE 
non–ST-elevation myocardial infarction; UFH  unfractionated heparin.an I
ferencry prevention of stroke and MI and for the prevention of
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ACC/AHA UA/NSTEMI Guideline Revision August 14, 2007:652–726tent closure and graft occlusion (121); however, the adverse
otential of ticlopidine (i.e., neutropenia and, rarely, throm-
otic thrombocytopenic purpura) (122) has limited its use.
Clopidogrel has undergone extensive clinical testing and
pplication. For secondary prevention, clopidogrel alone
as at least as effective as or modestly more effective than
SA in the Clopidogrel versus Aspirin in Patients at Risk of
schaemic Events (CAPRIE) trial (123). Thus, clopidogrel
s indicated in patients with UA/NSTEMI who are unable
o tolerate ASA. In patients with a history of gastrointes-
inal bleeding while taking ASA, drugs to minimize the risk
f recurrent bleeding (e.g., proton-pump inhibitors) should
e prescribed when a thienopyridine is administered (124).
In the acute setting, an oral loading dose of clopidogrel is
ypically used to achieve more rapid platelet inhibition. A
arge evidence base exists for the approved loading dose of
00 mg. Small to moderate-sized trials have reported
avorable outcomes with a 600- versus a 300-mg loading
ose in patients undergoing PCI (125); however, larger-
cale randomized trials are needed to rigorously establish the
ptimal loading dose.
The Clopidogrel in Unstable angina to prevent Recurrent
schemic Events (CURE) trial randomized 12,562 patients
ith UA and NSTEMI presenting within 24 h to placebo
r clopidogrel (loading dose of 300 mg followed by 75 mg
aily) and followed them for 3 to 12 months (118). All
igure 8. Management After Diagnostic Angiography in Patient
See dosing Table 6. †Evidence exists that GP IIb/IIIa inhibitors may not be necess
h earlier (Class I, Level of Evidence B for clopidogrel administration) and bivalirudi
FH is recommended if fondaparinux is selected as the anticoagulant (see dosing T
lbeit without any significant, flow-limiting stenoses, long-term treatment with antipla
spirin; CABG  coronary artery bypass graft; CAD  coronary artery disease; GP 
ention; pre angio  before angiography; UA/NSTEMI  unstable angina/non–ST-eleatients received ASA. Cardiovascular death, MI, or stroke 0ccurred in 11.5% of placebo and 9.3% of clopidogrel
atients (risk ratio [RR]  0.80, p less than 0.001).
lopidogrel also reduced in-hospital severe ischemia and
evascularization. A benefit was observed across subgroups
nd began within the first few hours. A small excess in
leeding was noted, which was increased in patients under-
oing CABG surgery within 5 d of stopping clopidogrel.
The PCI-CURE study was an observational substudy of
he 2,658 patients undergoing PCI within the CURE trial
126). Clopidogrel reduced the primary end point (a com-
osite of cardiovascular death, MI, or urgent target-vessel
evascularization within 30 d of PCI) by 30% (p 0.03) and
educed the incidence of cardiovascular death or MI by 31%
p  0.002). Therefore, clopidogrel is recommended in
atients who undergo PCI.
The Intracoronary Stenting and Antithrombotic Regi-
en–Rapid Early Action for Coronary Treatment (ISAR-
EACT)-2 trial tested whether patients undergoing PCI
ho were preloaded with clopidogrel 600 mg at least 2 h
efore the procedure, as well as ASA, would derive addi-
ional benefit from GP IIb/IIIa receptor antagonist therapy
74). The study randomized 2,022 patients to abciximab or
lacebo. The primary end point was reached in 90 patients
8.9%) assigned to abciximab versus 120 patients (11.9%)
ssigned to placebo, a 25% reduction in risk with abciximab
RR 0.75, 95% confidence interval [CI] 0.58 to 0.97, p 
th UA/NSTEMI
he patient received a preloading dose of at least 300 mg of clopidogrel at least
lected as the anticoagulant (Class IIa, Level of Evidence B). ‡Additional bolus of
). §For patients in whom the clinician believes coronary atherosclerosis is present,
gents and other secondary prevention measures should be considered. ASA 
rotein; IV  intravenous; LD  loading dose; PCI  percutaneous coronary inter-
myocardial infarction; UFH  unfractionated heparin.s Wi
ary if t
n is se
able 6
telet a
glycop.03) (74). However, this benefit was limited to patients
Table 6. Dosing Table for Antiplatelet and Anticoagulant Therapy in Patients With UA/NSTEMI
During PCI
Drug* Initial Medical Treatment
Patient Received Initial
Medical Treatment
Patient Did Not Receive
Initial Medical Treatment After PCI At Hospital Discharge
Oral Antiplatelet Therapy
Aspirin 162 to 325 mg nonenteric formulation,
orally or chewed
No additional treatment 162 to 325 mg nonenteric
formulation orally or
chewed
162 to 325 mg daily should be
given† for at least 1 month
after BMS implantation,
3 months after SES
implantation, and 6 months
after PES implantation, after
which daily chronic aspirin
should be continued
indefinitely at a dose of 75 to
162 mg
162 to 325 mg daily should be
given† for at least 1 month
after BMS implantation,
3 months after SES
implantation, and 6 months
after PES implantation, after
which daily chronic aspirin
should be continued
indefinitely at a dose of 75 to
162 mg
Clopidogrel LD of 300 to 600 mg orally
MD of 75 mg orally per day
A second LD of 300 mg orally
may be given to
supplement a prior LD of
300 mg
LD of 300 to 600 mg orally For BMS: 75 mg daily for at least
1 month and ideally up to 1
year. For DES, 75 mg daily for
at least 1 year (in patients
who are not at high risk of
bleeding) (See Fig. 9)
For BMS: 75 mg daily for at least
1 month and ideally up to 1
year. For DES, 75 mg daily for
at least 1 year (in patients
who are not at high risk of
bleeding) (See Fig. 9)
Ticlopidine LD of 500 mg orally
MD of 250 mg orally twice daily
No additional treatment LD of 500 mg orally MD of 250 mg orally twice daily MD of 250 mg orally twice daily
Anticoagulants
Bivalirudin 0.1 mg per kg bolus, 0.25 mg per kg
per h infusion
0.5 mg per kg bolus, increase
infusion to 1.75 mg per kg
per h
0.75 mg per kg bolus, 1.75
mg per kg per h infusion
No additional treatment or
continue infusion for up to 4 h
Dalteparin 120 IU per kg SC every 12 h
(maximum 10,000 IU twice daily)‡
IV GP IIb/IIIa planned: target
ACT 200 s using UFH
IV GP IIb/IIIa planned: 60 to
70 U per kg§ of UFH
No additional treatment
No IV GP IIb/IIIa planned:
target ACT 250 to 300 s
for HemoTec; 300 to 350 s
for Hemochron using UFH
No IV GP IIb/IIIa planned: 100
to 140 U per kg of UFH
Enoxaparin LD of 30 mg IV bolus may be given
MD  1 mg per kg SC every 12 h;
extend dosing interval to 1 mg
per kg every 24 h if estimated
creatinine clearance less than
30 mL per min
Last SC dose less than 8 h:
no additional treatment
Last SC dose greater than
8 h: 0.3 mg per kg IV bolus
0.5 to 0.75 mg per kg IV
bolus
No additional treatment
Fondaparinux 2.5 mg SC once daily. Avoid for
creatinine clearance less than
30 mL per min
50 to 60 U per kg IV bolus of
UFH is recommended by
the OASIS 5 Investigators¶
50 to 60 U per kg IV bolus of
UFH is recommended by
the OASIS 5 Investigators¶
No additional treatment
Continued on next page
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Table 6. Continued
During PCI
Drug* Initial Medical Treatment
Patient Received Initial
Medical Treatment
Patient Did Not Receive
Initial Medical Treatment After PCI At Hospital Discharge
Unfractionated
heparin
LD of 60 U per kg (max 4,000 U) as IV
bolus
MD of IV infusion of 12 U per kg per h
(max 1,000 U per h) to maintain
aPTT at 1.5 to 2.0 times control
(approximately 50 to 70 s)
IV GP IIb/IIIa planned: target
ACT 200 s
No IV GP IIb/IIIa planned:
target ACT 250 to 300 s
for HemoTec; 300 to 350 s
for Hemochron
IV GP IIb/IIIa planned: 60 to
70 U per kg§
No IV GP IIb/IIIa planned: 100
to 140 U per kg
No additional treatment
Intravenous Antiplatelet Therapy
Abciximab Not applicable Not applicable LD of 0.25 mg per kg IV bolus
MD of 0.125 mcg per kg per
min (max 10 meg per min)
Continue MD infusion for 12 h
Eptifibatide LD of IV bolus of 180 mcg per kg
MD of IV infusion of 2.0 mcg per kg per
min; reduce infusion by 50% in
patients with estimated creatinine
clearance less than 50 mL per min
Continue infusion LD of IV bolus of 180 mcg per
kg followed 10 min later by
second IV bolus of 180
mcg per kg
MD of 2.0 mcg per kg per
min; reduce infusion by
50% in patients with
estimated creatinine
clearance less than 50 mL
per min
Continue MD infusion for 18 to
24 h
Tirofiban LD of IV infusion of 0.4 mcg per kg per
min for 30 min
MD of IV infusion of 0.1 mcg per kg per
min; reduce rate of infusion by 50%
in patients with estimated creatinine
clearance less than
30 mL per min
Continue infusion LD of IV infusion of 0.4 mcg
per kg per min for 30 min
MD of IV infusion of 0.1 mcg
per kg per min; reduce rate
of infusion by 50% in
patients with estimated
creatinine clearance less
than 30 mL per min
Continue MD infusion for 18 to
24 h
Additional considerations include the possibility that a conservatively managed patient may develop a need for PCI, in which case an intravenous bolus of 50 to 60 U per kg is recommended if fondaparinux was given for initial medical treatment; the safety of this drug
combination is not well established. For conservatively managed patients in whom enoxaparin was the initial medical treatment, as noted in the table, additional intravenous enoxaparin is an acceptable option. *This list is in alphabetical order and is not meant to
indicate a particular therapy preference. †In patients in whom the physician is concerned abut the risk of bleeding, a lower initial ASA dose after PCI of 75 to 162 mg/d is reasonable (Class IIa, LOE: C). ‡Dalteparin was evaluated for management of patients with
UA/NSTEMI in an era before the widespread use of important therapies such as stents, clopidogrel, and GP IIb/IIIa inhibitors. Its relative efficacy and safety in the contemporary management era is not well established. §Some operators use less than 60 U per kg
of UFH with GP IIb/IIIa blockade, although no clinical trial data exist to demonstrate the efficacy of doses below 60 U per kg in this setting. For patients managed by an initial conservative strategy, agents such as enoxaparin and fondaparinux offer the convenience
advantage of SC administration compared with an intravenous infusion of UFH. They are also less likely to provoke heparin-induced thrombocytopenia than UFH. Available data suggest fondaparinux is associated with less bleeding than enoxaparin in conservatively
managed patients using the regimens listed. ¶Personal communication, OASIS 5 Investigators, July 7, 2006. Note that this regimen has not been rigorously tested in prospective randomized trials.
ACT  activated clotting time; BMS  bare-metal stent; GP  glycoprotein; IU  international unit; IV  intravenous; LD  loading dose; MD  maintenance dose; PCI  percutaneous coronary intervention; PES  paclitaxel-eluting stent; SC  subcutaneous; SES
 sirolimus-eluting stent; U  units; UA/NSTEMI  unstable angina/non-ST-elevation myocardial infarction; UFH  unfractionated heparin.
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.71, 95% CI 0.54 to 0.95, p  0.02 [p  0.07 for
nteraction]). Bleeding rates were similar in the 2 arms.
hus, it appears beneficial to add an intravenous GP
Ib/IIIa inhibitor to thienopyridine treatment if an invasive
trategy is planned in patients with high-risk features (e.g.,
levated cTn level; Figs. 6, 7, and 8).
The optimal timing of administration (“upstream” vs.
in-lab”) of the loading dose of clopidogrel for those who are
anaged with an early invasive strategy cannot be deter-
ined with certainty from the PCI-CURE trial. Given the
arly separation of the curves, clopidogrel is recommended
s initial, upstream therapy when there is a delay to coronary
ngiography (Figs. 6, 7, and 8).
Although clopidogrel has a role in patients with UA/
STEMI managed both conservatively and invasively
127), the optimal duration of therapy is uncertain. Most of
he incremental benefit of clopidogrel in CURE occurred
ithin the first 1 to 3 months, but favorable results were
bserved over the entire trial period, which averaged 9
igure 9. Long-Term Anticoagulant Therapy at Hospital Discharge
For aspirin (ASA) allergic patients, use clopidogrel alone (indefinitely), or try aspirin
aily. ‡Continue ASA indefinitely and warfarin longer term as indicated for specific co
mboli. §When warfarin is added to aspirin plus clopidogrel, an INR of 2.0 to 2.5 is
entricular; UA/NSTEMI  unstable angina/non–ST-elevation myocardial infarction.onths, and for up to 1 year (118,128). Pathological (129) cnd clinical evidence (130,131) suggests the need for longer-
erm therapy, that is, at least 1 year, in patients who receive
rug-eluting stents. Drug-eluting stents delay neointimal
overage of stent struts, increase late thrombotic events (by
pproximately 0.5%), and prevent restenosis. In contrast,
lopidogrel was not beneficial in a large trial of high-risk
rimary prevention patients (132).
Because clopidogrel increases the risk of bleeding during
ajor surgery, it has been recommended that it be withheld
or at least 5 d in patients scheduled for elective CABG
133,134). Thus, many hospitals that use an early invasive
pproach for UA/NSTEMI delay starting clopidogrel until
iagnostic angiography clarifies whether early CABG is
ndicated. However, when clopidogrel is given before cath-
terization, and urgent surgical intervention is indicated,
ome experience suggests that “early” bypass surgery may be
ndertaken by experienced surgeons at acceptable incre-
ental bleeding risk (135). More data are needed to
ormulate definitive recommendations on this issue.
Sulfinpyrazone, dipyridamole, prostacyclin, and prostacy-
UA/NSTEMI
sitization. †For clopidogrel-allergic patients, use ticlopidine 250 mg by mouth twice
ns such as atrial fibrillation; LV thrombus; or cerebral, venous, or pulmonary
mended. INR  international normalized ratio; LOE  level of evidence; LV  leftAfter
desen
nditio
recomlin analogs have not been demonstrated to be of benefit in
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oxane synthase blockers and thromboxane A2 receptor
ntagonists have been evaluated in ACS and have not
hown any advantage over ASA. A number of other
ntiplatelet drugs are currently available, and still others are
nder active investigation.
Considerable interpatient variability in inhibition of
latelet aggregation to a specific dose of clopidogrel has
een observed (136). Patients with diminished responsive-
ess appear to be at increased risk of ischemic events
137,138). Optimal strategies to avoid or overcome poor
esponsiveness remain to be established but might involve
onitoring of individual responsiveness and dose adjust-
ents (139,140).
. Anticoagulants
n increasing number of anticoagulants (previously referred
o as antithrombins) have become available for management
f patients with UA/NSTEMI. Anticoagulant strategies
ecommended (class I or IIa) on the basis of the current data
et are given in Figures 6, 7, and 8. Although each agent or
egimen reviewed (UFH, enoxaparin, fondaparinux, and
ivalirudin [invasive strategy only]) satisfies criteria for
ffectiveness, it is often difficult to conclude that one
ntithrombotic strategy is preferred over another, given
iffering study designs (blinded vs. unblinded; superiority
s. noninferiority) and questions of equipotent dosing;
iffering patient populations (higher vs. lower risk), dura-
ions of therapy, and strategies (invasive vs. conservative);
onfounding by open-label and crossover use of anticoagu-
ants; differing antiplatelet strategies; and differing clinical
ersus study protocols. The limitations of noninferiority
rials also must be noted (141). It is suggested that each
nstitution agree on an approved anticoagulant approach
ost consistent with local practice and preference.
. UNFRACTIONATED HEPARIN
nfractionated heparin (UFH) is a heterogeneous mixture
f polysaccharide chains of molecular weights that range
rom 5,000 to 30,000 Daltons and that have varying
nticoagulant activity (142). Unfractionated heparin accel-
rates the action of circulating antithrombin, which inacti-
ates factor IIa (thrombin), factor IXa, and factor Xa.
nfractionated heparin prevents thrombus propagation but
oes not lyse existing thrombi.
Meta-analysis of a relatively small, randomized database
uggests a reduction of 33% to 56% (p  0.06 to 0.03) in
arly ischemic events by the addition of UFH (143,144).
ost of the benefit is short term, with reactivation of the
hrombotic process (“rebound”) after the discontinuation of
FH contributing to the loss of early gain (145).
Unfractionated heparin binds to a number of plasma
roteins, blood cells, and endothelial cells, leading to the
oor bioavailability, especially at low doses, and marked
ariability in anticoagulant response. As a consequence, the
nticoagulant effect of heparin requires monitoring with the nctivated partial thromboplastin time (aPTT). A weight-
djusted dosing regimen provides more predictable antico-
gulation than a fixed-dose regimen (146,147). An initial
olus of 60 U per kg (maximum 4,000 U) is followed by an
nitial infusion of 12 U per kg per hour (maximum 1,000 U
er hour). Older age and female sex decrease UFH require-
ents. A therapeutic range equivalent to heparin levels of
.3 to 0.7 U/mL, assessed by anti-factor Xa determinations,
hich correlates with aPTT values between 60 and 80
econds, has been recommended (142). Nomograms should
e established at each institution to achieve aPTT values in
he target range of 1.5 to 2.5 times control aPTT values.
easurements should be made 6 h after any dosage change
nd whenever there are significant changes in clinical status
nd used to adjust UFH infusion until the aPTT exhibits a
herapeutic level.
During UFH therapy, complete blood counts and platelet
ounts are recommended to monitor for anemia and
eparin-induced thrombocytopenia, especially after pro-
onged (several days) infusions. The duration of UFH
herapy in most UA/NSTEMI trials has been 2 to 5 d. The
ptimal duration of therapy is uncertain and likely varies by
trategy.
. LOW-MOLECULAR-WEIGHT HEPARIN
he LMWHs are obtained through chemical or enzymatic
epolymerization of the polysaccharide chains of heparin to
rovide chains with different molecular-weight distributions
142,148). Approximately 25% to 50% of the pentasaccharide-
ontaining chains of LMWH preparations contain more
han 18 saccharide units, which inactivate both thrombin
nd factor Xa; LMWH chains of fewer than 18 saccharide
nits inactivate factor Xa but not thrombin. Therefore,
MWHs are relatively more potent in inhibiting factor Xa
han inactivating thrombin. Advantages of LMWH over
FH include decreased binding to plasma proteins and
ndothelial cells and dose-independent clearance, with a
onger half-life. This results in more predictable and sus-
ained anticoagulation with once- or twice-a-day subcuta-
eous administration that usually does not require labora-
ory monitoring. Different preparations of LMWHs vary in
ean molecular weights (ranging from 4,200 to 6,000
altons) and corresponding ratios of anti-Xa factor to
nti-IIa factor (1.9 to 3.8) (148).
Unstable angina/NSTEMI trials of LMWH and ASA
ompared with ASA alone or with UFH have generally
hown favorable results. Eight randomized trials have di-
ectly compared an LMWH with UFH (Table 7). Trials
ith dalteparin and nadroparin reported similar rates of
eath or nonfatal MI compared with UFH, whereas 5 of 6
rials of enoxaparin found point estimates for death or
onfatal MI that favored enoxaparin; the pooled OR was
.91 (95% CI 0.83 to 0.99). This incremental benefit of
noxaparin appeared to be driven largely by a reduction in
onfatal MI. With an early invasive strategy, outcomes with
TF
E
F
F
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Trial
(Reference) n LMWH/Dose UFH
End Point/
Drug Effect Analysis 95% CI p
Major Bleeding
(p)
RISC (150) 1,506 (a) 6 d*: dalteparin
120 IU per kg† SC
twice daily
(maximum
10,000 IU)
(b) During first 40 d:
dalteparin 7,500
IU SC once per
day
(a) 6 d: placebo
(b) During first 40 d:
placebo
(a) Death or new MI
(6 d): LMWH
1.8%, Placebo
4.8%
(b) Death or new MI
(during first 40
d‡): LMWH 8%,
placebo 10.7%
(a) RR 0.37
ARR 3%
(b) RR 0.75
ARR 2.7%
(a) 0.20 to
0.68
(b) 0.54 to
1.03
(a) 0.001
(b) 0.07
(a) LMWH 0.8%,
placebo
0.5%; ARR
0.3% (p 
NR)
(b) During first
40 d: LMWH
0.3%,
placebo
0.3%; ARR
0% (p  NR)
SSENCE
(41)
3,171 Enoxaparin 1 mg per
kg SC twice daily
(minimum 48 h,
maximum 8 d)
UFH IV bolus
(usually 5,000
units) and
continued IV
infusion
(a) Death, MI, or
recurrent angina
at 14 d: LMWH
16.6%, UFH
19.8%
(b) Death, MI, or
recurrent angina
at 30 d: LMWH
19.8%, UFH
23.3%
(a) OR at 14 d
 0.80
ARR 3.2%
(b) OR at 30 d
 0.81
ARR 3.5%
(a) 0.67 to
0.96
(b) 0.68 to
0.96
(a) 0.019
(b) 0.016
At 30 d: LMWH
6.5%, UFH 7%;
ARR 0.5% (p 
0.57)
RIC (151) 1,482 (a) Days 1 to 6:
dalteparin 120 IU
per kg SC twice
daily
(b) Days 6 to 45§:
dalteparin 7,500
IU SC once per
day
(a) Days 1 to 6: UFH
5,000 units IV
bolus and IV
infusion of 1,000
units per h for 48
h
(b) Days 6 to 45:
placebo SC once
daily
(a) Death, MI, or
recurrence of
angina (Days 1 to
6): LMWH 9.3%,
UFH 7.6%
(b) Death, MI, or
recurrence of
angina (Days 6 to
45): 12.3% in
both the LMWH
and UFH groups
(a) Death or MI
(Days 1 to 6):
LMWH 3.9%, UFH
3.6%
(b) Death or MI
(Days 6 to 45):
LMWH 4.3%,
placebo 4.7%
(a) RR 1.18
ARR
1.7%
(b) RR 1.01
ARR 0%
(a) RR 1.07
ARR
0.3%
(b) RR 0.92
ARR 0.4%
(a) 0.84 to
1.66
(b) 0.74 to
1.38
(a) 0.63 to
1.80
(b) 0.54 to
1.57
(a) 0.33
(b) 0.96
(a) 0.80
(b) 0.76
(a) Days 1 to 6:
LMWH 1.1%,
UFH 1.0%;
ARR 0.1%
(p  NR
(b) Days 6 to
45: LMWH
0.5%,
placebo
0.4%; ARR
0.1%
(p  NR)
RAX.I.S.
(152)
3,468 (a) Nadroparin 6 d:
nadroparin 86
anti-Xa IU per kg
IV bolus, followed
by nadroparin 86
anti-Xa IU per kg
SC twice daily for
6 d
(b) Nadroparin 14 d:
nadroparin 86
anti-Xa IU per kg
IV bolus, followed
by nadroparin 86
anti-Xa IU per kg
SC twice daily for
14 d
(a)  (b) UFH 5,000
units IV bolus and
UFH infusion at
1,250 units per h IV
for 6 d (plus or
minus 2 d)
Cardiac death, MI,
refractory angina,
recurrence of UA
at Day 14: LMWH
6 d 17.8%,
LMWH 14 d
20.0% UFH
18.1%
(a) ARR 0.3%
(b) ARR
1.9%
(a) 2.8
to 3.4
(b) 5.1
to 1.3
(a) 0.85
(b) 0.24
At 6 d: UFH
1.6%, LMWH
1.5%, ARR
0.1%
At 14 d: UFH
1.6%, LMWH
3.5%, ARR
1.9%
(p  0.0035)Continued on next page
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Trial
(Reference) n LMWH/Dose UFH
End Point/
Drug Effect Analysis 95% CI p
Major Bleeding
(p)
IMI 11B
(42)
3,910 (a) Inpatient:
enoxaparin 30 mg
IV bolus
immediately
followed by 1 mg
per kg SC every
12 h
(b) Outpatient:
enoxaparin 40 mg
SC twice per day
(patients weighing
less than 65 kg)
or 60 mg SC twice
per day (patients
weighing at least
65 kg)
(a) Inpatient: UFH
70 units per kg
bolus and
infusion at 15
units per h
titrated to aPTT
(treatment
maintained for a
minimum of 3
and maximum of
8 d at physician’s
discretion)
(b) Outpatient:
placebo SC twice
per day
Death, MI, urgent
revascularization
(a) At 48 h; LMWH
5.5% UFH 7.3%
(b) 8 d: LMWH
12.4%, UFH
14.5%
(c) 14 d: LMWH
14.2%, UFH
16.7%
(d) 43 d: LMWH
17.3%, UFH
19.7%
(a) OR 0.75
ARR 1.8%
(b) OR 0.83
ARR 2.1%
(c) OR 0.82
ARR 2.5%
(d) OR 0.85
ARR 2.4%
(a) 0.58 to
0.97 (b)
0.69 to
1.00
(c) 0.69 to
0.98
(d) 0.72 to
1.00
(a) 0.026
(b) 0.048
(c) 0.029
(d) 0.048
At 48 h: LMWH
0.8%, UFH
0.7%, ARR
0.1%
(p  0.14)
End of initial
hospitalization
LMWH 1.5%,
UFH 1%; ARR
0.5% (p
0.143)
Between day 8
and day 43:
LMWH 2.9%,
placebo
2.9%; ARR
0% (p 
0.021)
CUTE II
(153)
525 Enoxaparin 1 mg per
kg SC every 12 h
UFH 5,000 units IV
bolus and
maintenance
infusion at 1,000
units per h IV
adjusted to aPTT
(a) Death or
(b) MI at 30 d
(a) LMWH 2.5%,
UFH 1.9%
(b) LMWH 6.7%,
UFH 7.1%
(a) RR 1.3
ARR
0.6%
(b) RR 0.94
ARR 0.4%
(a) 0.06 to
3.93
(b) 0.45 to
2.56
(a) 0.77
(b) 0.86
LMWH 0.3%,
UFH 1%;
ARR 0.7%
(p  0.57)
NTERACT¶
(154)
746 Enoxaparin 1 mg per
kg SC every 12 h
UFH 70 units per kg
IV bolus followed
by continuous
infusion at 15
units per kg per h
Death or MI at 30 d:
LMWH 5.0%, UFH
9.0%
RR 0.55
ARR 4%
0.30 to
0.96
0.031 At 96 h: LMWH
1.8%;
UFH 4.6%;
ARR 2.8%
(p  0.03)
to Z**
(155)
3,987 Enoxaparin 1 mg per
kg SC every 12 h
UFH 4,000 units IV
bolus followed by
900 units per h
IV infusion for
patients weighing
at least 70 kg
UFH 60 units per kg
(maximum 4,000
units) IV bolus
followed by 12
units per kg per h
IV infusion for
patients weighing
less than 70 kg
All-cause death, MI,
or refractory
ischemia within
7 d of tirofiban
initiation: LMWH
8.4%, UFH 9.4%
HR 0.88
ARR 1%
0.71 to
1.08
NR LMWH 0.9%,
UFH 0.4%;
ARR 0.5%
(p  0.05)Continued on next page
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0).
The Enoxaparin Versus Tinzaparin (EVET) trial directly
ompared 2 LMWHs, enoxaparin and tinzaparin, in 436
atients with UA/NSTEMI. Enoxaparin was associated
ith a lower rate of death/MI/recurrent angina at 7 and
0 d than tinzaparin (149). Bleeding rates were similar.
Four trials evaluated the potential benefit of prolonged
dministration of LMWH after hospital discharge, with
ittle or no benefit beyond the acute phase (see Table 7)
157). In addition to providing ease of administration and
liminating the need for monitoring, LMWHs stimulate
latelets less than UFH (158) and less frequently cause
eparin-induced thrombocytopenia (159). They are associ-
ted with more frequent minor but not major bleeding. A
ost hoc analysis from the Superior Yield of the New
trategy of Enoxaparin, Revascularization and Glycoprotein
Ib/IIIa Inhibitors (SYNERGY) trial (Fig. 10) (156) sug-
ested that some of the excess bleeding seen with enoxapa-
in could be explained by crossover to UFH at the time of
CI. It thus appears reasonable to maintain consistent
nticoagulant therapy from the pre-PCI phase throughout
he procedure itself. For patients in whom CABG is
lanned, it is recommended that LMWH be discontinued
able 7. Continued
Trial
(Reference) n LMWH/Dose UFH
YNERGY††
(156)
9,978 Enoxaparin 1 mg per
kg SC every 12 h
UFH 60 units per kg
IV bolus
(maximum of
5,000 units) and
followed by IV
infusion of 12
units per kg per h
(maximum of
1,000 units per h
initially
Dea
M
3
r
L
U
or specific interventions and additional medications during the study, see individual study refer
ore than 5 mg per dL or intracranial or pericardial bleeding. ESSENCE: Major hemorrhage was
er liter or more, or a retroperitoneal, intracranial, or intraocular hemorrhage. TIMI 11B: Overt b
rop of greater than or equal to 3 g per dL; or the requirement of transfusion of at least 2 U of b
leeding criteria. TIMI major bleeding involved a hemoglobin drop greater than 5 g per dL (with or w
r cardiac tamponade. INTERACT: Major bleeding included bleeding resulting in death, or retrope
r equal to 3 g per dL. FRIC: A bleeding event was classified as major if it led to a fall in the hemog
f the study treatment. *Primary study end point was first 6 d. †Initial trial dose of 150 IU per k
4 patients or 6% major bleeding episodes and 9 patients or 14% minor episodes among 63 act
Primary study outcome was Days 6 to 45. All patients in ACUTE II received a tirofiban loading d
in. ¶All patients in INTERACT received eptifibatide 180 mcg per kg bolus followed by a 2.0 mcg
†Patients also received glycoprotein IIb/IIIa inhibitors, aspirin, clopidogrel; patients eligible for
uring percutaneous coronary intervention.
A to Z Aggrastat to Zocor study; ACUTE II Antithrombotic Combination Using Tirofiban and En
nterval; ESSENCE  Efficacy and Safety of Subcutaneous Enoxaparin in Unstable Angina and N
NTERACT  Integrilin and Enoxaparin Randomized Assessment of Acute Coronary Syndrome Tre
umber of patients; LMWH  low-molecular-weight heparin; MI  myocardial infarction; NR  no
noxaparin, Revascularization and Glycoprotein IIb/IIIA Inhibitors; TIMI 11B  Thrombolysis In Mnd UFH used during the operation. B. DIRECT THROMBIN INHIBITORS
irudin, the prototype direct thrombin inhibitor, has been
tudied extensively but with mixed results, including excess
leeding with higher doses (160,161). Bivalirudin is a
ynthetic analog of hirudin that binds reversibly to thrombin
nd inhibits clot-bound thrombin. Bivalirudin was investi-
ated in 13,819 patients with UA/NSTEMI in the Acute
atheterization and Urgent Intervention Triage strategy
ACUITY) trial (162). In a 2 2 factorial design, a heparin
UFH or enoxaparin), with or without upstream GP IIb/
IIa inhibition, was compared to bivalirudin, with or with-
ut upstream GP IIb/IIIa inhibition; a third arm with
ivalirudin alone and provisional GP IIb/IIIa inhibition was
lso included. The study was randomized but open-label.
ivalirudin compared with heparin (both with GP IIb/IIIa
nhibitors) gave noninferior 30-d rates of composite isch-
mia (7.7% vs. 7.3%), major bleeding (5.3% vs. 5.7%), and
et clinical outcomes (11.8% vs. 11.7%; Fig. 11). Bivalirudin
lone was comparable to heparin plus GP IIb/IIIa inhibi-
ion for the subgroup of patients who received a thienopy-
idine before angiography or PCI (composite ischemic
nd-point rate 7.0% vs. 7.3%), but it was inferior in patients
ho did not (ischemic event rate 9.1% vs. 7.1%, RR 1.29,
5% CI 1.03 to 1.63; p for interaction  0.054) (Fig. 12).
Point/
Effect Analysis 95% CI p
Major Bleeding
(p)
nonfatal
ing first
fter
ization
14.0%,
.5%,
HR 0.96
ARR 0.5%
0.86 to
1.06
0.40 TIMI minor:
LMWH
12.5%,
UFH 12.3%;
ARR 0.2%
(p  0.80)
TIMI major:
LMWH 9.1%,
UFH 7.6%
ARR 1.5%
(p  0.008)
GUSTO severe:
LMWH 2.7%,
UFH 2.2%;
ARR 0.5%
(p  0.08)
Major bleeding was classified as follows in the various trials: A to Z: decrease in hemoglobin of
as bleeding resulting in death, transfusion of at least 2 U of blood, a fall in hemoglobin of 30 g
sulting in death; a bleed in a retroperitoneal, intracranial, or intraocular location; a hemoglobin
YNERGY: TIMI and GUSTO criteria. ACUTE II: Severity was recorded on the basis of the TIMI trial
an identified site, not associated with coronary artery bypass grafting) or intracranial hemorrhage
l hemorrhage, or bleeding at a specific site accompanied by a drop in hemoglobin greater than
vel of at least 20 g per liter, required transfusion, was intracranial, or caused death or cessation
wice daily decreased to 120 IU per kg SC twice daily due to increased bleeding during first 6 d
ated patients). ‡Follow-up incomplete in 13 patients (8 dalteparin, 5 placebo) at their request.
0.4 mcg per kg per min over 30 min, followed by a maintenance infusion at 0.1 mcg per kg per
per min infusion for 48 h. **All patients enrolled in the A to Z Trial received aspirin and tirofiban.
ent even if LMWH or UFH given before enrollment, adjustments made to enoxaparin and UFH
in; aPTT activated partial thromboplastin time; ARR absolute risk reduction; CI confidence
ave Myocardial Infarction; FRIC  FRagmin In unstable Coronary disease; HR  hazard ratio;
; IU  international units; IV  intravenous; LD  loading dose; MD  maintenance dose; N 
ted; RR  relative risk; SC  subcutaneous; SYNERGY  Superior Yield of the New strategy of
ial Infarction 11B; U  unit; UA  unstable angina; UFH  unfractionated heparin.End
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omitant GP IIb/IIIa inhibition or a thienopyridine, ad-
inistered before angiography, to optimize outcomes if a
ivalirudin-based anticoagulant strategy is used.
. FACTOR XA INHIBITORS
actor Xa inhibitors act proximally in the coagulation
ascade to inhibit the multiplier effects of the downstream
eactions, thereby suppressing thrombin generation. Advan-
igure 10. SYNERGY Primary Outcomes at 30 D
I  confidence interval; MI  myocardial infarction; SYNERGY  Superior Yield of t
FH  unfractionated heparin.
igure 11. ACUITY Clinical Outcomes at 30 Dp for noninferiority. ACUITY  Acute Catheterization and Urgent Intervention Triage strategages of the pentasaccharide factor Xa inhibitor fondapa-
inux over UFH include decreased binding to plasma
roteins and endothelial cells and dose-independent clear-
nce with a longer half-life, which results in more predict-
ble and sustained anticoagulation and allows fixed-dose,
nce-daily subcutaneous administration. As with the LM-
Hs, fondaparinux does not require laboratory monitoring.
ondaparinux is renally cleared. The factor Xa inhibitors do
w strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors;he NeY; CI  confidence interval; GP  glycoprotein; UFH  unfractionated heparin.
n
a
a
S
f
P
d
s
d
t
d
P
a
t
T
r
w
h
s
o
(
e
e
6
d
6
O
t
s
r
h
E
T
a
s
M
m
p
a
(
w
c
u
w
w
o
e
m
f
t
t
n
3
W
F
A
u
691JACC Vol. 50, No. 7, 2007 Anderson et al.
August 14, 2007:652–726 ACC/AHA UA/NSTEMI Guideline Revisionot have any action against thrombin that is already formed,
possible explanation for the increased rate of catheter-
ssociated thrombosis with fondaparinux.
The Organization to Assess Strategies for Ischaemic
yndromes (OASIS)-5 investigators evaluated the use of
ondaparinux in 20,078 patients with UA/NSTEMI (163).
atients were randomized (double-blind, double-dummy
esign) to a control strategy of enoxaparin 1.0 mg per kg
ubcutaneous twice daily (reduced to 1.0 mg per kg once
aily for patients with an estimated creatinine clearance less
han 30 mL per min) or to fondaparinux 2.5 mg SC once
aily. Unfractionated heparin initially was not used with
CI, but because of an increased incidence of catheter-
ssociated thrombus, the protocol was amended to permit
he use of open-label UFH at the investigator’s discretion.
he OASIS-5 primary composite outcome (death, MI, or
efractory ischemia at 9 d) was similar in the 2 groups (579
ith fondaparinux [5.8%] vs. 573 with enoxaparin [5.7%];
azard ratio [HR] 1.01; 95% CI 0.90 to 1.13), which
atisfied prespecified noninferiority criteria (Fig. 13). Rates
f major bleeding at 9 d were lower with fondaparinux
2.2% vs. 4.1%, p less than 0.001), which yielded a lower
fficacy plus safety composite (Fig. 13). Primary composite
vents trended lower in the fondaparinux group at 30 d and
months; 6-month rates of death (5.8% vs. 6.5%) and
eath, MI, and stroke (11.3% vs. 12.5%) were also lower at
months with fondaparinux.
At present, on the basis of limited experience in
ASIS-5 and concerns raised by OASIS-6 (164), UFH (50
igure 12. ACUITY Composite Ischemia and Bleeding Outcomes
CUITY  Acute Catheterization and Urgent Intervention Triage strategY; CI  confid
nfractionated heparin.o 60 U per kg IV) is recommended with a fondaparinux ttrategy during angiography/PCI. Fondaparinux appears to
epresent a preferred anticoagulant strategy in those at
igher risk of bleeding managed with a noninvasive strategy.
. LONG-TERM ANTICOAGULATION
he long-term administration of warfarin or other coumarins
fter UA/NSTEMI or STEMI has been evaluated in several
mall and a few moderate-size trials with variable results (165).
oderate-intensity warfarin with low-dose ASA appears to be
odestly more effective than ASA alone when applied to
ost-MI patients treated primarily with a noninterventional
pproach, but it is associated with a higher risk of bleeding
166,167). The relevance of routine long-term anticoagulation
ith warfarin to contemporary practice is unclear given the
urrent routine use of clopidogrel and the much more frequent
se of an invasive strategy.
In contrast, occasional UA/NSTEMI patients present
ith a specific indication for oral anticoagulant therapy with
arfarin (i.e., atrial fibrillation, mechanical prosthetic valve,
r LV thrombus) in addition to ASA plus clopidogrel. The
vidence base for such “triple-anticoagulant therapy” re-
ains small. When triple-combination therapy is selected
or clear indications, on the basis of clinical judgment that
he benefit will outweigh the incremental risk of bleeding,
herapy should be given for the minimum time and doses
ecessary to achieve protection.
. Platelet GP IIb/IIIa Receptor Antagonists
hen platelets are activated by a number of mechanisms,
nterval; GP  glycoprotein; PCI  percutaneous coronary intervention; UFH ence iheir GP IIb/IIIa cell membrane receptors undergo a
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brinogen (168). The binding of fibrinogen molecules to
eceptors on adjacent platelets results in platelet aggrega-
ion. The platelet GP IIb/IIIa receptor antagonists act by
ccupying the receptors, preventing fibrinogen from bind-
ng and thereby preventing platelet aggregation. Experi-
ental and clinical studies have suggested that occupancy of
0% or more of the receptor population and inhibition of
latelet aggregation to adenosine diphosphate (5 to 20
icromoles per liter) by 80% or more results in potent
nticoagulant effects (169).
The 3 approved GP IIb/IIIa antagonists differ in phar-
acokinetic and pharmacodynamic properties (170). Abcix-
mab is a Fab fragment of a humanized murine antibody
hat has a short plasma half-life but strong affinity for the
eceptor. Platelet aggregation gradually returns to normal 24
o 48 h after discontinuation. Eptifibatide is a cyclic hep-
apeptide that contains the KGD (Lys-Gly-Asp) sequence;
irofiban is a nonpeptide mimetic of the RGD (Arg-Gly-
sp) sequence of fibrinogen. They bind with high specificity
o the GP IIb/IIIa receptor, but platelet aggregation returns
o normal 4 to 8 h after discontinuation of these 2 drugs,
onsistent with their relatively short half-lives of 2 to 3 h
171).
The efficacy of GP IIb/IIIa antagonists for the prevention
f PCI-related complications has been documented in
everal trials, many composed primarily of patients with UA
Table 8). Abciximab has been studied primarily in PCI
rials, in which it consistently reduced rates of MI and the
eed for urgent revascularization. In subgroups of patients
ho had ACS, abciximab reduced the 30-d risk of ischemic
igure 13. OASIS Cumulative Risks of Death, MI, or Refractory Isc
p for noninferiority. †p for superiority. CI  confidence interval; MI  myocardial infomplications after PCI by 60% to 80%. Two trials specif- acally studied patients with ACS. In the c7E3 Fab Anti-
latelet Therapy in Unstable Refractory Angina (CAP-
URE) trial (172), abciximab reduced the rate of death,
I, or urgent revascularization within 30 d from 15.9% to
1.3% (RR 0.71, p  0.012). Hence, abciximab is approved
or the treatment of UA/NSTEMI as an adjunct to PCI or
hen PCI is planned within 24 h. In contrast, the Global
se of Strategies to Open Occluded Coronary Arteries
GUSTO) IV-ACS trial (173) enrolled 7,800 patients with
A/NSTEMI in whom early (less than 48 h) revascular-
zation was not intended and found no benefit or adverse
rends in rates of death or MI. Although the explanation for
hese results is not clear, abciximab should not be used in
he management of patients with UA/NSTEMI in whom
n early invasive management strategy is not planned.
Tirofiban was studied in the Platelet Receptor Inhibition
n Ischemic Syndrome Management (PRISM) (182) and
latelet Receptor Inhibition in Ischemic Syndrome Man-
gement in Patients Limited by Unstable Signs and Symp-
oms (PRISM-PLUS) (181) trials (Table 8). The PRISM
rial compared tirofiban with heparin in 3,232 patients with
A/NSTEMI. The primary composite outcome (death,
I, or refractory ischemia at the end of a 48-h infusion) was
educed from 5.6% to 3.8% (RR 0.67, p 0.01). At 30 days,
he frequency of the composite outcome was similar in the
groups, but the rate of death or MI trended lower with
irofiban (7.1% vs. 5.8%), and mortality was reduced (3.6%
s. 2.3%, p  0.02). Benefit primarily occurred in patients
ith elevated troponin. PRISM-PLUS randomized 1,915
A/NSTEMI patients to tirofiban alone, UFH alone, or
he combination for 48 to 108 h (181). The tirofiban-alone
ia
; OASIS 5  Fifth Organization to Assess Strategies for Ischemic Syndromes.hemrm was dropped during the trial because of an adverse early
Table 8. UA/NSTEMI Outcome of Death or Myocardial Infarction in Clinical Trials of GP IIb/IIIa Antagonists Involving More Than 1,000 Patients
Trial (Year) Study Population Drugs
Results
ARR, % RR 95% CI p
Placebo GP IIb/IIIa
n % n %
PCI trials
EPIC (1994) (174) High-risk PTCA Abciximab 72/696 10.3 49/708 6.9* 3.4 0.68 0.47 to 0.95 0.022
EPILOG (1997) (175) All PTCA Abciximab 85/939 9.1 35/935 3.7* 5.4 0.41 0.28 to 0.61 Less than 0.001
CAPTURE (1997) (172) UA Abciximab 57/635 9.0 30/630 4.8 4.2 0.53 0.35 to 0.81 0.003
IMPACT II (1997) (176) All PTCA Eptifibatide 112/1328 8.4 93/1349 6.9 1.5 0.83 0.63 to 1.06 0.134
RESTORE (1997) (177) UA Tirofiban 69/1070 6.4 54/1071 5.0 1.4 0.78 0.55 to 1.10 0.162
EPISTENT (1998) (178) Elective stenting Abciximab 83/809 10.2 38/794 4.8* 5.4 0.46 0.32 to 0.68 Less than 0.001
ESPRIT (2000) (179) Elective stenting Eptifibatide 104/1024 10.2 66/1040 6.3 3.9 0.62 0.46 to 0.84 0.0016
ISAR-REACT (2004) (180) Elective stenting with clopidogrel
pretreatment
Abciximab 42/1080 3.9 43/1079 4.0 0.1 1.02 0.68 to 1.55 0.91
ACS trials
PRISM-PLUS (1998) (181) UA/NQWMI Tirofiban 95/797 11.9 67/733* 9.1* 2.8 0.70 0.51 to 0.96 0.03
PRISM (1998) (182) UA/NQWMI Tirofiban 115/1616 7.1 94/1616 5.8† 1.3 0.82 0.61 to 1.05 0.11
PURSUIT (1998) (183) UA/NQWMI Eptifibatide 744/4739 15.7 67/4722 1.4* 14.3 0.09 0.07 to 0.12 Less than
0.0001
PARAGON A (1998) (184) UA/NQWMI Lamifiban 89/758 11.7 80/755 10.6*† 1.1 0.90 0.68 to 1.20 0.48
GUSTO IV ACS (2001) (173) UA/NQWMI Abciximab 209/2598 8.0 450/5202‡ 8.7 0.7 1.08 0.92 to 1.26 0.36
PARAGON B (2002) (185) UA/NQWMI Lamifiban 296/2597 11.4 278/2628 10.6 0.8 0.94 0.77 to 1.09 0.32
ISAR-REACT (2006) (74) UA/NSTEMI§ Abciximab 116/1010 11.5 87/1012 8.6 2.9 0.75 1.57 to 0.92 0.03
All PCI trials 624/7581 8.2 408/7606 5.4 2.8 0.65 0.58 to 0.74 Less than
0.0001
All ACS trials 1548/13 105 11.8 1036/15 656 6.6 5.2 0.56 0.52 to 0.60 Less than
0.0001
All PCI and ACS trials 2172/20 686 10.5 1444/23 262 6.2 4.3 0.59 0.55 to 0.63 Less than
0.0001
*Best treatment group selected for analysis. †Platelet GP IIb/IIIa antagonist without heparin. ‡Pooled results for 24- and 48-h infusion arms. §Used an invasive (PCI) strategy; all patients received clopidogrel.
ACS acute coronary syndrome; CAPTURE  c7E3 Fab Antiplatelet Therapy in Unstable Refractory Angina; CI  confidence interval; EPIC  Evaluation of c7E3 for the Preventic of Ischemic Complications; EPILOG  Evaluation of PTCA and Improve Long-term Outcome
by c7E3 GP IIb/IIIa receptor blockade; EPISTENT  Evaluation of Platelet IIb/IIIa Inhibitor for STENTing; ESPRIT  Enhanced Suppression of Platelet Receptor GP IIb/IIIa using Integrilin Therapy; GUSTO IV ACS  Global Use of Strategies to Open Occluded Coronary
Arteries IV; IMPACT II Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis II; ISAR-REACT Intracoronary Stenting and Antithrombotic Regimen-Rapid Early Action for Coronary Treatment; NQWMI non–Q-wave myocardial infarction; PARAGON Platelet
IIb/IIIa Antagonism for the Reduction of Acute coronary syndrome events in a Global Organization Network; PCI  percutaneous coronary intervention; PRISM  Platelet Receptor Inhibition in Ischemic Syndrome Management; PRISM-PLUS  Platelet Receptor Inhibition
in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms; PTCA  percutaneous transluminal coronaryangioplasty; PURSUIT  Platelet Glycoprotein IIb/IIIa in Unstable 16 Angina: Receptor Suppression Using Integrilin Therapy; RESTORE
 Randomized Efficacy Study of Tirofiba for Outcomes and REstenosis; RR  risk ratio; UA  unstable angina; UA/NSTEMI  unstable angina/non–ST-elevation myocardial infarction.
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ompared with UFH alone reduced the primary composite
nd point of death, MI, or refractory ischemia at 7 d (from
7.9% to 12.9% RR 0.68, p  0.004), as well as at 30 days
by 22%, p 0.03) and at 6 months (19%, p 0.02). Death
r nonfatal MI was reduced at 7 d (43%, p 0.006), at 30 d
30%, p  0.03), and at 6 months (22%, p  0.06).
ncremental benefit was observed both before and after PCI.
nalysis of coronary angiograms, obtained after 48 h,
howed reduced thrombus burden and improved coronary
ow (186). Tirofiban, in combination with heparin, is
pproved for the treatment of patients with ACS, including
atients managed medically and those undergoing PCI.
Eptifibatide, added to standard management until hospi-
al discharge or for 72 h, was studied in the PURSUIT trial,
hich enrolled 10,948 UA/NSTEMI patients (183). The
rimary outcome of death or nonfatal MI at 30 days was
educed from 15.7% to 14.2% with eptifibatide (RR 0.91, p
0.042). Event rate reduction (31%) was substantially
reater in those undergoing PCI within 72 h (16.7% to
1.6%). Benefits were maintained at 6-month follow-up.
ptifibatide is approved for the treatment of patients with
CS (UA/NSTEMI) who are treated medically or with
CI.
In summary, the CAPTURE, PRISM-PLUS, and PUR-
UIT trials each showed a significant reduction in the rate
f death or MI during the phase of medical management
nd an augmented benefit after PCI. A meta-analysis of the
large, placebo-controlled GP IIb/IIIa antagonist trials
including GUSTO IV) involving 31,402 patients with
A/NSTEMI not routinely scheduled to undergo coronary
evascularization suggested a modest overall benefit in
educing the risk of death or MI by 30 d (11.8% vs. 10.8%,
R 0.91 and 95% CI 0.84 to 0.98, respectively; p 0.015)
t a modest increase (from 1.4% to 2.4%) in major bleeding
vents (187). Treatment effect was greater among higher-
isk patients with troponin elevation and ST-segment de-
ression. These and other data have elevated troponin level
o a major factor in decision making for the use of these
gents in UA/NSTEMI. Although not specified in these
rials, PCI or CABG was performed in 19% of patients
ithin 5 d and in 38% within 30 d. These subgroups noted
greater risk reduction (OR 0.79, 95% CI 0.68 to 0.91 and
R 0.89, 95% CI 0.80 to 0.98, respectively) than in those
ot undergoing intervention (OR 0.95, 95% CI 0.86 to
.05). These findings in the context of other PCI trial data
uggest that GP IIb/IIIa inhibitors are of substantial benefit
n patients with UA/NSTEMI who undergo PCI, are of
odest benefit in patients who are not routinely scheduled
o undergo revascularization (but who may do so), and are of
uestionable benefit in patients who do not undergo revas-
ularization.
Glycoprotein IIb/IIIa antagonists increase the risk of
leeding, most commonly mucocutaneous or vascular access
ite bleeding. No trials have shown an excess of intracranial
leeding. Aspirin has been used with the intravenous GP iIb/IIIa receptor blockers in all trials, and adjunctive UFH
ppears beneficial (181,183). Hence, clinical recommenda-
ions call for the concomitant use of heparin with GP
Ib/IIIa inhibitors. Lower heparin doses diminish the
leeding risk associated with GP IIb/IIIa blockade in the
etting of PCI and likely the medical phase of management
s well. Thrombocytopenia is an uncommon (less than
.5%) complication of these agents that is reversible but is
ssociated with increased bleeding risk.
Several trials have demonstrated that GP IIb/IIIa inhib-
tors can be used with LMWH in ACS patients (155,156).
he A to Z Trial (Aggrastat to Zocor; 3,987 patients) found
onsignificant trends toward fewer ischemic end points but
ore frequent bleeding with enoxaparin than with UFH
155). In the larger SYNERGY trial, 10,027 patients with
igh-risk ACS were randomized to UFH or enoxaparin.
lycoprotein IIb/IIIa antagonists were administered to 57%
f patients, and 92% underwent coronary angiography.
ates of the primary end point of death or MI by 30 d were
imilar (14.0% vs. 14.5%) (Fig. 10), and the therapies
ffered similar protection against ischemic events during
CI, although enoxaparin was associated with a 1.5%
ncrease in bleeding events (156).
A challenge for the current guidelines is the integration of
he GP IIb/IIIa antagonist studies from the 1990s with
ore recent studies using preangiography clopidogrel load-
ng and newer anticoagulants. The current evidence base
nd expert opinion suggest that for UA/NSTEMI patients
n whom an initial invasive strategy is selected, either an
ntravenous GP IIb/IIIa inhibitor or clopidogrel should be
dded to ASA and anticoagulant therapy before diagnostic
ngiography (upstream) for lower-risk, troponin-negative
atients, and that both should be given before angiography
or high-risk, troponin-positive patients (Class I recom-
endations). For UA/NSTEMI patients in whom an initial
onservative (i.e., noninvasive) strategy is selected, the
vidence for benefit is less; for this strategy, the addition of
ptifibatide or tirofiban to anticoagulant and oral antiplate-
et therapy may be reasonable for high-risk UA/NSTEMI
atients (Class IIb recommendation). The randomized trial
atabase has shown no benefit of fibrinolysis versus standard
herapy in UA/NSTEMI patients (191). Fibrinolytic ther-
py is not recommended for the management of ACS
atients without ST-segment elevation, a posterior-wall
I, or a presumably new left bundle-branch block.
. Initial Conservative Versus
nitial Invasive Strategies
. General Principles and Care Objectives
wo treatment pathways have emerged for treating
A/NSTEMI patients: the early “invasive strategy” and
n initial “conservative strategy” (192,192a). Patients
reated with an invasive strategy generally will undergo
oronary angiography within 4 to 24 h of admission. The
nvasive strategy can be subdivided into 2 groups. The
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aphy/revascularization urgently because of ongoing isch-
mic symptoms or hemodynamic or rhythm instability.
ith these patients, GP IIb/IIIa antagonists or clopi-
ogrel may be delayed at the physician’s discretion until
he time of angiography (Figs. 6, 7, and 8). The second,
arger group comprises others with UA/NSTEMI who
re designated by patient/physician discretion or after
isk assessment to benefit from “early” but nonurgent
ngiography/intervention. For these patients, “upstream”
herapy with GP IIb/IIIa antagonists and/or clopidogrel
s recommended, with greater delays to angiography
eing associated with greater incremental benefit of
ggressive antiplatelet therapy. In contrast, the “conser-
ative strategy” (or “selective invasive management”) calls
or invasive evaluation only with symptomatic failure of
edical therapy or other objective evidence of recurrent
r latent ischemia.
The primary objective in selecting a treatment strategy in
A/NSTEMI is to yield the best long-term clinical outcome.
stimating the risk for an adverse outcome is paramount for
etermining which strategy is best applied to individual pa-
ients. General characteristics favoring one or the other strategy
re presented in Table 5. Although general guidelines can be
ffered, individual judgment is required.
. Rationale for the Conservative Strategy
he conservative strategy seeks to avoid the routine early use
f invasive procedures unless patients experience refractory
r recurrent ischemic symptoms or develop hemodynamic
nstability. With this strategy, an early echocardiogram
hould be considered to identify significant LV dysfunction.
n addition, an exercise or pharmacological stress test is
ecommended before or shortly after discharge to identify
atients with latent ischemia who could benefit from revas-
ularization. The use of aggressive anticoagulant and anti-
latelet agents has reduced the incidence of adverse out-
omes in patients managed conservatively.
. Rationale for the Invasive Strategy
he routine use of angiography within 24 h of hospital
dmission provides an invasive approach to risk stratifica-
ion. It can identify the 10% to 20% of patients with no
ignificant coronary stenoses as well as the approximately
0% with 3-vessel disease with LV dysfunction or left main
AD who derive a substantial survival benefit from CABG
Section V). For the other approximately 60% to 70%, PCI
f the culprit lesion can reduce subsequent hospitalizations
nd the need for multiple antianginal drugs. Contemporary
nticoagulant and antiplatelet therapies have lessened the
arly hazard of PCI. Excluding those in need of urgent
ntervention, 2 alternatives for the invasive approach have
merged: early (“immediate”) or deferred angiography (i.e.,
efore or after a 12- to 48-h window). Support for imme-
iate angiography comes from the Intracoronary Stenting
ith Antithrombotic Regimen Cooling-off Study (ISAR- sOOL) trial (193). In that trial, all 410 UA/NSTEMI
atients were treated with intensive medical therapy, includ-
ng ASA, heparin, clopidogrel (600-mg loading dose), and
he intravenous GP IIb/IIIa receptor inhibitor tirofiban, and
ere randomized to immediate angiography (median time
.4 h) or delayed angiography after a prolonged “cooling off”
eriod (median 86 h) before catheterization. Patients ran-
omized to immediate angiography had fewer deaths or
Is at 30 d (5.9% vs. 11.6%, p  0.04). Importantly, this
ifference was attributed to events that occurred before
atheterization. Additional data comparing these 2 invasive
trategies are needed.
. Comparison of Invasive and Conservative Strategies
rior meta-analyses have concluded that routine invasive
herapy is better than a conservative or selectively invasive
pproach (194). In contrast, the Invasive versus Conserva-
ive Treatment in Unstable coronary Syndromes (ICTUS)
rial (192) favored a strategy of selective invasive therapy.
CTUS randomized 1,200 UA/NSTEMI patients to rou-
ine invasive or selective invasive management. At the end
f 1 year, there was no significant difference in the compos-
te ischemic end point. Results were unchanged during
-year follow-up (192a). ICTUS required troponin positiv-
ty. Thus, troponin alone might not be an adequate single
riterion for strategy selection. Proposed explanations for
he lack of incremental benefit with an invasive strategy
nclude the high rate of revascularization in the selective
nvasive therapy arm (47%), more aggressive medical ther-
py (statins, clopidogrel) in both arms, routine use of
lopidogrel in the conservative arm, and limited power
wing to the relatively low rate of hard end points (195).
iven the results of ICTUS, these guidelines recognize that
n initially conservative (selective invasive) strategy may be
onsidered as a treatment option in stabilized UA/
STEMI patients. Additional comparative trials of a selec-
ive versus a routine invasive strategy are encouraged using
ggressive contemporaty medical therapies in both arms.
In the RITA-3 trial (Third Randomized Intervention
reatment of Angina), 1,810 UA/NSTEMI patients were
andomized to interventional versus conservative treatment.
t 1 year, death and MI rates were similar, but at 5 years,
significant reduction in death or MI emerged in the early
nvasive treatment arm (196). Benefits were seen mainly in
igh-risk patients, which supports appropriate risk stratifi-
ation. Long-term outcomes of the FRagmin and fast
evascularization during InStability in Coronary artery dis-
ase (FRISC II) trial have also been published (197). At 5
ears, the invasive strategy was favored for the primary end
oint of death or nonfatal MI (HR 0.81, p  0.009).
enefit was confined to men, nonsmokers, and patients with
or more risk factors.
A contemporary meta-analysis of 7 randomized trials
f management strategies in UA/NSTEMI, including IC-
US, supports the long-term benefit of an early invasivetrategy (Fig. 14) (198). Among 8,375 patients, the inci-
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ACC/AHA UA/NSTEMI Guideline Revision August 14, 2007:652–726igure 14. Relative Risk of Outcomes With Early Invasive Versus Conservative Therapy in UA/NSTEMI
: Relative risk of all-cause mortality for early invasive therapy compared with conservative therapy at a mean follow-up of 2 years. B: Relative risk of recurrent nonfatal myo-
ardial infarction for early invasive therapy compared with conservative therapy at a mean follow-up of 2 years. C: Relative risk of recurrent unstable angina resulting in
ehospitalization for early invasive therapy compared with conservative therapy at a mean follow-up of 13 months. Modified from the Journal of the American College of Cardi-
logy, 48, Bavry AA, Kumbhani DJ, Rassi AN, Bhatt DL, Askari AT. Benefit of early invasive therapy in acute coronary syndromes a meta-analysis of contemporary randomized
linical trials, 1319–25, Copyright 2006, with permission from Elsevier (198). CI  confidence interval; FRISC-II  FRagmin and fast Revascularization during InStability in
oronary artery disease; ICTUS  Invasive versus Conservative Treatment in Unstable coronary Syndromes; ISAR-COOL  Intracoronary Stenting with Antithrombotic Regimen
OOLing-off study; RITA-3  Third Randomized Intervention Treatment of Angina trial; RR  risk ratio; TIMI-18  Thrombolysis In Myocardial Infarction-18; TRUCS  Treat-
ent of Refractory Unstable angina in geographically isolated areas without Cardiac Surgery; VINO  Value of first day angiography/angioplasty In evolving Non-ST segment
levation myocardial infarction: Open multicenter randomized trial.
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August 14, 2007:652–726 ACC/AHA UA/NSTEMI Guideline Revisionence of all-cause mortality at 2 years was 4.9% in the early
nvasive group compared with 6.5% in the conservative
roups (RR 0.75, 95% CI 0.63 to 0.90, p 0.001). Nonfatal
I (7.6% vs. 9.1%, respectively, RR 0.83, 95% CI 0.72 to
.96, p 0.012) and hospitalization (RR 0.69, 95% CI 0.65
o 0.74, p less than 0.0001) also were reduced. See the
ull-text guidelines for discussion of individual trials.
. SUBGROUPS
aveats about the application of invasive and conservative
trategies in several subgroups of interest, including women
Section VII.A), diabetics (Section VII.B), older patients
Section VII.D), and those with chronic kidney disease (Sec-
ion VII.E), are addressed in Section VII. Patients with PCI
ithin the previous 6 months and those with prior CABG
epresent subgroups for which coronary angiography without
receding functional testing is generally indicated.
Management decisions must account for extensive co-
orbidities, such as 1) advanced or metastatic malignancy
ith a limited life expectancy, 2) intracranial pathology that
ontraindicates the use of systemic anticoagulation or causes
evere cognitive or physical limitations, 3) end-stage cirrho-
is, and 4) CAD that is known from previous angiography
ot to be amenable to revascularization.
. Risk Stratification Before Discharge
. GENERAL PRINCIPLES AND CARE OBJECTIVES
mportant predischarge prognostication is derived from
areful initial assessment, the patient’s hospital course,
nd response to anti-ischemic and anticoagulant therapy.
ormal risk assessment tools, such as GRACE and
IMI, can be useful not only for in-hospital and short-
erm assessments but also for longer term (6-month)
ssessment of risk (Table 4, Fig. 3). Coronary angiogra-
hy and revascularization represent powerful modifiers of
isk and tools for prognostication. Cardiac biomarkers
i.e., troponins and BNPs) add to the assessment of
ostdischarge and in-hospital risk. An assessment of LV
unction by any of several methods is generally recom-
ended to guide therapy and assess prognosis. Noninva-
ive stress testing before or shortly after discharge also
rovides very useful supplemental information to clini-
ally based risk assessment (Table 9).
The goals of noninvasive testing are to 1) determine the
resence or absence of ischemia in patients with a low or
ntermediate likelihood of CAD and 2) estimate prognosis.
detailed discussion of noninvasive stress testing in CAD
s presented in the ACC/AHA Guidelines for Exercise
esting, the ACC/AHA Guidelines for the Clinical Use of
ardiac Radionuclide Imaging, and the ACC/AHA
uidelines for the Clinical Application of Echocardiogra-
hy (Table 9) (31,199–201). Noninvasive criteria for esti-
ating risk as high, intermediate, or low are summarized in
able 9.
Stress echocardiography and nuclear ventriculographyepresent important alternatives. Myocardial perfusion im- mging with pharmacological stress is particularly useful in
atients who are unable to exercise. Cardiac magnetic
esonance is a newer imaging modality that can effectively
nd simultaneously assess cardiac function, perfusion (ie.,
ith adenosine stress), and viability (202).
. NONINVASIVE TEST SELECTION
here are no conclusive data comparing various noninvasive
ests. Furthermore, prognostic information is largely extrap-
lated from studies in stable angina/chronic CAD popula-
ions. Hence, test selection may be based primarily on
ndividual patient characteristics, physician judgment, and
est expertise and availability (204). Low- and intermediate-
isk patients may undergo symptom-limited stress testing if
hey have been clinically stable for 12 to 24 h. Earlier stress
esting (i.e., within 3 to 7 d after UA/NSTEMI) is superior
o later testing (i.e., at 1 month) (205) in that it identifies
atients at risk for adverse events within the first month.
. SELECTION FOR CORONARY ANGIOGRAPHY
oronary angiography provides detailed structural informa-
ion as the basis for assessing prognosis and directing
able 9. Noninvasive Risk Stratification
igh risk (greater than 3% annual mortality rate)
Severe resting LV dysfunction (LVEF less than 0.35)
High-risk treadmill score (score 11 or less)
Severe exercise LV dysfunction (exercise LVEF less than 0.35)
Stress-induced large perfusion defect (particularly if anterior)
Stress-induced multiple perfusion defects of moderate size
Large, fixed perfusion defect with LV dilation or increased lung uptake
(thallium-201)
Stress-induced moderate perfusion defect with LV dilation or increased lung
uptake (thallium-201)
Echocardiographic wall-motion abnormality (involving more than 2
segments) developing at low dose of dobutamine (10 mg per kg per min
or less) or at a low heart rate (less than 120 beats per min)
Stress echocardiographic evidence of extensive ischemia
ntermediate risk (1% to 3% annual mortality rate)
Mild/moderate resting LV dysfunction (LVEF  0.35 to 0.49)
Intermediate-risk treadmill score (11 to 5)
Stress-induced moderate perfusion defect without LV dilation or increased
lung intake (thallium-201)
Limited stress echocardiographic ischemia with a wall-motion abnormality
only at higher doses of dobutamine involving less than or equal to 2
segments
ow risk (less than 1% annual mortality rate)
Low-risk treadmill score (score 5 or greater)
Normal or small myocardial perfusion defect at rest or with stress*
Normal stress echocardiographic wall motion or no change of limited resting
wall-motion abnormalities during stress*
Although the published data are limited, patients with these findings will probably not be at low
isk in the presence of either a high-risk treadmill score or severe resting LV dysfunction (LVEF
ess than 0.35). Reproduced from Table 23 in Gibbons RJ, Abrams J, Chatterjee K, et al.
CC/AHA 2002 guideline update for the management of patients with chronic stable angina: a
eport of the American College of Cardiology/American Heart Association Task Force on Practice
uidelines (Committee to Update the 1999 Guidelines for the Management of Patients With
hronic Stable Angina). 2002. Available at: http://www.acc.org/qualityandscience/clinical/
tatements.htm (203).
LV  left ventricular; LVEF  left ventricular ejection fraction.anagement. When combined with LV angiography, it also
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ndications for coronary angiography are interwoven with
ndications for possible therapeutic plans such as PCI or
ABG. In contemporary practice, many intermediate- and
igh-risk patients receive coronary angiography as part of an
nvasive management strategy. In addition, coronary an-
iography is usually indicated in other UA/NSTEMI pa-
ients who have either recurrent symptoms or ischemia
espite adequate medical therapy or who develop high-risk
eatures clinically (Tables 5 and 9) (205a).
. Coronary Revascularization
. General Principles and Care Objectives
s discussed in Section IV, coronary angiography is useful for
efining the coronary artery anatomy in patients with UA/
STEMI and for identifying subsets of high-risk patients who
an benefit from early revascularization. Coronary revascular-
zation (PCI or CABG) is performed to improve prognosis,
elieve symptoms, prevent ischemic complications, and im-
rove functional capacity. The indications for coronary revas-
igure 15. Revascularization Strategy in UA/NSTEMI
There is conflicting information about these patients. Most consider CABG to be pr
nary artery; PCI  percutaneous coronary intervention UA/NSTEMI  unstable angiularization in patients with UA/NSTEMI are similar to those Nor patients with chronic stable angina and are presented in
reater detail in the ACC/AHA Guidelines for the Manage-
ent of Patients With Chronic Stable Angina (31) and in the
CC/AHA Guidelines for Coronary Artery Bypass Graft
urgery (206) and the 2005 ACC/AHA/SCAI Guidelines
pdate for Percutaneous Coronary Intervention (5). These
ndications are tempered by individual patient characteristics.
election criteria for coronary revascularization in patients with
A/NSTEMI are, in general, similar to those for patients with
table angina (122). Revascularization appears to be of most
enefit when performed early in the hospital course, particu-
arly in those with high-risk characteristics. See Figure 15 for
etails of the decision tree.
In recent years, stenting, other technological advances,
nd the use of improved antiplatelet and anticoagulant
gents have improved the safety and durability of PCI in
A/NSTEMI. Stenting has reduced the risks of both acute
essel closure and late restenosis. Drug-eluting stents have
educed the risk of restenosis but modestly increase the risk
f late coronary thrombotic events (129–131).
Published success rates of PCI in patients with UA/
le to PCI. CABG  coronary artery bypass graft; LAD  left anterior descending cor-
n–ST-elevation myocardial infarction.eferabSTEMI are high overall. Outcomes have approached those
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August 14, 2007:652–726 ACC/AHA UA/NSTEMI Guideline Revisionf elective surgery with the use of stents and potent antiplatelet
herapy (207–209). The use of drug-eluting stents for UA/
STEMI has increased dramatically in recent years, with
avorable rates of early death and recurrent infarction (210).
. Platelet Inhibitors and PCI
lycoprotein IIb/IIIa receptor antagonists and thienopyri-
ines represent important therapeutic advances in patients
ith UA/NSTEMI, particularly in the setting of PCI, as
eviewed in Section IV.B. Key trials of these agents in the
ettings of PCI and UA/NSTEMI are summarized in Table
. Only 1 comparative trial (TARGET: Do Tirofiban And
eoPro Give similar Efficacy Trial) directly compared these
gents (tirofiban vs. abciximab) in patients undergoing PCI
ith intended stenting. An advantage of abciximab in
reventing early ischemic events was observed among the
ubgroup presenting with UA/NSTEMI (211). An insuffi-
ient loading dose of tirofiban to achieve an optimal early
periprocedural) antiplatelet effect has been proposed as a
ossible explanation for this difference (212).
Whether GP IIb/IIIa inhibition is still useful in UA/
STEMI patients undergoing PCI who have received a high
oading dose (600 mg) of clopidogrel was raised by a study in
n elective setting (ISAR-REACT) (213). To address this
ssue, ISAR-REACT 2 enrolled patients with UA/NSTEMI
ndergoing PCI, loaded them with clopidogrel 600 mg at least
h before the procedure, and then randomized them to receive
ither abciximab or placebo at the time of PCI (74). As
iscussed earlier, the primary end point of death, nonfatal
einfarction, or urgent target-vessel revascularization within
0 d was reduced by 25% in the abciximab group, an advantage
imited entirely to patients with an elevated troponin level.
hese findings have been incorporated into the overall UA/
STEMI treatment algorithm shown in Figures 6, 7, and 8.
Comparisons of PCI and CABG are summarized in the
ext section.
. Surgical Revascularization
ramatic changes in surgical technique and in medical and
ercutaneous therapies have occurred over the past 2 de-
ades, limiting the implications of older trial results for
ontemporary practice. The Bypass Angioplasty Revascu-
arization Investigation (BARI) trial, the largest randomized
omparison of CABG and percutaneous transluminal cor-
nary angioplasty (PTCA) in multivessel CAD (214, 215),
bserved a survival benefit with CABG that was confined to
atients with diabetes mellitus. The Coronary Angioplasty
ersus Bypass Revascularization Investigation (CABRI) also
howed a survival benefit for CABG in patients with
iabetes and multivessel CAD (216). An Emory University
tudy also was confirmatory (217). However, a CABG-
elated advantage was not reproduced in the BARI registry
218), which suggests that physicians might be able to
ecognize characteristics of CAD in diabetic patients that
ermits the safe selection of either revascularization therapy. PHannan et al. (219) compared 3-year risk-adjusted sur-
ival rates in 29,646 CABG patients and 29,930 PTCA
atients undergoing revascularization in the state of New
ork in 1993. Anatomic extent of disease was the only
ariable that interacted with revascularization therapy to
nfluence survival. Patients with 1-vessel disease not involv-
ng the LAD had higher survival rates with PTCA, whereas
atients with proximal LAD stenosis and 3-vessel disease
ad higher survival rates with CABG. A follow-up study
sing the same registry compared 37,212 patients who
nderwent CABG with 22,102 patients who underwent
CI using stents (220). The unanticipated finding was that
he risk-adjusted long-term mortality of patients in all 5
natomic subsets assessed was lower with CABG.
The most recent randomized comparisons of PCI and
ABG surgery can be summarized as follows: The Angina
ith Extremely Serious Operative Mortality Evaluation
AWESOME] trial found comparable survival with CABG
nd PCI, which included stenting or atherectomy (221).
imilarly, the ARTS trial (Arterial Revascularization Ther-
py Study), which compared coronary stenting with CABG
222) and which included but was not limited to patients
ith UA, found identical 3-year survival rates free of stroke
nd MI (222). A meta-analysis of 4 trials of CABG versus
CI with bare-metal stenting for multivessel disease be-
ween 1995 and 2000 also reported no difference in the
rimary composite end point of death, MI, and stroke or
eath alone between the CABG and the stent groups. None
f these trials adequately reflect current interventional car-
iology practice, which includes a broad use of drug-eluting
tents, double- or triple-antiplatelet therapy, and newer
nticoagulants. Surgical management also has evolved, and
isk-adjusted mortality for CABG has declined progres-
ively (223).
Nevertheless, when data from available trials and cohort
tudies are combined, these data suggest that it is reasonable
o consider CABG to be a preferred revascularization
trategy for most patients with 3-vessel disease, especially if
t involves the proximal LAD, and for patients with mul-
ivessel disease and treated diabetes mellitus or LV dysfunc-
ion (Fig. 15). However, it would be unwise to deny
ontemporary PCI to a patient with diabetes mellitus and
ess severe CAD on the basis of the current information
224,225).
I. Late Hospital Care, Hospital Discharge,
nd Post-Hospital Discharge Care
. General Principles and Care Objectives
wo broad goals during the hospital discharge phase are 1)
o prepare the patient for normal activities to the extent
ossible and 2) to use the acute event as an opportunity to
eevaluate care, focusing on lifestyle and aggressive risk
actor modification. Patients who have undergone successful
CI with an uncomplicated course are usually discharged
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enerally are discharged 4 to 7 d later. Low-risk patients
ay be discharged soon after noninvasive testing or coro-
ary angiography. Management of high-risk, unstable pa-
ients often requires more prolonged and vigilant inpatient
are.
Inpatient oral anti-ischemic, antiplatelet, and other sec-
ndary preventive medications used in the nonintensive
hase generally should be continued after discharge A
ultidisciplinary team is ideal to prepare the patient for
ischarge.
. Long-Term Medical Therapy
atients with UA/NSTEMI require secondary prevention
t discharge. The acute phase of UA/NSTEMI is usually
ver within 1 to 3 months, after which most patients assume
course of chronic CAD. Therefore, chronic secondary
revention measures are similar to those for other CAD
atients (3,8,12,13,31) (see Section VI.C below). Recom-
endations for lipid lowering are fully discussed elsewhere
3,12,13).
. Postdischarge Risk Assessment and Follow-Up
atient-specific risk within 1 year can be predicted on the
asis of clinical information and the ECG. The PURSUIT,
IMI, and GRACE risk models, introduced in Section
II.B, are also useful for postdischarge risk assessment (see
ig. 3).
At discharge, detailed discharge instructions for post-
A/NSTEMI patients should include education on medi-
ations, diet, exercise, and smoking cessation (if appropri-
te); referral to a cardiac rehabilitation/secondary prevention
rogram (when appropriate); and the scheduling of a timely
ollow-up appointment. Low-risk medically treated patients
nd revascularized patients should return in 2 to 6 weeks,
nd higher-risk patients should return within 14 d. When
table, typically by 1 to 3 months after discharge, patients
ay be followed up as for stable CAD.
Minimizing the risk of recurrent cardiovascular events
equires optimizing patient compliance with prescribed
herapies and recommended lifestyle modifications.
. Risk Factor Modification
health care team with expertise in aggressively managing
AD risk factors should work with patients and their
amilies, including patients who have undergone revascular-
zation (226), to educate them in detail regarding specific
argets for LDL-C and HDL-C (3,12,13), blood pressure
6), diabetes mellitus, diet and weight management (12),
hysical activity (12), tobacco cessation (12), and other
ppropriate lifestyle modifications (226,228). There is a
ealth of evidence that cholesterol-lowering therapy re-
uces vascular events in patients with CAD and hypercho-
esterolemia (229) or mild cholesterol elevation after MI
230,231). Indeed, there is mounting evidence that statin
herapy is beneficial regardless of baseline LDL-C levels A232–234). More aggressive lipid lowering further lowers
ardiovascular event rates and is safe, although the incre-
ental impact on mortality over moderate lipid-lowering
emains to be clearly established (235).
Data on the utility of ACE inhibitors in stable CAD in
he absence of HF or LV dysfunction have been conflicting.
meta-analysis of 3 major trials (HOPE [Heart Outcomes
revention Evaluation], EUROPA [EUropean trial on
eduction Of cardiac events with Perindopril in patients
ith stable coronary Artery disease], and PEACE [Preven-
ion of Events with Angiotensin Converting Enzyme Inhi-
ition]) supports a benefit across the risk spectrum studied
236); however, the absolute benefit is proportional to
isease-related risk, with those at lowest risk benefiting least
236,237). All patients with elevated systolic or diastolic
lood pressures should be educated and motivated to
chieve systolic and diastolic blood pressures in the normal
ange (i.e., less than 140/90 mm Hg; 130/80 mm Hg if the
atient has diabetes or chronic kidney disease) (6,12).
For patients who smoke, tobacco cessation has substantial
otential to improve survival (238). Physician counseling,
eferral to a smoking cessation program, and the use of
harmacological agents (239–242) are recommended (239).
Overweight patients should be instructed in a weight loss
egimen, with emphasis on the importance of regular
xercise and a lifelong prudent diet to maintain ideal body
ass index.
Glycemic control is discussed in Section VII.B.
The use of NSAIDS and COX-2–selective inhibitors
hould be minimized in post-UA/NSTEMI patients be-
ause of an increase in cardiovascular risk (112,243,244).
ardiovascular risk associated with NSAID use may be
owest with naproxen, which has antiplatelet activity
111,243). An AHA scientific statement on the use of
SAIDS has recommended a stepped-care approach to
usculoskeletal pain control to minimize risk (245).
Folic acid/B-vitamin supplementation given to reduce
omocysteine levels did not reduce the risk of CAD events
n 2 major trials (246,247), and its routine use for secondary
revention is not recommended. Antioxidant vitamins (C,
, beta carotene) also have not demonstrated benefit in
econdary prevention and are not recommended (13).
See Section I.C.5.B for lipid lowering and other risk
actor modification recommendations.
. Physical Activity
egular physical activity is important to improving func-
ional capacity and well-being, losing weight and main-
aining weight loss, and reducing other risk factors such
s insulin resistance (248,249). Exercise training gener-
lly can begin within 1 to 2 weeks after revascularized
A/NSTEMI (249). Unsupervised exercise may target a
eart rate range of 60% to 75% of maximum predicted;
upervised training (see next section) may target a some-
hat higher heart rate (70% to 85% of maximum) (249).
dditional restrictions apply when residual ischemia is
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een developed for cardiac and general populations to
elp guide exercise prescriptions (250). In addition to
erobic training, mild- to moderate-resistance training
ay be considered and may start 2 to 4 weeks after
erobic training has begun (251).
. Cardiac Rehabilitation
ardiac rehabilitation has been shown to improve exercise
olerance without increasing cardiovascular complications,
o improve exercise tolerance and reduce cardiovascular
ymptoms, and to improve blood lipid levels; it has also been
hown to reduce cigarette smoking in conjunction with a
moking cessation program, to decrease stress, and to
mprove psychosocial well-being (252). A limited, con-
rolled evidence base also suggests a beneficial potential on
ardiovascular outcomes (253,254). The benefits of rehabil-
tation after uncomplicated UA/NSTEMI with revascular-
zation and modern medical therapy are less clear in com-
arison with STEMI or complicated NSTEMI, and
hysician judgment is recommended. Comprehensive car-
iac rehabilitation involves individualized risk factor assess-
ent, education, and modification, as well as prescribed
xercise, and may occur in a variety of settings (255).
lternative approaches, including home exercise, Internet-
ased programs, and transtelephonic monitoring/supervision,
lso can be implemented effectively and safely for selected
atients (256).
. Return to Work and Disability
ardiac functional status and LVEF are not strong
redictors of return to work, although physical require-
ents of work play a role (257,258). Psychological
ariables such as trust, job security, feelings about dis-
bility, absence of depression, pre-event functional inde-
endence, and expectations of recovery are more predic-
ive (257,259). Resumption of full employment also is
ower with diabetes mellitus, older age, Q-wave MI, and
reinfarction angina (258). Cardiac rehabilitation pro-
rams can contribute to return to work (260). Contem-
orary information on the impact of current aggressive
nterventional treatment of UA/NSTEMI, with short-
ned hospital length of stay and early rehabilitation, on
eturn to work and disability is needed. In PAMI
Primary Angioplasty in Myocardial Infarction)-II, a
tudy of primary PTCA in low-risk patients with MI,
atients were encouraged to return to work at 2 weeks
261). Although the actual timing of return to work was
ot reported, no adverse events occurred as a result of this
trategy.
. Other Activities
aily walking can be encouraged immediately in all
atients. In stable patients without complications, sexual
ctivity with the usual partner can be resumed within 1
eek to 10 d. For stable patients, driving can begin 1 seek after discharge if otherwise in compliance with state
aws. After complicated MI, driving should be delayed
ntil 2 to 3 weeks after symptoms have resolved. Air
ravel within the first 2 weeks of MI should be under-
aken only if a patient has no angina, dyspnea, or
ypoxemia at rest or fear of flying, flies with a compan-
on, carries NTG, and avoids rushing and increased
hysical demands of travel. Low-risk patients with UA/
STEMI who are revascularized and otherwise stable
ay accelerate their return to work, driving, flying, and
ther normal activities (often, within a few days).
. Patient Records and Other Information Systems
ffective medical record systems, including electronic sys-
ems, that document the course and plan of care should be
stablished or enhanced. Tools such as the ACC’s “Guide-
ines Applied in Practice” and the AHA’s “Get With the
uidelines” can improve quality of care and patient safety.
eliable health care information relevant to UA/NSTEMI
atients is available, and patient access to it should be
ncouraged (http://www.heartauthority.com; http://
ww.nhlbi.nih.gov/health/dci/index.html; http://
ww.nlm.nih.gov/medlineplus/tutorial.html; http://
ww.fda.gov/hearthealth/index.html).
II. Special Groups
. Women
. Profile of UA/NSTEMI in Women
omen present at an older age but account for a
onsiderable proportion of UA/NSTEMI. Women are
ore likely to have hypertension, diabetes mellitus, and
F with preserved systolic function; to manifest UA
ather than NSTEMI; to have atypical symptoms (e.g.,
rimarily dyspnea); and to have causes unrelated to CAD
22,32,262–265,266) Women have similar rates of ST
epression but less often have elevated biomarkers (267).
evertheless, the prognostic value of elevated biomarkers
s similar in women and men (268). Coronary angiogra-
hy reveals less extensive CAD in women and a higher
roportion (as high as 37%) with nonobstructive CAD
262,269). This profile makes it challenging to confirm
he diagnosis of UA/NSTEMI and is a likely cause of
nderutilization or overutilization of therapies in women
267). Unlike STEMI, female sex is not a risk factor for
dverse outcomes for UA/NSTEMI when adjusted for
aseline characteristics (22,203,267,270 –277).
. Stress Testing
ndications for noninvasive testing in women are the same
s in men (203,270). Exercise ECG testing is less predictive
n women, however, primarily because of the lower pretest
robability of CAD (271–273). Perfusion studies with
estamibi have good sensitivity and specificity in women
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or the exclusion of CAD (276).
. Management
. PHARMACOLOGICAL THERAPY
omen derive the same treatment benefit as men from
SA, clopidogrel, anticoagulants, beta blockers, ACE in-
ibitors, and statins, but they are given ASA and other
nticoagulant less frequently (278). A meta-analysis of GP
Ib/IIIa antagonists in UA/NSTEMI reported an apparent
ack of efficacy and possible harm in women (187); however,
omen with elevated troponin levels received the same
eneficial effect as men. Higher rates of dosing errors and
ubsequent bleeding with antiplatelet and anticoagulant
herapy have been reported for women than for men (279).
reatinine clearance (Cockroft-Gault formula) and weight-
ased adjustments of medications, where recommended,
an reduce this risk.
. CORONARY ARTERY REVASCULARIZATION
ngiographic success and late outcomes after PCI for
omen, including those presenting with UA/NSTEMI,
ave improved and are generally similar to men, although in
ome series, early complications occurred more frequently in
omen (264,280,281). Similarly, more recent studies show
favorable outlook for women with ACS undergoing
ABG (262,282,282a).
. INITIAL INVASIVE VERSUS INITIAL CONSERVATIVE STRATEGY
linical trials of UA/NSTEMI have consistently demon-
trated a benefit with an invasive strategy for men (see
ection IV.C), but results in women have been conflicting.
meta-analysis of trials in the era of stents and GP IIb/IIIa
ntagonists has failed to show a survival benefit of a direct
nvasive strategy in women at 6 to 12 months (OR for
omen 1.07, 95% CI 0.82 to 1.41; OR for men 0.68, 95%
I 0.57 to 0.81) (283).
In TACTICS (Treat Angina with Aggrastat and deter-
ine Cost of Therapy with Invasive or Conservative Strat-
gy) TIMI-18, there was a reduction in the composite risk
f death, nonfatal MI, or rehospitalization for UA in
omen with intermediate (3 to 4) or high (5 to 7) TIMI risk
cores undergoing an early invasive strategy that was similar
o that in men (284). In contrast, women with a low TIMI
isk score had an increased risk of events (OR 1.59, 95% CI
.69 to 3.67) with the invasive versus the conservative
trategy, whereas low-risk men had similar outcomes with
he 2 strategies. However, the number of events was small (n
26 events), and the probability value for interaction did
ot achieve significance (p  0.09). Similarly, women with
n elevated troponin T benefited from an invasive strategy
adjusted OR 0.47, 95% CI 0.26 to 0.83), whereas the
rimary end point was significantly more frequent in women
but not men) treated invasively with a negative troponin
OR 1.46, 95% CI 0.78 to 2.72) (284). The FRISC II (197)
nd RITA-3 (196,269,285) randomized trials reported im- droved outcomes with an invasive strategy only in men, but
high percentage of women were low risk, and an assess-
ent of outcomes by risk or troponin status has not been
eported.
In summary, women with UA/NSTEMI and high-risk
eatures, including elevated cardiac biomarkers, appear to
enefit from an invasive strategy with adjunctive GP IIb/
IIa antagonist use, although more data are needed. There is
o benefit of a direct invasive strategy for low-risk women,
nd the weight of evidence suggests that there may be excess
isk in this group, for which a conservative strategy is
ecommended.
. Diabetes Mellitus
. Profile and Initial Management of Diabetic and
yperglycemic Patients With UA/NSTEMI
oronary artery disease accounts for 75% of deaths in
atients with diabetes, and approximately 20% to 25% of
atients with UA/NSTEMI have diabetes mellitus
215,286). Diabetic patients with UA/NSTEMI have more
evere CAD (286–288), more ulcerated plaques and intra-
oronary thrombi (289), more vascular comorbidities, and
re more often post-CABG patients (290). Diabetic auto-
omic dysfunction raises the threshold for the perception of
ngina, which confounds the diagnosis of UA/NSTEMI
291). Importantly, diabetes mellitus is an independent
redictor of death, MI, or readmission with UA (292).
Glucose level on admission to the hospital is a significant
redictor of 1-year mortality (293); however, the optimal
pproach to managing hyperglycemia remains uncertain
294–296). Pending additional trials that include ACS
atients, a reasonable approach may be to target a blood
lucose goal of less than 150 mg per dL during the first 3 d
n the intensive care unit/critical care unit in very ill patients
e.g., those with ventilators or on parenteral feeding) (297).
hereafter, or in less ill patients, a more intensive insulin
egimen could be instituted, with a goal of normoglycemia
80 to 110 mg per dL).
. Coronary Revascularization
n advantage for CABG over PTCA was found in treated
atients with diabetes mellitus in the randomized BARI
286), CABRI (216), and Emory University trials (217), as
iscussed in Section V.C. Specifically, mortality was lower
n patients who received internal thoracic artery grafts.
owever, a CABG-related advantage was not reproduced
n the BARI registry population (218), which suggests that
hysicians might be able to recognize characteristics of
AD in diabetic patients that permit the safe selection of
ither revascularization therapy. Similarly, in the Duke
niversity registry study, although outcome was worse in
iabetic patients, there was no differential effect of PCI
ersus CABG (298).
Stents have improved the outcome of patients with
iabetes mellitus who undergo PCI. In a study with histor-
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uperior to that after PTCA, and the restenosis rate was
educed (63% vs. 36%, diabetes vs. no diabetes, with balloon
TCA at 6 months [p  0.0002] compared with 25% and
7% with stents [p  NS]) (299). Nevertheless, “BARI-
ike” comparisons of long-term survival after PCI with
requent stenting versus CABG have reported better risk-
djusted long-term survival in diabetic subgroups with
-vessel disease treated with CABG (300).
Glycoprotein IIb/IIIa antagonists improve the outcome
f PCI in patients with diabetes mellitus. In the Evaluation
f PTCA to Improve Long-term Outcome by c7E3 GP
Ib/IIIa receptor blockade (EPILOG), abciximab resulted
n a greater decline in death/MI over 6 months after PCI in
atients with diabetes mellitus (HR 0.36, 95% CI 0.21 to
.61) than in those without diabetes (HR 0.60, 95% CI 0.44
o 0.829) (301). A similar differential benefit in diabetic
atients has been reported for tirofiban (225). In the
valuation of IIb/IIIa Platelet Inhibitor for STENTing
EPISTENT) trial, which studied 2,399 patients, 21% with
iabetes and 20% with UA (178), abciximab reduced the
0-d event rate (death, MI, or urgent revascularization) in
iabetic patients from 12.1% (stent plus placebo) to 5.6%
stent plus abciximab; p  0.040). At 6 months, revascu-
arization of target arteries was reduced by more than 50%
16.6% vs. 8.1%, p  0.02). Death or MI was reduced to a
imilar degree in diabetic and nondiabetic patients (303),
nd benefits were maintained at 1 year (304).
Data on outcomes in diabetic patients with the contem-
orary use of drug-eluting stents, GP IIb/IIIa inhibitors,
nd long-term clopidogrel are limited. However, given the
iffuse nature of diabetic CAD, the relative benefits of
ABG over PCI may persist for diabetic patients, even in
he era of drug-eluting stents.
. Post-CABG Patients
verall, up to 20% of patients presenting with UA/
STEMI have previously undergone CABG (290). Con-
ersely, approximately 20% of post-CABG patients develop
A/NSTEMI during an interval of 7.5 years (305). Post-
ABG patients who present with UA/NSTEMI are at
igher risk than those who have not undergone surgery.
. Pathological Findings
athologically, post-CABG patients have a particular ten-
ency for atherosclerotic and thrombotic lesions to develop
n SVGs, as well as native-vessel progression, which can
ead to UA/NSTEMI (306). Angiographically, SVGs more
requently have friable plaques, complex lesions, thrombi,
nd total occlusions than native vessels (307). Approxi-
ately 50% of SVGs develop obstructive lesions within 5
ears and more than 90% at greater than 10 years (307), and
here is a high rate of early graft failure in current practice
occlusion in up to one third at 1 year). Thus, SVG disease
s a serious and unstable process. o. Clinical Findings and Approach
ost-CABG patients are more frequently male, older, and
iabetic; have more extensive CAD; and have more prior
Is and LV dysfunction than non-CABG patient present-
ng with UA/NSTEMI. Resting ECG abnormalities often
imit the utility of ECG stress testing, but myocardial stress
erfusion imaging or dobutamine echocardiography can
elp to identify and define areas of ischemia. Given complex
isease with many anatomic possibilities that cause isch-
mia, there should be a low threshold for angiography in
ost-CABG patients with UA/NSTEMI.
Revascularization with either PCI or reoperation may be
onsidered in post-CABG patients with UA/NSTEMI on
he basis of individual characteristics. Stents are generally
referred to balloon angioplasty of SVGs (308). When
ossible, PCI of a native vessel is preferred to PCI of an
VG. Embolization of friable atherosclerotic can increase
he risk of PCI-related complications (309). Despite rela-
ively similar early outcomes, post-CABG patients experi-
nce up to twice the incidence of adverse events (death, MI,
r recurrent UA) during the first year, which is attributable,
t least in part, to a lower rate of complete revascularization
305,310).
. Older Adults
he terms “elderly” or “older adults” are often used to refer
o those aged 75 years and older. Older adults account for
ore than one-third of UA/NSTEMI patients (311) and
resent with special challenges. First, they more often
resent with atypical symptoms, including dyspnea and
onfusion (312). Second, they are more likely to have altered
ardiovascular physiology, including hypertension or hypo-
ension, cardiac hypertrophy, and HF and LV dysfunction,
specially diastolic dysfunction (313), and they more fre-
uently have other cardiac comorbidities. Third, older
atients tend to be treated with a greater number of
edications, have reduced renal function, and are at greater
isk for adverse drug interactions. Hence, older age is
ssociated with both higher disease severity and greater
reatment risk (311).
. Pharmacological Management
verall, older subgroups in clinical trials have relative or
bsolute risk reductions that are relatively similar to those
f younger patients for many commonly used treatments
or UA/NSTEMI. Despite this, older patients less often
eceive an early invasive strategy and key pharmacother-
pies, including anticoagulants, beta blockers, clopi-
ogrel, and GP IIb/IIIa inhibitors (44,311,314). With
his said, proper drug selection and dose adjustment are
eeded to account for altered drug metabolism, distribu-
ion, and elimination, as well as exaggerated drug effects.
n a community-based registry, 38% of UA/NSTEMI
atients aged 75 years or older received an excessive dose
f UFH, 17% received excessive LMWH, and 65%
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311); 15% of major bleeding could be attributed to
xcess dosing (279). Mortality and length of stay were
reater with excessive dosing. Altered pharmacodynamic
esponses to drugs also result from lower cardiac output,
lasma volume, and vasomotor tone and responsiveness.
. Functional Studies
lder persons often have difficulty performing exercise
esting and have a higher prevalence of preexisting ECG
bnormalities. In such patients, pharmacological stress test-
ng with cardiac imaging can be useful.
. Contemporary Revascularization Strategies in
lder Patients
xperience has shown that coronary stenting can be per-
ormed in older patients with high procedural success and
cceptably low complication rates (315). Similarly, an inva-
ive strategy in UA/NSTEMI can benefit older patients
ith UA/NSTEMI. In the TACTICS TIMI-18 trial
316), the early invasive strategy conferred an absolute
eduction in total ischemic events of 10.8 percentage points
nd a relative risk reduction of 50% (10.8% vs. 21.6%; p 
.016) in patients older than 75 years. Benefits came with an
ncreased risk of major bleeding events (16.6% vs. 6.5%; p
.009). Thus, selection of older patients for an early invasive
trategy remains challenging and requires clinical judgment
nd individual application; however, age alone should not
reclude the use of a PCI-based strategy.
Operative morbidity and mortality rates also increase for
ABG with advanced age, but outcomes have progressively
mproved and are favorable compared with medical therapy;
uality of life improves as well (317). A contemporary
eview of 662,033 patients enrolled in the Society of
horacic Surgeons National Cardiac Database (318) found
CABG operative mortality rate of 2.8% for patients 50 to
9 years of age, 7.1% for patients 80 to 89 years of age, and
1.8% for patients aged 90 years or greater. Risk was lower
n the absence of certain factors (renal failure, emergency
urgery, and noncoronary vascular disease). Thus, with
ppropriate selection, CABG surgery can be an appropriate
evascularization strategy, even in the oldest patient sub-
roups.
. Chronic Kidney Disease
hronic kidney disease is a potent risk factor for cardiovas-
ular disease and qualifies as a coronary risk equivalent
319). Chronic kidney disease is also a risk factor for adverse
utcomes after MI, including NSTEMI (47,320,321). Of
oncern, however, is the underrepresentation of patients
ith renal disease in randomized controlled trials (322).
imited evidence and current opinion suggest that when
ppropriately monitored, cardiovascular medications and
nterventional strategies can be safely applied to these
atients (320). However, bleeding risk is higher because of
latelet dysfunction and dosing errors (279). Renin- cngiotensin-aldosterone inhibitors can impose a greater risk
f hyperkalemia and worsening renal function. Angiography
arries an increased risk of contrast-induced nephropathy,
nd PCI is associated with a higher rate of early and late
omplications (322). Thus, chronic kidney disease carries a
ar worse prognosis, but unlike in several other high-risk
ubsets, the value of aggressive therapeutic interventions is
ess certain and should be further studied.
In patients with chronic kidney disease or chronic kidney
isease and diabetes mellitus who are undergoing angiog-
aphy, isosmolar contrast material has been shown to lessen
he rise in creatinine: It reduced the risk of contrast-induced
ephropathy in both a randomized clinical trial (RE-
OVER [Renal Toxicity Evaluation and Comparison Be-
ween Visipaque (Iodixanol) and Hexabrix (Ioxaglate) in
atients With Renal Insufficiency Undergoing Coronary
ngiography]) comparing iodixanol with ioxaglate (323)
nd a meta-analysis of 2,727 patients from 16 randomized
linical trials (324).
An assessment of renal function is critical to proper
edical therapy of UA/NSTEMI. Many cardiovascular
rugs used in UA/NSTEMI patients are renally cleared;
heir doses should be adjusted for estimated creatinine
learance. Clinical studies and labeling that defines adjust-
ents for several of these drugs have been based on the
ockroft-Gault formula for estimating creatinine clearance,
hich should be used to generate dose adjustments.
. Cocaine and Methamphetamine Users
he widespread use of cocaine and, more recently, meth-
mphetamines and their known association with UA/
STEMI makes it mandatory to consider these drugs as a
otential cause of UA/NSTEMI, because pathophysiology
nd therapy for these drugs are distinctive.
. Pathophysiology and Presentation
he potential of cocaine to induce coronary spasm has been
emonstrated both in vitro (325) and in vivo (326–328).
reatment with calcium antagonists inhibits or reverses
ocaine-induced vasoconstriction (328,329). Cocaine also in-
reases platelet responsiveness and reduces anticoagulant fac-
ors, which predisposes the individual to coronary thrombosis
326,330).
Cocaine users can develop chest discomfort that is indis-
inguishable from UA/NSTEMI secondary to coronary
therosclerosis. Thus, UA/NSTEMI patients should be
uestioned about the use of cocaine and methamphetamines
331).
. Treatment
nitial management of cocaine-induced ACS should include
ublingual NTG and a calcium antagonist (e.g., diltiazem 20
g IV) (326,332). If ST-segment elevation is present and the
atient is unresponsive to initial treatment, immediate coro-
ary angiography is preferred over fibrinolytic therapy. After
ocaine use, increased motor activity causing CK and CK-MB
e
t
u
s
a
a
a
b
m
a
d
3
A
c
p
c
s
a
i
m
G
V
u
c
a
u
1
A
N
h
m
a
f
l
v
s
(
s
T
e
s
d
v
l
n
p
2
V
n
c
i
s
a
c
d
m
(
a
d
m
o
t
H
1
C
a
d
i
a
m
c
r
e
d
i
p
e
l
t
h
2
P
n
c
b
e
i
p
X
f
c
i
t
fi
e
f
C
a
705JACC Vol. 50, No. 7, 2007 Anderson et al.
August 14, 2007:652–726 ACC/AHA UA/NSTEMI Guideline Revisionlevations can occur in the absence of MI (333); hence,
roponin levels should be used to assess myocardial injury. The
se of beta blockers for cocaine-induced ischemia is controver-
ial (334). If used, labetalol, an alpha and beta blocker, has been
dvocated, because it has been shown not to induce coronary
rtery vasoconstriction (335). However, NTG and calcium
ntagonists are preferred (332,334). Cocaine users with possi-
le/probable UA/NSTEMI should be observed and managed
edically for 9 to 24 h. Thereafter, if the ECG and biomarkers
re normal and the patient is stable, the patient can be
ischarged (336).
. Methamphetamine Use and UA/NSTEMI
lthough methamphetamine abuse has increased dramati-
ally, the evidence base for UA/NSTEMI after metham-
hetamine use and its treatment is limited to a few publi-
ations of case reports and small series (337–339). These
uggest a clinical presentation that resembles cocaine-
ssociated ACS. Therapy similar to that for cocaine-
nduced UA/NSTEMI is reasonable pending information
ore specific to methamphetamine use.
. Variant (Prinzmetal’s) Angina
ariant angina (Prinzmetal’s angina, periodic angina) is an
nusual form of UA that usually occurs spontaneously, is
lassically characterized by transient ST-segment elevation,
nd spontaneously resolves or resolves with NTG use,
sually without progression to MI.
. Clinical Picture, Pathogenesis, and Diagnosis
nginal discomfort usually occurs at rest, simulating UA/
STEMI. Attacks can be precipitated by emotional stress,
yperventilation, exercise, or exposure to cold and occur
ore frequently in the early morning. Patients with variant
ngina are generally younger and, except for smoking, have
ewer coronary risk factors (340,341). Occasionally, pro-
onged vasospasm can result in MI, atrioventricular block,
entricular tachycardia, or sudden death (342,343).
The cause of variant angina is epicardial coronary artery
pasm, most commonly focal but potentially at more than 1 site
344). ST-segment elevation implies transmural ischemia as-
ociated with complete or near-complete coronary occlusion.
hese sites can be angiographically normal (presumably with
ndothelial dysfunction or inapparent plaques) (345) or may
how nonobstructive or obstructive CAD (346). The key to
iagnosis is the documentation of transient ST-segment ele-
ation during chest discomfort. Both noninvasive tests (ambu-
atory ECG recording, morning treadmill exercise) and coro-
ary angiography (which can include pharmacological
rovocation) can be useful in diagnosis.
. Treatment and Prognosis
ariant angina is usually responsive to NTG, long-acting
itrates, and calcium antagonists (347–349), which are ionsidered first-line therapies. (Beta blockers have theoret-
cal adverse potential, and their clinical effect is controver-
ial.) Smoking should be discontinued. Patients with very
ctive disease can require a combination of nitrates and 2
alcium antagonists of different classes (i.e., a dihydropyri-
ine with verapamil or diltiazem). Alpha-receptor blockers
ay be tried in resistant patients (350). Coronary spasm
with or without provocation) that occurs during coronary
ngiography should be treated with 0.3 mg of NTG infused
irectly into the coronary artery involved. Prognosis with
edical therapy is usually good in the presence of a normal
r near-normal coronary arteriogram (351) but is worse in
he presence of CAD (352).
. Cardiovascular “Syndrome X”
. Definition and Clinical Picture
ardiovascular “syndrome X” refers to with a syndrome of
ngina or angina-like discomfort with exercise, ST-segment
epression on exercise testing or other objective signs of
schemia (353), and normal or nonobstructed coronary
rteries on arteriography (354). Syndrome X is more com-
on in women than in men (354–357). Chest discomfort
an be typical or atypical (356), may occur with activity or at
est, and may or may not respond to NTG (358). Prolonged
pisodes can simulate UA/NSTEMI. The cause of syn-
rome X is not well understood but has been postulated to
nvolve microvascular dysfunction and/or abnormal pain
erception (359,360). Recent data from the Women’s Isch-
mia Syndrome Evaluation (WISE) (361,362) suggest that
ong-term prognosis might not be as benign as previously
hought: Women with no or minimal obstructive disease
ad a 9.4% occurrence of MI or death by 4 years.
. Treatment
ersistence of symptoms is common, and many patients do
ot return to work (358). The demonstration of normal
oronary arteries on angiography can be reassuring. Beta
lockers and calcium antagonists can reduce the number of
pisodes of chest discomfort (363,364). Nitrates are effective
n one-half of patients. Imipramine 50 mg daily can benefit
atients with chronic pain syndromes, including syndrome
(365). Estrogen in postmenopausal women can reduce the
requency of chest pain episodes (366) but can increase
ardiovascular risk. Statin therapy and exercise training can
mprove exercise capacity, endothelial function, and symp-
oms (367,368). Cognitive behavioral therapy can be bene-
cial (369). Other causes of chest discomfort, especially
sophageal dysmotility, should be ruled out. Coronary risk
actor reduction is appropriate, especially if even minimal
AD is present. Transcutaneous electrical nerve stimulation
nd spinal cord stimulation have been used for pain control
n highly symptomatic, refractory cases (370).
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